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Cancer has an enormous impact on modern society, on a yearly basis a significant 
number of patients dies as a consequence of this disease. Hence, a lot of effort is 
put in the elucidation of the molecular causes of cancer and in the development of 
new and better treatment options to cure cancer. Normally cancer is treated by 
surgical resection, radio- or chemotherapy. The latter is very frequently used, but 
unfortunately characterized by its devastating  side-effects. 
It would mean a huge breakthrough if one could develop a drug or a drug-
delivery system that allows efficient treatment of the tumor site leaving other 
tissues unharmed. However, such time and space controlled drug-delivery 
remains a holy grail in medicine. It is the wish of every scientist or physician to 
design or have access to a device that only delivers therapeutic molecules at a 
certain target site (e.g. a tumor) but for the time being no such device has made it 
to the clinic. To design such a “magic bullet”, a concept that was first described 
by Ehrlich in the beginning of the 20th century, one needs to develop a drug 
carrier that responds to a stimulus applied by an external force or produced by 
the target tissue itself. 
Pressure can be used as such an external trigger and an interesting source of 
pressure can be ultrasound. In this thesis we will focus on the development of 
small gas filled “microbubbles” that can be loaded with a drug-containing 
nanoparticle and that in response to a high intensity ultrasound field release their 
payload only there where ultrasound is applied. Additionally, this technique also 
benefits from the fact that ultrasound can be used diagnostically for imaging 
applications in combination with microbubbles. Hence it would become possible 
to image where the drug is located exactly while the imaging modality itself is 
able to trigger drug release from the microbubbles. 
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Drug-loaded microbubbles are promising drug-delivery vehicles, however 
specific issues that will help enabling the translation of these systems into the 
clinic need to be resolved. This thesis generally aims at developing an ideal 
carrier for ultrasound guided drug-delivery, which will help this technique to 
move on from bench to bedside.  
In chapter 1, we highlight the most recent insights in (molecular) cancer 
development, to finally focus on strategies for site-directed cancer therapy and 
more particularly ultrasound assisted drug-delivery with microbubbles. Here, we 
emphasize on the basic aspects of ultrasound physics and its applications in drug-
delivery and finally we describe the most recent advances in the use of 
microbubbles for this application.  
In chapter 2 we describe the development of a safe, stable and easy to produce 
formulation of liposome-loaded microbubbles by simple self-assembly of the 
involved components. We also show that this formulation is able to deliver very 
low doses of the anticancer drug doxorubicin (DOX) into cells efficiently. To 
allow targeting and hence drug-delivery with liposome-loaded microbubbles to 
specific cell types we’ve introduced a targeting moiety to our formulation 
(chapter 3). We show that anti N-cadherin targeted liposome-loaded 
microbubbles allow such cell type specific drug delivery to N-cadherin 
expressing cells in a mixture of 2 different cell types.  
In chapter 4 we compare drug-delivery from liposome-loaded microbubbles in 
function of the type of microbubble shell and in function of the type of liposome 
(thermosensitive or standard) loaded on the surface of the microbubble. We show 
that lipid-shelled microbubbles loaded with thermosensitive drug-filled 
liposomes are most efficient for drug-delivery applications in vitro. Finally, all 
Aim and outline of this thesis 
 
 
22 
 
these newly developed and optimized materials were tested in xenograft tumor 
bearing mice (chapter 5)  
In chapter 6 we elucidate the mechanisms behind sonoporation which allows 
efficient uptake of drugs into cells. Here we investigate the intracellular fate of 
adeno associated virus (AAV) vectors loaded on the surface of the microbubbles 
with confocal scanning laser microscopy. We observe a direct cytoplasmic 
delivery of the loaded AAV vectors which explains a the effects observed in our 
material optimization studies in vitro. 
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Chapter 1 
 
General introduction  
Bart Geers1, Heleen Dewitte1, Stefaan C. De Smedt1 and Ine Lentacker1 
Parts of this chapter have been published in the journal of controlled release, 164, 
2012 p246-255 Crucial factors and emerging concepts in ultrasound-triggered drug-
delivery 
1 laboratory of General Biochemistry and Physical Pharmacy, Harelbekestraat 72, 9000 Ghent, Belgium 
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THE IMPACT OF CANCER ON MODERN SOCIETY 
Next to cardiovascular disorders cancer is the most important cause of death and 
its influence on mortality will inevitably become more and more important in the 
following years as population ages [1-3]. Taking a closer look at the frequency 
different types of cancers occur (table 1), one can observe that hormonal (or 
related) cancers like breast and prostate cancer are the most frequently occurring 
types of cancer. However, other cancers like lung cancer, colorectal cancers or 
pancreatic cancer have a significant impact on mortality as well.  
Because of its devestating impact on mortality and morbidity of the population 
the disease causes a significant economic burden [4] as well. The total cost of 
cancer (in Europe) is estimated at 54 billion Euros per year. 
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Table 1: Total incidence and mortality of the different types of cancers in both sexes in Belgium. 
(Eurostat). 
Type of Cancer Incidence Mortality 
Prostate 9986 1571 
Breast 9691 2421 
Colon and rectum 8039 3109 
Lung 7140 6532 
Bladder 2202 880 
Non-Hodgkin 
lymphoma 
1912 653 
Kidney 1676 603 
Oral cavity and 
pharynx 
1676 538 
Melanoma of skin 1594 293 
Stomach 1476 914 
Leukemia 1447 940 
Corpus uteri 1380 189 
Pancreas 1093 1397 
Esophagus 947 703 
Ovary 929 712 
Multiple myeloma 829 462 
Brain/nervous 
system 
790 614 
Larynx 663 266 
Cervix uteri 663 198 
Thyroid 659 83 
Liver 466 715 
Hodgkin 
lymphoma 
292 74 
Testis 280 11 
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Consequently it is clear that a deepened understanding on the underlying 
pathofysiologic and molecular processes and the development of new and more 
effective therapies should be elaborated in the following years. In the next 
paragraphs we will shortly highlight a) recent insights in cancer development, b) 
the most important therapeutic interventions for cancer treatment c) we will have 
a look at some emerging concepts in cancer treatment with a clear focus on site-
directed image guided drug-delivery) and finally we will look deeper into the 
concept of ultrasound and microbubble assisted drug delivery. 
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CANCER DEVELOPMENT AND ITS MOLECULAR MECHANISMS 
Understanding the complex biomolecular nature of cancer isn’t easy and requires 
insight in different scientific fields. Since life expectancy has changed 
dramatically in the past century the occurrence of this intriguing disease has 
grown. Cancer still remains somehow enigmatic because a lot of scientific 
questions about it remain unsolved. Here, we would like to give a short overview 
of the latest developments made in the understanding of this disease. 
Cancer was essentially described as a malfunctioning of the genetic control 
mechanisms of cell growth and division [5,6]. But thanks to the increased 
technological development a deeper understanding in the basic molecular 
mechanisms has elucidated some of the more important aspects the disease 
especially during the last half of the 1990s. 
Hanahan and Weinberg [7] described the six hallmarks of cancer (or the cancerous 
cell) in their 2002 review on cellular cancer development. According to their work 
a cancer cell or a “cancerous” tissue is characterized by the following hallmarks:  
• Sustaining proliferative cell signaling 
• Evading cell growth suppression 
• Enabling replicative cellular immortality  
• Activating invasion and metastasis 
• Inducing angiogenesis 
• Resisting apoptosis 
These hallmarks not only emphasize that cancer basically is a cellular 
malfunctioning, the hallmarks point out the interaction with the surrounding 
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tissue as well. Inducing angiogenesis for example implies the integration and 
expression of pro-angiogenic factors at the tumor site that are not expressed by 
the tumor cells themselves. Indeed, the idea that a tumor is simply characterized 
by a group of “out of control” cells is slightly old-fashioned. The complex 
interactions of the cancer cell with its (micro) environment is probably more 
important than the deregulated cellular functions of the tumor cells themselves. 
Therefore Hanahan and Weinberg decided to add four extra hallmarks or hallmark 
characteristics in a follow-up review published in 2011 [8], namely: 
• Evasion of immune destruction 
• Deregulating cellular energetics 
• Increased genome instability and mutational burden 
• Inflammatory responses promoting the tumor 
Figure 1 gives an interpretation of these modern insights and summarizes what 
might happen in tumor onset and progression. We hypothesize that normal tissue 
will acquire cancer-cell capacities upon accumulation of genetic instabilities 
inside the tissue. These can be due to aging but toxic stress (e.g.: tobacco smoke), 
environmental factors (e.g.: dioxins, UV-light) or viral infections (human 
papillomavirus (HPV) [9] or human immunodeficiency virus (HIV) [10]) can as 
well induce cells to acquire a cancerous phenotype. The onset and progression of 
cancer can be divided into 2 phases namely: primary tumor formation and 
metastatic disease respectively. 
1st Phase: primary tumor formation 
Typically most tumor cells will first acquire “cellular” hallmark characteristics. 
Tumor suppressor genes will be switched off and oncogenes will become 
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expressed enabling replicative immortality and evading tumor suppression. 
Interestingly the metabolism of the cells changes as well, because of the 
inadequate energy supplies to the cells [11]. 
Not only the tumor cell itself undergoes significant changes, the tumor micro-
environment changes too and plays an active role in the occurrence of neoplasms 
[12-15]. New blood vessels will be formed to supply energy to the energy 
consuming cancer cells [16-19]. An inflammatory response is induced and 
immune cells are attracted to the tumor [20]. This immune response will not 
necessarily lead to the destruction of the tumor. It is observed that tumor cells 
evade this immune response [21] and that the molecular stress provided by this 
response even enhances tumor growth and its instability. The expression of 
matrix-metallo-proteases (MMPs) in tumors for example is significantly 
upregulated in some specific tumors [22]. This indicates indeed that immune 
response (MMP activity is related to the presence of immune cells like 
lymphocytes and neutrophils) has a modulatory effect on the tumor 
microenvironment.  
We would also like to note that very recently, research on primary tumors focuses 
on abnormal cell phenotypes that arise as the tumor develops. Since a tumor is 
basically a hostile environment and tumor cells lack the necessary control 
mechanisms, we can envisage a tumor as a site where forced evolution can take 
place. Tumor cells can for example acquire resistance against anticancer drugs [15] 
[23]. Tumor cells can also adapt to the hostile tumor environment by 
transforming into a “dormant” phenotype. These dormant cancer cells are not 
characterized by expressing cancer cell hallmarks, however these cells can give 
rise to new tumors occurring multiple years after resection of the initial tumor. 
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These cells are often referred to as cancer stem cells (CSCs) [24] and their 
appearance is related to poor outcome and morbidities.  
 
Figure 1: Schematic depiction of the process of tumor growth and cancer development. 
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2nd Phase: metastatic disease 
The 2nd and last stage of cancer development is metastatic disease. Metastases are 
formed by tumor cells that try to escape the hostile tumor environment by 
acquiring an invasive phenotype [25,26]. This results in the appearance of tumor 
cells in the bloodstream (i.e.: circulating tumor cells CTCs). These CTCs can 
accumulate at certain areas where metastatic colonization can occur. Mostly, one 
can observe the appearance of liver, lung or peritoneal metastasis as shown by 
Hess et al. in a review of adenocarcinoma metastases [27]. Metastases can as well 
occur in environments that are “functionally” predetermined as metastatic niches 
like e.g. bone [28,29] and lymph node metastasis [30]. Bone marrow and lymph 
nodes indeed are tissues that are characterized by high concentrations of 
lymphatic cells or that have a lot of cellular activity. As said before these cells and 
their activity can sustain and remodel the cellular micro-environment and can 
hence construct an ideal environment for metastatic colonization. Metastasis is 
the last stage in cancer development and metastatic cancers are characterized by 
their poor outcome.  
CLINICAL CANCER THERAPIES 
Although its impact on mortality is significant, cancer can be cured if detected in 
an early stage of its development. In what follows we will give a short overview 
of the treatment options for cancer. 
Surgical resection 
Surgical resection normally is the first line treatment in tumors that are located in 
accessible tissues (e.g.: colorectal, breast, prostate or lung cancer). This is mostly 
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effective since the diseased tissue will be removed. In order to reduce the risk of 
relapse and metastases chemotherapy can be given as an adjuvant therapy [31]. 
Radiation therapy  
Tumors that are not readily accessible for surgical resection can be treated with 
ionizing radiation. The ionizing radiation will destroy DNA in the radiated zones 
which leads to apoptosis of cancer cells. Despite its tumor killing efficiency there 
are cases reported of accidents with conventional radiotherapy which is a major 
drawback of this technique.  
Chemotherapy 
Chemotherapeutic drugs are used to eradicate remaining tumor cells upon 
surgical resection or as first line treatment in tumors that are not readily 
accessible. These small molecules can be classified according to their molecular 
structure or mode of action. The most frequently used (according to the Belgian 
drug repository/BCFI) are:  
Alkylating agents 
These are molecules containing highly reactive alkyl-groups (like N-mustard 
derivatives or platinum derivatives) that are able to alkylate cellular components 
like DNA. Hereby, cellular control mechanisms and DNA transcription and 
replication become deregulated resulting in apoptosis of the affected cell [35].  
Chemotherapeutic antibiotics  
Some antibiotics (produced by the Streptomyces fungus) do not specifically target 
bacterial biomolecular structures or processes, but interfere with human cellular 
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processes as well. These antibiotics (e.g.: doxorubicin [36]) can be used for the 
treatment of solid (breast, Kaposi’s sarcoma) tumors. 
Antimetabolites  
Antimetabolites are molecules which are structurally similar to components 
involved in (nucleic acid) metabolism (e.g.: 5-fluorouracil) [37]. These molecules 
may become integrated into newly formed nucleotides and hence hamper nucleic 
acid synthesis in dividing cells [38]. 
Topoisomerase inhibitors  
Topoisomerases are enzymes that maintain DNA-topology. Inhibition of these 
enzymes (by specific inhibitors like irinotecan [39]) by specific inhibitors hampers 
DNA supercoiling by these enzymes and hence DNA replication and 
transcription. 
Microtubule inhibitors  
Some molecules like taxanes [40] or vinca-alkaloïds [41,42], inhibit microtubule 
formation upon cell division. Hereby, they are able to block mitosis and induce 
apoptosis in these dividing cells. 
Personalized chemotherapy based on tumor profiling 
An innovative new way of administering anti-cancer drugs is chemotherapy 
based on tumor profiling [43]. Due to recent technological advances it is 
nowadays possible to screen certain tumors for specific biomolecular markers. 
Screening for overexpression of the HER2 (Human Epidermal growth factor 
Receptor 2) protein in breast cancer is a textbook example of this kind of 
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personalized medicine [44]. HER2 is upregulated in some breast cancers and is 
treated by administration of the monoclonal antibody trastuzamab or Herceptin© 
[45-49]. Earlier HER2 overexpression was associated with poor outcome in breast 
cancer. Nowadays and thanks to Herceptin treatment HER2 positive tumors 
indeed show better therapeutic outcome.  
Problems? 
Despite their effectiveness chemotherapeutics still have their limitations and 
adverse effects [50,51]. Most patients suffer from nausea, hair loss or immune 
depression upon chemotherapy or radiation. This is caused by the high doses of 
drug needed to kill adequate amounts of tumor cells and the narrow therapeutic 
index of these drugs.  
As envisioned in figure 2 it would mean a huge breakthrough if one could 
develop a drug or a drug-delivery system that allows efficient treatment of the 
tumor site leaving other tissues unharmed. However, such time and space 
controlled drug-delivery remains a holy grail in medicine. It is the wish of every 
scientist or physician to design or have access to a device that only delivers 
therapeutic molecules at a certain target site (e.g. a tumor) but for the time being 
no such device has made it to the clinic. To design such a “magic bullet”, a 
concept that was first described by Ehrlich in the beginning of the 20th century, 
one needs to develop a drug carrier that responds to a stimulus applied by an 
external force or produced by the target tissue itself. Cancer treatment as well is 
nowadays more focused on a more personalized approach. In this case, every 
tumor will be analyzed in detail before an ideal treatment scheme can be set up. 
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Figure 2: Schematic depiction of (A) the standard approach of chemotherapy and (B) tumor-directed 
drug-delivery. 
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TUMOR-DIRECTED DRUG-DELIVERY WITH NANOMEDICINES 
As explained above, cancer therapy needs more subtle ways of treatment with 
anticancer drugs. Nano-sized drug-containing particles, or nanomedicines, are 
able to specifically accumulate in tumors [52,53]. In the next part of this chapter 
we will shortly highlight some examples of tumor-directed cancer therapy with 
nanomedicines that emerged in the past decades and may become or are being 
used in the clinic. As schematically depicted in figure 3, nanomedicines are (at 
least in one dimension) nanometer-sized particles (1-200 nm) that are filled with 
one or more therapeutic agents [54]. The latter can be a drug, but can as well be 
an imaging contrast agent. Usually nanoparticles are coated with 
polyethylenglycol (PEG) to avoid recognition by the immune system and 
compartments of the reticula endothelial system (RES) [55] and hence reach long 
circulation times (48 h) [56] allowing efficient accumulation of the nanomedicines 
in tumors. 
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Figure 3: Schematic representation of a nanomedicine. 
Macromolecular structures like nanomedicines are able to selectively penetrate 
into the tumor tissue via enhanced permeation and retention (EPR) as 
schematically depicted in figure 4. Maeda et al. [57-59] first described this concept 
more than 20 years ago and it remains up to now an important paradigm in 
tumor-directed drug-delivery. Basically, EPR is based upon the fact that tumor 
vascularization is leaky and disorganized. Not only the leaky nature of the 
neovascularization in the tumor can stimulate tumor accumulation of 
nanomedicines, but they can also have a targeting moiety incorporated [60]. 
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Attaching such targeting moieties to a nanoparticle not only allows accumulation 
of nanomedicines in the blood vessel (due to upregulated of expression of e.g. 
VEGFR, but may also allow tumor cell specific accumulation of these particles in 
the stroma of the tumor by targeting overexpressed folate receptors on tumor 
cells for example [61-63]. Nanoparticles can also be made sensitive to an external 
trigger (as explained below); such a trigger allows localized delivery of the 
therapeutic or diagnostic agent incorporated in the nanoparticle. 
 
Figure 4: Schematic representation of the wide potential of delivery of therapeutic molecules with 
(targeted) nanomedicines. 
Liposomes  
The archetypal nanomedicine is a drug-filled liposome. Liposomes are 
nanoparticles that are confined by a phospholipid double membrane [64] as 
depicted in figure 5. Hence liposomes can be regarded as small containers with an 
intraliposomal space where a therapeutic moiety can be stored in without being 
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affected by blood components. The incorporation of cationic phospholipids may 
allow complexation of nucleic acids like pDNA, siRNA or mRNA, this type of 
complexes are called lipoplexes [65,66]. Liposomes can also be loaded with a drug 
by incorporation of a complexation buffer (e.g.: ammonium sulfate) in the 
intraliposomal space, amphiphilic drugs like doxorubicin can hence be loaded 
into liposomes with high efficiency [67]. 
 
Figure 5: Schematic depiction of the structure of a liposome.  
(Nano)theranostics 
Every tumor is different; therefore it is important to evaluate tumor 
characteristics with a medical imaging modality. Magnetic Resonance imaging 
(MRI) [68,69] and functional positron emission tomography (PET) [70] are very 
useful tools for this purpose. MRI shows high spatial resolution and anatomic 
detail, where PET can provide sensitive molecular detection of small tumor 
volumes using contrast agents like F18-FDG (fluorodeoxyglucose) [71]. Imaging 
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hence provides essential information on tumor size, metabolic status and off 
course therapeutic evolution for a specific patient [72].  
Coupling an imaging modality to a nano-sized drug-delivery vehicle would allow 
direct and personalized information on the process of drug-delivery (i.e.: 
theranostics). Theranostics is an emerging field that focuses on the combination of 
therapy with diagnostics via medical imaging techniques (e.g.: MRI, ultrasound) 
[73,74]. It involves the use of agents that are able a) to visualize a specific 
pathological process and b) simultaneously deliver a drug at this site. Kiessling et 
al [75] reported recently on the current status of different preclinical and clinical 
theranostic applications. It would be a breakthrough if one could design a drug-
loaded (nano)particle which specifically detects pathophysiological processes like 
cancer and which delivers its drug at the site where a diagnostic signal is 
observed. De Smet et al. [76] described a thermosensitive nanoparticle (liposome) 
that contained both a drug and a MRI contrast agent. This contrast agent however 
will only give a significant MR relaxation signal upon release of the drug out of 
the liposome [77], due to thermally induced liposomal membrane destabilization. 
De Smet et al. show a correlation between drug release and contrast agent release. 
This kind of approach indeed can provide patient specific information during the 
administration of the drug thanks to an integrated approach that is “image 
guided”. 
Drug-delivery triggered by an external stimulus 
Different external stimuli such as electromagnetic waves (IR, UV of visible light) 
or magnetic and electrochemical forces can be used to trigger drug release form 
nanoparticles at the tumor site only, as reviewed by Timko et al [78]. As explained 
in the previous section one can locally increase the temperature inside a tumor, 
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hence temperature sensitive particles that are loaded with a chemotherapeutic 
will only release their content in areas where the temperature is increased. This 
temperature increase can be monitored by MR thermometry since hyperthermia 
is only allowed up to 42°C. Recently, shear stress has been described as an 
external trigger for drug-release from nanoparticles as well [79]. Such 
nanoparticles may be useful in tissues/tumors where blood vessels are obstructed. 
Not only temperature can be used as an external trigger to induce drug release, 
pressure can be used as an external trigger as well and an interesting source of 
pressure can be ultrasound. This thesis will further explore the use of these 
systems as drug-delivery agents and more specifically their use for small 
molecule delivery. 
ULTRASOUND-TRIGGERED DRUG-DELIVERY 
Ultrasound  
Sound is a longitudinal pressure wave, when the frequency of this wave exceeds 
20 kHz, which is the typical human audible range, it is called ultrasound [80]. 
Ultrasound waves are generated by transducers which are piëzo-electric crystals 
producing elastic vibrations upon electrical stimulation. Basically, an ultrasound 
wave is characterized by alternating regions of high and low pressure, as shown 
in figure 6, and is usually transmitted in pulses (i.e. a defined number of cycles) 
with a certain frequency, amplitude and wavelength (defined in table 2). 
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Table 2: parameters characterizing the ultrasonic wave. 
 
Frequency f Number of pressure cycles per sec 
(Hz) 
Wavelength λ Time between two equivalent 
points in the waveform 
Amplitude A Interval between both peak 
pressures (peak positive 
pressure (PPP) and peak 
negative pressure (PNP))  
 
 
 
 
Figure 6: Schematic representation of an ultrasound wave. 
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Imaging 
Ultrasounds most well-known application is medical imaging (e.g. echography). 
Ultrasound Imaging is based on the fact that an ultrasound wave becomes 
reflected by tissues with an acoustic impedance different from the surrounding 
medium [82]. This “scattered” ultrasound signal or “echo” can be received by the 
ultrasound transducer which can transform this received signal into an electrical 
signal. By measuring the time, amplitude and frequency interval between the 
outgoing pulse and the incoming scattered pulse one is able to build up an 
ultrasound image. 
Ultrasound contrast imaging 
Gramiak et al. [90] discovered in 1968 that the injection of agitated saline enhanced 
ultrasound echo contrast in the aortic root. The reason for this enhanced contrast 
was the presence of small gas bubbles due to agitation of the saline. This concept 
was further developed and resulted in the birth of imaging with ultrasound 
contrast agents (UCA’s) or microbubbles. Ultrasound contrast imaging is based 
upon the fact that these compressible gas bubbles start to oscillate under influence 
of the ultrasonic pressure field (as explained below). Figure 7 gives an example of 
an ultrasound image of the same tumor obtained by “standard” ultrasound 
imaging and by ultrasound contrast imaging. This example indicates clearly, that 
standard imaging is more suitable for determining tissue delineation, there where 
contrast enhanced images show the internal blood flow in the tissue. 
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Figure 7: Example of an ultrasound image of a tumor with “standard” ultrasound imaging and 
contrast enhanced ultrasound imaging. 
Biomedical and therapeutic applications of ultrasound 
Ultrasound can be used in both diagnostic (ultrasound imaging) and therapeutic 
applications. The type of ultrasound used in these applications largely depends 
on the mechanical power of the ultrasound wave. This mechanical power is 
defined by the mechanical index (MI) and depends on frequency and pressure 
amplitude of the ultrasound pulse [81]. 
𝑀𝑀𝑀𝑀 =  𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑁𝑁𝑃𝑃𝑁𝑁𝑃𝑃𝑁𝑁𝑁𝑁𝑁𝑁𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
�𝑓𝑓𝑃𝑃𝑃𝑃𝑓𝑓𝑃𝑃𝑃𝑃𝑓𝑓𝑓𝑓𝑓𝑓
 
As shown in figure 8 biomedical applications of ultrasound can be classified into 
3 categories based upon the ultrasound frequency and hence MI used. A) high 
frequency (>3 MHz) ultrasound is usually used in diagnostic imaging (low MI) or 
therapeutic application using high acoustic pressures; b) In drug-delivery with 
ultrasound contrast agents and ultrasound contrast imaging usually frequencies 
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around 1 MHz are used and finally c) low frequency ultrasound is used in 
therapeutic applications using destructive shock waves. 
 
Figure 8: Ultrasound applications in function of frequency. 
The higher the mechanical index, the more likely it becomes that ultrasound 
induces bio-effects in the affected tissue [83,84], which can be used therapeutically. 
Ultrasound energy can be absorbed by the tissue, which leads to heat formation 
[85]. For this purpose, high frequency ultrasound characterized by high acoustic 
pressures can be used to cause localized overheating and hence mechanical 
killing of cells without any surgery. Therefore, ultrasound needs to be focused 
into a small volume which causes strong mechanical (heating) effects in the focus 
of the ultrasound beam leaving other tissues unharmed. This technique is called 
high intensity focused ultrasound (HIFU) [86,87] and is used clinically for tumor 
ablation. As shown above low frequency ultrasound can be used for therapeutic 
application as well. Low frequency ultrasound produces high MI shock waves 
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that can dissolve bile or kidney stones [88] (e.g.: Lithotripsy). These high MI 
shock waves can be used to destroy drug-loaded  liposomes as well [89].  
Ultrasound contrast agents (microbubbles) 
As shown in figure 9, microbubbles are micron sized (1-10µm) gas bubbles 
(microbubbles) stabilized by a shell. An overview of commercially available 
products is given in table 3. 
 
Figure 9: Schematic representation of an ultrasound contrast agent (UCA) or “microbubble”. 
Gas bubbles are essentially instable and without an appropriate coat they will 
immediately dissolve. The latter is a consequence of the surface tension between 
the gas-liquid interfaces. Surface tension (σ) results in an increased pressure at the 
concave sides of the microbubble and this ΔP (difference in hydrostatic pressure 
between the inside and the outside of the microbubble (with radius r)) is given by 
the Laplace equation.  
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(Laplace equation) ΔP = 2𝜎𝜎
𝑃𝑃
 
This equation indeed tells us that in case of a relatively small microbubble (2 µm); 
an internal overpressure will exist unless one is able to decrease the surface 
tension. Indeed, as shown in table 3, most commercially available microbubbles 
do have a surfactant shell (albumin/phospholipid) and contain a hydrophobic gas 
that does not directly dissolve in the blood compartment. Both albumin and 
phospholipids have the advantage that these materials can spontaneously adsorb 
to newly formed hydrophobic gas bubbles, moreover these materials are elastic 
and withstand differences in pressure and hence are well suited for application as 
UCA’s [91]. Polymeric shells (cross-linked albumin, poly-L-lactic acid (PLLA)) are 
stiffer and their response to ultrasound is more difficult to model [92]. 
Table 3: Overview of commercially available UCA’s. 
Name Manufacturer Year Gas Coating Approved  Available 
Optison GE healthcare 1997 C3F8 Human 
albumin 
EU/USA EU/USA 
Sonovue Bracco 2001 SF6 Phospholipids EU, China, 
Korea, 
India, 
Hong 
Kong, 
Singapore 
EU, China, 
Korea, 
India, 
Hong 
Kong, 
Singapore 
Definity Lantheus 2001 C3F8 Phospholipids Worldwide Worldwide 
Sonazoid Amersham 2006 C4F10 Phospholipids Japan Japan 
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Biophysical aspects of microbubbles 
Microbubbles are suitable contrast agents because of their interaction with the 
ultrasound wave [93]. As schematically depicted in figure 10, the highly 
compressible microbubble will start to oscillate in response to the exerted cycles 
of positive and negative pressure. These oscillations itself produce ultrasonic 
signals that can be detected by the ultrasound transducer. Increased pressure will 
compress the microbubbles while negative pressure will induce rarefaction of the 
bubbles. This process, called cavitation, has been investigated in detail by Bouakaz, 
Versluis and de Jong [94] using high speed light microscopy. Driven at a pressure 
of at least tens of kilopascals it is observed that microbubble oscillations contain a 
wide range of frequency components [95,96]. Hence the echoes resulting from 
microbubble oscillation contain components that can be used for “microbubble-
specific” imaging; hence it is indeed possible to observe single microbubbles in 
ultrasound contrast imaging. Cavitation at higher acoustical pressures will induce 
more violent microbubble oscillations, eventually resulting in microbubble 
destruction (so called ‘inertial cavitation’) [97]. Microbubble destruction can result 
in fragmentation of the microbubbles and/or in the dissolution of the 
encapsulated gas [98]. Inertial cavitation can be useful in imaging, this to evaluate 
blood flow abnormalities by means of destruction replenishment imaging [99].  
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Figure 10: Schematic of the behavior of a microbubble during ultrasound application. 
Microbubbles and ultrasonic drug-delivery 
The use of microbubbles for drug-delivery has drew attention to the scientific 
community when Unger et al. [100] reported on this type of drug-delivery in the 
late 1990s. Basically drug-delivery with microbubbles is based on inertial 
cavitation of the microbubble at high acoustic pressures which, as described 
earlier, results in the destruction or fragmentation of the microbubble. If a drug is 
located in the vicinity of a microbubble or is associated with it, a high pressure 
ultrasound wave can trigger a) release of drugs from the microbubbles and/or b) 
uptake of drugs into cells or tissues. Drug-associated microbubbles can be 
visualized with ultrasound imaging as well, hence enabling image-guided drug-
delivery. 
Having a closer look at the basic mechanisms behind ultrasonic drug-delivery 
with microbubbles one can easily envision that the ultrasound wave itself will 
General Introduction 1 
 
50 
 
play a major role in this process. An ultrasound wave basically has 3 
characteristics that may play a role in ultrasonic drug-delivery with microbubbles: 
a) the number of cycles per ultrasound pulse, b) the peak negative pressure and c) 
the frequency. In most ultrasonic drug-delivery related reports ultrasound waves 
with a frequency of around 1 MHz are used, the major reason being that the 
frequency which allows the microbubbles to respond upon ultrasound exposure 
indeed depends on the size of the bubbles which, in most studies, is between 1 
and 3 µm. Peak negative pressure will define the type of microbubble cavitation 
(stable or inertial cavitation) as this pressure defines the mechanical index of the 
ultrasound wave.  
If one compares ultrasound settings used in different studies where microbubbles 
are used for drug-delivery, the number of acoustic cycles (i.e.  the number of 
acoustic oscillations per ultrasound pulse) applied to the samples differs 
significantly. As shown by Mannaris et al. [101], bubbles can oscillate at lower 
pressures when up to 100 cycles are used. However, when more cycles are 
applied combined with higher pressures, the bubbles become instantaneously 
destroyed. Subsequently, under such conditions one does no longer study 
microbubble related effects on drug-delivery but rather effects from ultrasound 
forces. These forces may play an important role in in vivo drug and gene delivery, 
although this still has not been investigated in detail. Studies on ultrasonic drug-
delivery were indeed performed, reporting the use of 10000 cycles and high 
acoustic pressure [102]. This study clearly shows these settings do have an effect 
on drug-delivery and the effects generated will not be caused by imploding 
microbubbles. 
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Sonoporation 
Cell membranes can become temporarily permeablized (so-called sonoporation) 
due to the localized mechanical effects related to microbubble implosion [103]. 
This process is believed to be an important driving force for drug-delivery with 
ultrasound and microbubbles. Different mechanisms of sonoporation are 
described in literature. 
Membrane poration enabling direct cytoplasmic entry of molecules 
At higher acoustic pressures (above a threshold of approximately 500 kPa [104]), 
the microbubbles will highly likely show inertial cavitation. This may result in the 
formation of shock waves and micro-jets directed towards the cell membranes 
[105-107]. Microjets are directed towards the cell surface because the hydrostatic 
pressure of the fluid surrounding the bubble will be stronger at the side of the 
microbubble opposite from the membrane (as shown in figure 11). These 
mechanical effects will induce shear stress on the cell membranes which may 
become locally and temporarily perforated. Different studies report that such 
effects may indeed porate cell membranes [104,108-110] and may facilitate the 
delivery of nanoparticles into the cytoplasm of cells [111,112]. 
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Stimulation of endocytosis 
 In other studies lower acoustic pressures are used. Under these conditions, the 
bubble will “gently” oscillate and disturb its surroundings. If a microbubble is 
located near the cell membrane, these gentle oscillations may induce cell 
membrane instabilities which may stimulate endocytosis [104,113]. 
Temporal window upon sonoporation and two-step delivery protocols 
Several research groups have demonstrated the existence of cell membrane pores 
upon applying ultrasound lasting in the order of seconds to minutes [110,114-116]. 
However, Yudina and colleagues recently claimed pore opening lasting up to 24h 
[117]. This was evidenced by evaluating the uptake of the small molecule Sytox 
Green as a function of time in sonoporated glioma cells. Although a further 
confirmation of the observations of Yudina et al. would be useful, these findings 
open up new perspectives for ultrasonic drug-delivery. 
The same group also proposed a two-step delivery protocol combining the 
benefits of temperature sensitive liposomes (being liposomes that release their 
content at temperatures around 41°C) and sonoporation [118]. A proof of concept 
paper was published using TO-PRO-3 loaded thermosensitive liposomes and 
diagnostic microbubbles. Upon heating by high intensity focused ultrasound 
(HIFU), TO-PRO-3 became released from the temperature sensitive liposomes 
while the membrane permeabilization promoted the uptake of TO-PRO-3 in the 
cancer cells. Based upon their findings that drug uptake can last for several hours 
after sonoporation, the authors also suggested it could be even more 
advantageous first to sonoporate the tissue (taking advantage of the temporal 
window), followed by different applications of the nanoparticles. 
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Figure 11: Bio-effects caused by microbubble implosion. 
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ADVANCES IN MICROBUBBLE DESIGN 
As schematically represented in figure 12, four types of ‘microbubble 
modficiations’ have been reported so far for ultrasonic drug-delivery: a) drug-
loaded microbubbles; b) in situ formed microbubbles or nanodroplets; c) 
acoustically active liposomes (sometimes called ‘nanobubbles’) and d) targeted 
microbubbles.  
 
Figure 12: Schematic overview of microbubble modifications reported for ultrasonic drug-delivery. (A) 
envisions drug-loaded microbubbles releasing their associated payload upon insonation, (B) shows 
nanodroplets that are able to extravasate due to Enhanced Permeation and Retention (EPR) and form 
microbubbles after phase transition in situ, (C) depicts nano-sized acoustically active lipospheres in 
tumor tissue and finally (D) shows microbubbles associated with a targeting moiety that adhere to 
target molecules in tissue expressing pathophysiologic epitopes. 
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Drug-loaded microbubbles  
Since the 90s a number of research groups have attempted to design 
microbubbles which can carry a therapeutic payload. As shown in figure 13 drug-
delivery from microbubbles by ultrasound is an attractive concept for various 
reasons; a) using low acoustic pressures the drug-loaded microbubbles can be 
visualized, being attractive for ‘image guided drug-delivery’; b) many drugs, 
especially biological drugs like nucleic acids and proteins need to be protected 
from degradation upon administration, which can be accomplished by 
formulating them associated with microbubbles; c) the loading of the drugs into 
microbubbles can also prevent their uptake in untreated tissue (i.e. tissue that is 
not exposed to ultrasound) and thus reduce side-effects; d) upon applying 
ultrasound, both local drug release and cell membrane permeabilization 
(sonoporation) can occur. 
 
Figure 13: Schematic overview of the wide potential of drug-loaded microbubbles. 
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Figure 14 shows the most important strategies of drug loading in microbubbles. A 
straightforward strategy to load the microbubbles with drugs is associating them 
with the shell or more particularly with its building blocks. Another way of 
loading is by encapsulating the drug into an oil reservoir present in the core of the 
microbubble. Finally, drugs can also be packed into nanoparticles that are 
subsequently attached to the microbubble’s surface. The following section gives 
an update on the recent progress in the design of drug-loaded microbubbles. For 
a complete overview on drug-loaded microbubbles we refer to Lentacker et al. and 
Tinkov et al. [119,120]. 
 
Figure 14: Schematic overview of the most important ways of drug loading into a microbubble. 
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Loading through electrostatic binding 
A first strategy to attach therapeutics to the microbubble shell is through 
electrostatic interactions, initially explored to load microbubbles with pDNA. As 
an example, Frenkel et al. [121] used albumin-shelled microbubbles as a template 
for pDNA attachment. A layer-by-layer approach can be used to alternately 
deposit cationic polymers and anionic nucleic acids   on the microbubble shell, 
which clearly improves the electrostatic loading of the microbubbles with nucleic 
acids [122]. Sirsi et al. [123] recently reported on lipid-shelled microbubbles that 
were covalently coated with PolyEthyleneGlycol-PolyEthyleneImine (PEG-PEI) 
copolymers. followed by the electrostatic deposition of pDNA onto such 
cationically charged microbubbles. Ultrasound induced gene expression in tumor 
tissue was clearly observed, being significantly higher than the gene expression in 
control samples being untreated tumors. Similar results were obtained with 
plasmid conjugated microbubbles, that showed a significant increase in gene 
transfection in smooth muscle cells as well [124]. 
Tinkov et al. [125] described an attractive method to complex Doxorubicin (DOX) 
onto microbubbles using electrostatic interactions. They prepared an anionic 
microbubble by incorporating an anionic phospholipid 1,2-dipalmitoyl-sn-
glycero-3-phospho-1'-rac-glycerol (DPPG) in the shell which can form a complex 
with the cationic glycane-group in the DOX molecule. This method showed 
efficient incorporation of DOX into the microbubbles’ shell (up to 40 µg DOX per 
ml microbubble dispersion); tumor cell destruction was obtained after injection of 
these bubbles in rats bearing pancreatic tumors and exposure of the tumor to 
ultrasound. The same strategy was recently used by Ting et al. [126] to prepare 
1,3-bis(chloroethyl)-1-nitrosurea (BCNU) loaded microbubbles. Focused 
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ultrasound was used to locally implode BCNU carrying microbubbles at the 
blood brain barrier (BBB) of rats. This resulted in a significantly higher uptake of 
BCNU in glioma tumors implanted in the rats and a slower tumor progression 
when compared to BBB disruption with microbubbles and ultrasound co-
administered with BCNU.  
A serious drawback of electrostatic drug loading of microbubbles could be 
premature release of the drug in the body. Indeed, once injected in the 
bloodstream charged blood components like serum albumin can compete or 
interact with the charged microbubble shell. This can result in a release of the 
attached drug or in the formation of large aggregates which can block the 
vasculature [127]. Sirsi and colleagues also showed that charged microbubbles 
can influence circulation times by adhering nonspecifically to the vasculature 
close to the injection place. This can have a significant impact on the amount of 
microbubbles reaching the target tissue.  
Drug reservoirs 
As an alternative, some research groups have tried to create a drug reservoir 
inside the microbubble. One example is the use of double emulsion techniques to 
obtain polymer coated oil–filled microcapsules [128]. Another technique, as 
described by Tartis et al. [129], involves the incorporation of a drug-containing oil-
phase within lipid-coated microbubbles. These oil filled microbubbles retain their 
responsiveness to ultrasound and can be destructed at higher ultrasound 
intensities thereby releasing their content. The fact that only lipid-soluble drugs 
can be incorporated however, limits the use of such systems.  
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Another, more versatile method to prepare drug-loaded microbubbles, is the 
attachment of multiple drug reservoirs (i.e. drug-loaded nanoparticles) to the 
microbubbles’ surface. The major benefit of this concept is that it creates a higher 
drug loading capacity, as plenty of small drug-filled pods are attached to the 
surface. Another advantage is that different types of therapeutics can become 
stored in microbubbles. Liposomes, for example, can be loaded with both 
hydrophilic and hydrophobic drugs and can carry larger molecules like pDNA, 
siRNA or mRNA [130]. Biotinylated lipid coated bubbles can be easily prepared 
by introducing a phospholipid containing a PEG-biotin group into the 
microbubble shell. Such biotin containing bubbles can be incubated with avidin, 
enabling the subsequent attachment of biotinylated (drug containing) 
nanoparticles. Our group showed that this concept can be used to enhance the 
uptake and therapeutic efficiency of both small (DOX) [131] and high molecular 
weight drugs (pDNA, siRNA, mRNA) [112,132,133].  
Ultrasound responsive liposomes (nanobubbles) 
A major disadvantage of microbubbles as drug carriers is their relatively large 
size (1-6µm). Due to this feature, microbubbles have a rather short half-life, i.e. in 
the order of minutes [130,134]. Upon injection such microbubbles will circulate a 
few times, but will inevitably get stuck in the lungs where gas exchange occurs. 
Consequently, microbubble-ultrasound triggered drug-delivery will be mainly 
restricted to cardiovascular targets and to tumor endothelia. 
 To solve this problem, several papers report on so-called nanobubbles [135,136], 
also called ‘bubble liposomes’ [137], which are smaller than 1 µm, combining the 
benefits of a liposome (small size, long circulation time) with ultrasound 
responsiveness. These small bubbles are generally prepared by sonicating 
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liposomes in the presence of fluorinated gases. With these nanobubbles successful 
delivery of pDNA, siRNA and coumarin [138] has been demonstrated both in in 
vitro and in vivo models.  
In situ generation of microbubbles from nanodroplets 
A very intelligent suggestion for circumventing the short half-life of drug-loaded 
microbubbles is the design of nanoscopic droplets based on perfluorocarbons 
with a relatively low boiling point (e.g. perfluoropentane or perfluorohexane). 
These so-called ‘nanodroplets’ can convert into their gaseous form upon 
ultrasound exposure. The advantage of the use of liquid perfluorocarbons  is that 
they can be emulsified in water when stabilized by an appropriate surfactant (e.g. 
pluronic, lipids) [139-141]. Such nanodroplets are typically smaller than 200nm, 
which allows them to extravasate from the leaky tumor vasculature. [142]. When 
the tumor tissue is subsequently treated with ultrasound, a liquid to gas phase 
transition occurs due to a local temperature increase in combination with the low 
pressure phase generated by the ultrasound [143]. As a consequence,  ultrasound 
responsive microbubbles are formed in situ. 
Alternatively, perfluorocarbons with a low boiling point can be encapsulated in 
inorganic mesoporous silica-nanoparticles which can incorporate various types of 
drugs as well [144][145]. Perfluorocarbon-drug-loaded silica-nanoparticles may 
well provide a solution for the different challenges we are facing with regard to 
drug-loaded ultrasound contrast agents, namely sufficient extravasation in tissues 
and high loading of (multiple) compounds. 
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Targeted microbubbles for drug-delivery 
Recently there is growing interest in the use of ‘targeted microbubbles’ for 
diagnostic molecular imaging. Such microbubbles should be able to interact with 
molecules that become expressed in specific pathologies. In this case antibodies 
[146] or even nanobodies [147] are coupled to the surface of the bubbles, typically 
through avidin-biotin coupling [148]. Aptamers, nucleic acids that show affinity 
for specific molecules, can be used as targeting moieties as well [149]. Aptamer-
loaded nanobubbles [150] have been described and show potential for targeting 
specific cell types. Clearly, targeted microbubbles can be of interest for drug-
delivery as well as the amount of drug closely located near the target tissue may 
become enhanced [151].  
Therapeutic moieties benefiting from ultrasound-triggered delivery 
 The therapeutic moieties reported in the context of ultrasonic delivery can be 
divided in three different groups (Figure 15): a) low molecular weight drugs like 
some anticancer drugs, b) large biomolecules like genetic drugs and proteins and, 
finally, c) drugs encapsulated in nanoparticles.  
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Figure 15: Schematic representation of different therapeutic moieties which can be delivered using 
microbubbles and ultrasound.  
Depending on its characteristics a drug can benefit from ultrasound triggered 
drug-delivery differently, as ultrasound and microbubbles will either enhance the 
uptake of a molecule or particle that shows limited uptake or it will localize their 
bioavailability. 
Small therapeutic molecules 
The “small therapeutics” used in ultrasonic drug-delivery studies are mostly 
antineoplastic drugs like DOX or Paclitaxel. Upon injection such low molecular 
weight drugs will distribute throughout the body and easily accumulate in 
different cell types, causing cytotoxic (side) effects. The most important reason 
why these drugs would benefit from ultrasonic drug-delivery is the fact that drug 
uptake would become limited to the ultrasound treated tissue. A more efficient 
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localized delivery to the tumor can substantially reduce the required dose and 
lower side effects.  
Large therapeutic molecules 
Large molecules like nucleic acids (pDNA, siRNA, mRNA) and proteins are 
under investigation for ultrasonic delivery as well. Unlike small molecules these 
macromolecules show inefficient uptake in target tissues. As Figure 15 envisions, 
ultrasound mediated microbubble destruction can be used to locally permeablize 
cell membranes which should enhance the uptake of large molecules. 
 The most important studies report on the delivery of genes into cells, in vitro 
and/or in vivo. Most studies involve pDNA, associated with a microbubble [152] 
or co-administered [153,154] with them. Due to its negative electrostatic loading 
pDNA will not penetrate into cells, but if it is located near a microbubble 
imploding in the vicinity of a cell it may profit from the temporal permeablization 
of the cell membrane (sonoporation) [116].  
Drugs encapsulated in nanoparticles  
Not only single molecules can benefit from ultrasonic delivery. Several 
publications have shown that microbubbles and ultrasound can be used to 
improve the extravasation of a variety of nanoparticles that can be loaded with a 
drug or have a therapeutic effect themselves. PLGA nanoparticles [155], magnetic 
nanoparticles [156], liposomes and lipoplexes [157], gold nanoparticles and silica 
nanoparticles [158] were used in combination with microbubbles and ultrasound. 
Through encapsulating the drug molecules in nanoscopic particles they become 
well protected against degradation, which is a major challenge, especially for 
biological drugs. 
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Preclinical evidence 
Searching for in vivo evidence for ultrasonic drug-delivery with microbubbles, a 
difference is observed between the number of studies reporting the co-
administration approach (i.e. the co-administration of drugs and microbubbles), 
and the number of reports in which drug-loaded microbubbles are studied. 
There is clear preclinical evidence available in literature with regard to the co-
administration approach. Many studies, as e.g. performed by Hynynen, 
McDannold and co-workers, show enhanced drug-delivery after injection of 
diagnostic microbubbles (Sonovue® or Definity®) and applying ultrasound 
allowing bubbles to implode at the target site. For example, enhanced drug [159] 
or Magnetic Resonance (MR) contrast-agent [160] delivery into the brain of rats 
has been shown. In these brain delivery studies, a transient disruption of the 
Blood Brain Barrier (BBB), induced by microbubble implosion has been reported. 
An enhanced delivery of Evans blue in muscles [161] has been shown as well 
following the co-administration approach. The progress in this particular field 
has been reviewed by Vykhodtseva et al.[162].  
The number of in vivo studies with drug-loaded microbubbles is rather limited, is 
probably due to the fact that ‘loading microbubbles with drugs’ is a recent 
strategy in ultrasonic drug-delivery. Indeed, while in co-administration approved 
commercial (clinically used) microbubbles can be used, custom-made (still often 
poorly characterized) drug-loaded microbubbles need to be designed. Rapoport et 
al. showed reduced tumor growth with Paclitaxel-loaded nanodroplets [163]. 
Tinkov [164] showed enhanced DOX-uptake in tumors with DOX-loaded 
microbubbles. Acoustically active pDNA bubble liposomes resulted in enhanced 
gene transfection in the mouse abdomen [165]. Finally, Müller et al. [166] reported 
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an improved gene transduction in the heart of rats using microbubbles with 
adeno-associated viral vectors electrostatically attached to the surface of the 
bubbles.  
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Liposome-loaded microbubbles have been recently introduced as a 
promising drug delivery platform for ultrasound guided drug delivery. 
In this paper we design liposome-loaded (lipid-shelled) microbubbles 
through the simple self-assembly of the involved compounds in a single 
step process. We thoroughly characterized the liposome-loading of the 
microbubbles and evaluated the cell killing efficiency of this material 
using doxorubicin (DOX) as a model drug. Importantly, we observed 
that the DOX liposome-loaded microbubbles allowed killing of 
melanoma cells even at very low doses of DOX. These findings clearly 
prove the potential of liposome-loaded microbubbles for ultrasound 
targeted drug delivery to cancer tissues. 
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INTRODUCTION  
Microbubbles are gas filled microspheres that are a few microns in size, are 
usually filled with an hydrophobic gas and are stabilized by a surfactant (lipid, 
protein or polymer) shell, to enhance their shelf life and circulation time in blood 
after injection. Because of the difference in density between the gas core of the 
microbubble and the surrounding fluid, microbubbles start to oscillate when 
subjected to high frequency (1-10 MHz) ultrasound. This “cavitation” of 
microbubbles has been intensively studied by means of high speed optical 
imaging [1-3] and can be divided into respectively stable and inertial cavitation. 
In an ultrasound field with a low acoustical pressure microbubbles are stably 
cavitating and will oscillate around a given diameter. Inertial cavitation on the 
other hand occurs at higher acoustical pressures, the movement of the 
microbubbles becomes more violent which leads to destruction of the 
microbubbles [4]. This microbubble destruction produces distinct nonlinear 
acoustic echoes which are very useful in contrast enhanced ultrasound imaging 
[5]. Cavitation of microbubbles may also induce biological and mechanical effects 
on the surrounding space which may be particularly useful for drug delivery [6]. 
When microbubble collapse occurs in the vicinity of cells it has been shown that 
plasma membranes are temporarily permeabilized through the formation of 
transient pores in the cellular membrane, induced by micro-jets and shockwaves 
produced after microbubble collapse [3,7]. This phenomenon is called 
sonoporation [6]. It is believed that sonoporation is strongly dependent on the 
acoustical properties of the applied ultrasound field [8,9]. Such transient pores 
also enhance the uptake of macromolecules in cells [10]. Recent studies show that 
sonoporation effects may last up to 24 hours after ultrasound treatment [11]. The 
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use of microbubbles in combination with ultrasound may even induce openings 
in the blood-brain barrier which could be of interest to tackle drug delivery into 
the brain which currently remains a huge challenge [12,13]. 
Only if the drug molecules are physically located in the vicinity of microbubbles 
subjected to ultrasound, it is expected that sonoporation will enhance drug 
uptake by cells. Moreover, as these effects will only occur where and when 
ultrasound is applied, drug delivery is expected only to happen in the insonated 
tissue. Hence, for ultrasound targeted drug delivery it is crucial to design 
microbubbles which can be loaded with drug molecules. Meanwhile a number of 
concepts for drug loaded microbubbles are under investigation [14-16]. Basically, 
microbubbles can be loaded with drugs in three ways: (a) the drug can be 
incorporated in the microbubble shell [17], (b) (lipophilic) drugs can be 
incorporated in an inner oil phase present in the microbubbles [18] or (c) 
“colloidally drug loaded microbubbles” can be obtained through the attachement 
of drug containing nanoparticles (like e.g. liposomes) on the microbubbles’ 
surface as reviewed by Bohmer et al. and Lentacker et al. [19,20]. Independent on 
the way the microbubbles become loaded with drugs, they should fulfill at least 
the following requirements: (a) the microbubbles should be loaded with a 
sufficient amount of drug; (b) the shelf-life of the drug-loaded microbubbles 
should be long enough and (c) the drug-loaded microbubbles should be designed 
without the incorporation of toxic or immunogenic substances. We believe that 
loading the surface of microbubbles with drug containing liposomes is a 
promising concept for ultrasound guided drug delivery as: (a) more drugs can be 
loaded on microbubbles compared with other loading strategies, (b) a plethora of 
knowledge is available on liposomes for drug delivery which can be perfectly 
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used to develop the colloidally loaded microbubble concept and (c) importantly, 
certain liposomes are safe and even already used in clinical practice. 
Recently doxorubicin (DOX)-liposome loaded microbubbles [21] and lipoplex-
loaded microbubbles (containing pDNA or siRNA) could be designed and it was 
found that in combination with ultrasound, such microbubbles strongly 
improved both doxorubicin (DOX) cytotoxicity and pDNA [16,22] and siRNA [23] 
delivery to cells in vitro. However, the complex microbubble preparation method, 
the immunogenic nature of avidin-biotin chemistry used to link the 
liposomes/lipoplexes to the microbubbles and the successive washing steps, made 
these materials not ideal for easy clinical use. It is clear that the concept of 
liposome-/lipoplex-loaded microbubbles needs further development and 
improvement. In this work we faced the challenge to design DOX-liposome 
loaded lipid shelled microbubbles through the self-assembly of the involved 
compounds. Importantly, the method we propose involves just a single step and 
allows to make a sterile material. As illustrated in Figure 1 and further explained 
in the results section, to a mixture of phospholipids, so named “functionalized 
DOX-liposomes” (i.e. DOX-liposomes containing maleimide functionalized PEG-
lipids) and a hydrophobic gas were added. We show that under appropriate 
conditions these compounds self-assemble into DOX-liposome loaded 
microbubbles which are responsive to ultrasound and efficiently kill cells.  
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Figure 1: Schematic depiction of the preparation of liposome-loaded through self-assembly of the 
different constituents: Drug loaded liposomes containing DSPE-PEG-maleimide and perfluorobutane 
(C4F10) gas were added to vials containing: DPPC and DSPE-PEG-SPDP dissolved in a 
glycerin:propyleneglycol:H2O mixture (A) and were mechanically activated using a Capmix™ device. 
This mechanical activation gives rise to lipid-shelled microbubbles (B) loaded with liposomes. These 
microbubbles are filled with the hydrophobic C4F10 gas (C). The liposomes become coupled to the 
microbubbles’ surface through covalent thiol-maleimide linkages (D). Note that the microbubbles are 
a few microns in size while the liposomes are some hundreds of nanometers. 
MATERIALS AND METHODS 
Preparation and characterization of functionalized microbubbles 
“Functionalized microbubbles” (i.e. microbubbles containing thiol-functionalized 
PEG-lipids) were prepared starting from a lipid solution being a mixture of 1,2-
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dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[PDP(polyethylene glycol)-2000] (DSPE-PEG-PDP) 
(Avanti polar lipids, Albaster, AL) in a 1:2:7 glycerine-propyleneglycol-H2O 
solvent (Sigma-aldrich,Bornem,Belgium), the molar ratio of the lipids in the lipid 
solutions was respectively 97:3, 92:8 and 65:35. The lipid solution was prepared as 
follows. Aliquots of both lipids, dissolved in CHCl3, were transferred into a round 
bottom flask. After CHCl3 evaporation, the lipid film was dissolved in a 1:2:7 
glycerine-propyleneglycol-H2O mixture to obtain a clear solution with a final 
lipid concentration of 4 x 10-4 mmol/ml (or 2 x 10-4 mmol/ml for microbubbles 
used in the cell experiments). Aliquots of this lipid solution were transferred into 
2.5 ml chromatography vials, which headspace was filled with C4F10 gas (F2 
chemicals, Preston, UK). Finally, functionalized microbubbles (with an average 
size of 3µm) were obtained by high speed shaking of the lipid solution in a 
Capmix™ device (3M-ESPE, Diegem, Belgium) during 15 sec. The size and the 
concentration of the microbubbles in the dispersion (i.e. number of microbubbles 
per mL) were determined with a Beckman-coulter Multisizer 4 (Beckman-coulter, 
Brea, CA) 
Preparation of non-functionalized microbubbles 
Preparation of so named “non-functionalized microbubbles” occurred as 
described above for the functionalized bubbles, however 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DSPE-
MPEG) (Avanti polar lipids, Albaster, AL) was used as a PEG-lipid instead of 
DSPE-PEG-PDP.  
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Preparation and characterization of bodipy-labeled and DOX-liposomes 
Bodipy-labeled liposomes were prepared by transferring DPPC, DSPE-PEG-
maleimide) (Avanti polar lipids, Albaster, AL), cholesterol (Sigma-alldrich, 
Bornem, Belgium) and cholesteryl-bodipy (Invitrogen, Merelbeke, Belgium), all 
dissolved in CHCl3, in a 49:15:35:1 molar ratio to a round bottom flask. After 
CHCl3 evaporation, the remaining lipid film was rehydrated with HEPES buffer 
(50 mM, pH 7.4, Sigma-alldrich, Bornem, Belgium) to obtain a liposomal 
dispersion with a final lipid concentration of 16 mg/ml. The liposomal dispersion 
was hereafter extruded through a 200 nm filter using a mini-extruder at 60 °C 
(Avanti polar lipids, Albaster, AL).  
DOX-liposomes were prepared as described by Lentacker et al. [21]. Briefly, DPPC, 
DSPE-PEG-maleimide and cholesterol dissolved in CHCl3 at a concentration of 20 
mg/ml and 10 mg/ml respectively, were transferred in a round bottom flask in a 
49:15:36 molar ratio. After evaporation the remaining lipid film was rehydrated 
with ammonium sulfate buffer (250 mM) to obtain a liposomal dispersion with a 
final lipid concentration of 16 mg/ml. The resulting liposome dispersion was 
extruded through a 200 nm filter using a mini-extruder at 60 °C. After extrusion 
the excess of ammonium sulfate was removed by overnight dialysis against 
distilled water (MWCO: 8000 Da, Spectra/Por Biotech, Compton, CA). Hereafter 
the liposomal dispersion was aliquoted into 450 µl aliquots and liposomes were 
loaded with DOX by adding 50 µl of a doxorubicin.HCl (Sigma-alldrich, Bornem, 
Belgium) 10 mg/ml solution. Non-encapsulated DOX was removed in a second 
overnight dialysis against distilled water. Final DOX concentration was evaluated 
using absorbance spectrometry using an Envision plate-reader and reached 
between 0.5 and 0.8 mg/ml (Perkin-elmer, Waltham, MA) 
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Preparation of liposome-loaded microbubbles 
Liposome-loaded microbubbles were prepared by adding a certain volume of the 
liposome dispersion to the lipid solution used for the preparation of 
microbubbles (see above, under 1.1 and 1.2). Liposome-loaded microbubbles were 
obtained by high-speed shaking of this liposome/lipid mixture in a Capmix™ 
device. The loading of the microbubbles with (bodipy-containing) liposomes was 
visualized using a Nikon EZC1 confocal microscope equipped with a 60x lens 
imaging using the 490 nm excitation light, while fluorescence was detected at 551 
nm.  
Evaluation of the loading of the microbubbles with liposomes by flow 
cytometry 
How different parameters influence the loading of microbubbles with bodipy-
labeled liposomes was determined using a flow cytometer (BD FACScalibur, 
Erembodegem, Belgium). Therefore 300 µl of (bodipy-) liposome-loaded 
microbubbles were diluted in 300 µl of HEPES buffer. The 488 nm laser of the 
flow cytometer was used to excite the bubbles while the emitted fluorescence was 
detected in the 530 nm channel FL1. Results were expressed as mean fluorescence 
per microbubble using unloaded microbubbles as a blank. For measurements on 
microbubbles in plasma, platelet poor plasma was obtained by centrifuging 
whole blood samples first at 300 g for 10 min and subsequently at 3200 g for 10 
min. 20 µl of (bodipy-) liposome-loaded microbubbles were suspended in 150 µl 
of plasma and diluted with 200 µl Hepes buffer. All the flow cytometry 
experiments were performed in triplicate and the presented data are the mean 
values. 
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Evaluation of the loading of the microbubbles with liposomes by Coulter 
Counter measurements 
The loading of the microbubbles with liposomes was further studied by the 
electrical sensing zone method with a Beckman-Coulter Multisizer 4 Coulter 
Counter. For each Coulter Counter experiment 20 µl of (liposome-loaded) 
microbubbles were diluted in 10 ml of Phosphate Buffered Saline (PBS, GIBCO, 
Merelbele, Belgium); 50 µl of this dilution was applied in the Multisizer 4 which 
was equipped with a 20 µm aperture tube. The liposome-loaded microbubbles 
used in the Coulter Counter experiments were obtained by transferring 1 ml of 
lipid solution (lipid concentration: 4 x 10-4 mmol/ml) and respectively 0, 35, 100 
and 200 µl bodipy liposomes into a 2.5 ml chromatography vial, followed by 
high-speed shaking in the Capmix™ device.  
 We determined respectively the number of (unloaded and liposome-
loaded) microbubbles per mL and the volume of all bubbles present in 1 ml of 
dispersion (i.e. “total volume per ml”). The volume of a single microbubble could 
then be determined by equation (1).  
(1) 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑝𝑝𝑣𝑣𝑝𝑝 𝑏𝑏𝑣𝑣𝑏𝑏𝑏𝑏𝑣𝑣𝑣𝑣 = 𝑡𝑡𝑣𝑣𝑡𝑡𝑡𝑡𝑣𝑣  𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣  𝑝𝑝𝑣𝑣𝑝𝑝  𝑣𝑣𝑣𝑣 𝑛𝑛𝑣𝑣𝑣𝑣𝑏𝑏𝑣𝑣𝑝𝑝  𝑣𝑣𝑜𝑜  𝑏𝑏𝑣𝑣𝑏𝑏𝑏𝑏𝑣𝑣𝑣𝑣𝑏𝑏  𝑝𝑝𝑣𝑣𝑝𝑝  𝑣𝑣𝑣𝑣  
The volume increase of a microbubble upon loading with liposomes (i.e. 
“liposome volume per bubble”) could be calculated by equation (2) below.  
(2)l𝑖𝑖𝑝𝑝𝑣𝑣𝑏𝑏𝑣𝑣𝑣𝑣𝑣𝑣 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑝𝑝𝑣𝑣𝑝𝑝 𝑏𝑏𝑣𝑣𝑏𝑏𝑏𝑏𝑣𝑣𝑣𝑣 =
𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑣𝑣𝑜𝑜 𝑡𝑡 𝑣𝑣𝑣𝑣𝑡𝑡𝑙𝑙𝑣𝑣𝑙𝑙 𝑏𝑏𝑣𝑣𝑏𝑏𝑏𝑏𝑣𝑣𝑣𝑣 −  𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑣𝑣𝑜𝑜 𝑡𝑡𝑛𝑛 𝑣𝑣𝑛𝑛𝑣𝑣𝑣𝑣𝑡𝑡𝑙𝑙𝑣𝑣𝑙𝑙 𝑏𝑏𝑣𝑣𝑏𝑏𝑏𝑏𝑣𝑣𝑣𝑣) 
Dividing this liposome volume per microbubble by the volume of a single 
(spherical) liposome (with an average diameter of approximately 200 nm as was 
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determined by dynamic light scattering) gives an estimation of the amount of 
liposomes loaded on one microbubble (equation 3). 
(3) 𝑛𝑛𝑣𝑣𝑣𝑣𝑏𝑏𝑣𝑣𝑝𝑝 𝑣𝑣𝑜𝑜 𝑣𝑣𝑖𝑖𝑝𝑝𝑣𝑣𝑏𝑏𝑣𝑣𝑣𝑣𝑣𝑣𝑏𝑏 𝑝𝑝𝑣𝑣𝑝𝑝 𝑏𝑏𝑣𝑣𝑏𝑏𝑏𝑏𝑣𝑣𝑣𝑣 = 𝑣𝑣𝑖𝑖𝑝𝑝𝑣𝑣𝑏𝑏𝑣𝑣𝑣𝑣𝑣𝑣  𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣  𝑝𝑝𝑣𝑣𝑝𝑝  𝑏𝑏𝑣𝑣𝑏𝑏𝑏𝑏𝑣𝑣𝑣𝑣  (2)
𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣  𝑣𝑣𝑜𝑜  𝑣𝑣𝑛𝑛𝑣𝑣   𝑣𝑣𝑖𝑖𝑝𝑝𝑣𝑣𝑏𝑏𝑣𝑣𝑣𝑣𝑣𝑣  
All measurements were performed at least in triplicate and results are 
presented as the mean of three different measurements. 
Ultrasound induced DOX-release 
The release of doxorubicin from the liposomes was determined by fluorescence 
measurements. The following samples were prepared for the release experiments. 
One ml of lipid solution was mixed with 10 or 20 µl of DOX-liposomes with a 
DOX-concentration of 0.1 mg/ml and C4F10 gas. After shaking the lipid/liposome 
mixture in the Capmix™ device the mixture was diluted with PBS to a final 
volume of 10 ml and injected in an OpticellTM (Biocrystal, Westerville, OH) plate. 
This plate was submerged in a water bath (37°C) with an absorbing rubber and 
subjected to ultrasound during 15 s using the Sonitron device (Artison 
Corporation, Inola, OK, USA) equipped with a 2 cm ultrasound probe [22,24]. 
This probe was used with an ultrasound frequency of 1 MHz with 20 % duty 
cycle at an ultrasound intensity of 2 W/cm2. Subsequently, the fluorescence of 
each sample was measured in a Wallac envision plate reader (λexc 500 nm, λem 550 
nm). Each experiment was performed at least in triplicate. 
Cell culture and cytotoxicity tests 
BLM cells [24] (melanoma cells) were cultured in F12-supplemented Dulbecco’s 
modified Eagles medium (DMEM-F12) which contained 1% 
Penicillin/Streptomycin, 2mmol/l glutamine, 10 % Fetal bovine serum (FBS) (all 
purchased from Gibco, Merelbeke, Belgium) and 100 mmol/l HEPES pH 7.2. Cells 
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were grown in a humidified incubator at 37°C in a 5 % CO2 atmosphere. BLM 
cells were seeded in Opticell™ plates (1.3 x 106 cells per Opticell™) and were 
grown to 90 % confluence, which was reached two days after seeding. Before 
experiments were performed, cells were washed with PBS. Subsequently, DOX-
liposome loaded microbubbles were added to the cells. The following samples 
were prepared for the cytotoxicity experiments. To 500 µl of lipid solution (lipid 
concentration of 2 x 10-4 mmol/ml) respectively 10, 100, 250 or 500 µl of DOX 
liposomes (with a DOX concentration of 0.54 mg/ml) were added; HEPES-buffer 
(50 mM, pH 7.4) was added until a final volume of 1 ml was reached. Before 
shaking vials were filled with C4F10 gas. After shaking in the Capmix™ device, the 
1 ml microbubble dispersion was added to 10 ml of optimem and this mixture 
was added to the cells in Opticell™ plates. Subsequently, these plates were 
submerged in a warm water bath (37°C) with a bottom of ultrasound absorbing 
rubber. Ultrasound was delivered by moving the Sonitron ultrasound probe over 
the whole plate during 10-15 sec. We used 1 MHz ultrasound with a 20 % duty 
cycle with an ultrasound intensity of 2 W/cm2. During ultrasound application 
cells were located on the top membrane of the Opticell™, in this way 
microbubbles are directly contacting the cells during sonication. After ultrasound 
application cell displacement was evaluated by means of microscopy and was 
always minimal with the microbubble concentrations used for these experiments. 
After 4 hours of incubation, microbubbles were removed; cells were washed with 
PBS and incubated in fresh culture medium. After 24 hours cells were washed 
and the MTT reagent (Cell proliferation kit I, Roche diagnostics, Leuven, Belgium) 
was added for 4 hours. Subsequently, the sollubilization reagent was added and 
cells were incubated overnight to allow cell lysis at 37°C. The next day, the 
absorbance of each plate was measured in an absorbance plate reader at 
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respectively 590 nm (OD590) to determine the formed formazan and at 690 nm 
(OD690) as a reference. The results of the cytotoxicity measurements are expressed 
as percentages; the viability of the cells which were only treated with optimem 
was considered to be 100 %, while the viability of cells exposed to phenol was 
considered to be 0 %. Experiments were performed at least in triplicate. 
Statistical analysis 
All data are presented as means +/- one standard deviation. A student’s t-test was 
performed to determine whether datasets differed significantly. A p-value 
smaller than 0.05 was regarded as significant. 
RESULTS 
Preparation of liposome-loaded microbubbles by self-assembly  
As schematically presented in Figure 1, to make liposome-loaded microbubbles, 
to a mixture of the (functionalized) lipids DPPC and DSPE-PEG-SPDP, dissolved 
in a glycerin-propylene glycol-water solvent at a concentration below their critical 
micellar concentration [25], liposomes containing DSPE-PEG-maleimide were 
added. We observed that liposomes dispersed in the lipid solution are stable and 
can be stored during at least several weeks (data not shown). Therefore we stored 
the liposome/lipid dispersion at 4°C in chromatography vials. To “activate” the 
mixture, which refers to formation of liposome loaded microbubbles (Figure 1C), 
the vials’ headspaces were filled with perfluorobutane gas and subsequently 
mixed with a high speed shaking-device (Capmix™ or Vialmix™). The Capmix™ 
disperses the lipophilic perfluorobutane in the lipid solution. Hence, the 
hydrophobic tails of the dissolved lipids interact with the dispersed gas and 
stabilize the gas bubbles formed. Because functionalized (SPDP-) PEG-lipids were 
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used which can interact with the functionalized (maleimide-)PEG-lipids of the 
liposomes (Figure 1D), liposome-loaded microbubbles were spontaneously 
formed during this process as can be seen in the confocal image in Figure 2B and 
its corresponding transmission image (Figure 2A) clearly show bodipy-labeled 
liposomes at the surface of the microbubbles. 
 
Figure 2: Microscopy and Coulter Counter studies of liposome-loaded microbubbles: Transmission 
image (A) and confocal image (B) of a (bodipy-labeled) liposome-loaded microbubble. Size 
distributions of unloaded and liposome loaded microbubbles as obtained by Coulter Counter 
measurements (C) show an increase in mean size when liposomes are bound to the microbubbles’ 
surface. 
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Subsequently we measured the size distribution and microbubble concentration 
of respectively unloaded and loaded microbubbles by Coulter Counter (Figure 
2C). The unloaded microbubbles showed an average volume diameter of 3.6 µm 
while the diameter of liposome-loaded microbubbles equaled 4.0 µm. The 
microbubble dispersions contained respectively 1.23 x109 (unloaded) and 1.04 x 
109 (loaded) microbubbles/ml. The 400 nm increase in average diameter of the 
bubbles upon loading with liposomes strongly indicates the formation of a single 
liposome layer at the microbubble surface as the hydrodynamic diameter of a 
single liposome is about 200 nm.  
Improving the liposome-loading of the microbubbles  
Clearly, the more liposomes could be loaded onto the microbubble shell, the more 
drug could be released when the microbubble collapses. In a next step we 
evaluated whether the microbubble loading could be increased by using higher 
amounts of DSPE-PEG-SPDP lipids in the microbubble shell. We evaluated the 
amount of liposomes loaded per bubble through the use of bodipy-labeled 
liposomes and quantifying the fluorescence of the bodipy-liposome-loaded 
microbubbles through flow cytometry. Figure 3 clearly shows that the mean 
fluorescence per bubble increases upon a) adding more liposomes to the mixture 
and b) using higher amounts of DSPE-PEG-SPDP in the lipid mixture. Coulter 
Counter measurements on the corresponding bubbles also clearly indicate that 
upon using 35% DSPE-PEG-SPDP the microbubbles become substantially larger 
which explains the increased loading capacity of these microbubbles as more 
surface space per bubble is available. We noticed that it is possible to incorporate 
even higher amounts of DSPE-PEG-SPDP-lipids in the bubbles; however, the 
resulting microbubbles were unstable. Hence, we concluded that the use of a 35% 
molar ratio of DSPE-PEG-SPDP-lipids is optimal for liposome loading.  
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Figure 3: flow cytometry measurements of liposome-loading with increased PEGylation: Results of 
flow cytometry on bodipy-liposome loaded microbubbles: mean fluorescence per bubble in function 
of the amount of bodipy-liposomes added to the lipid mixture.  
Behavior of liposome-loaded microbubbles in plasma  
Clearly, successful ultrasound triggered drug release assumes that the 
microbubbles keep the drug as long as ultrasound energy is not applied. To judge 
whether liposome-loaded microbubbles remain stable once injected in plasma 
and do not release drug due to interactions with plasma components, we 
performed flow cytometry measurements on microbubbles loaded with bodipy-
liposomes dispersed in human platelet poor plasma (Figure 4). We could not 
observe significant differences in the fluorescence of liposome-loaded 
microbubbles dispersed in respectively plasma and buffer indicating that 
liposome-loaded microbubbles remain stable in plasma. Hence we predict that 
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the liposomes will remain bound to the bubbles after injection in the bloodstream, 
at least as long as they are not exposed to ultrasound.  
 
 
Figure 4: flow cytometry assessment of the stability of liposome-loading in plasma: Results of flow 
cytometry on bodipy-liposome-loaded microbubbles: mean fluorescence per bubble in function of the 
amount of bodipy-liposomes added to the lipid mixture. 
 
 Aspecific interactions between the liposomes and the microbubbles  
Subsequently we evaluated whether liposomes can stick (i.e. become aspecifically 
bound) to the microbubbles. Therefore we prepared microbubbles with DSPE-
MPEG lipids without functional end groups, thereby avoiding covalent binding. 
Figure 5A shows the fluorescence of non-functionalized microbubbles exposed to 
bodipy-liposomes, as measured through flow cytometry. Clearly, liposomes bind 
aspecifically to the microbubbles. However, as could be expected, liposome 
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loading of the microbubbles through covalent interactions enables significantly 
higher loading, which is of interest for use in drug delivery. One could speculate 
about the nature of the aspecific interactions between the liposomes and 
microbubbles. Entanglements between PEG-chains on the liposomes and 
microbubbles may contribute to this phenomenon.  
 
Figure 5: Flow cytometry assessment of aspecific liposome-loading: Results of flow cytometry on 
bodipy-liposome loaded microbubbles: mean fluorescence per bubble in function of the amount of 
bodipy-liposomes added to the lipid mixture. The microbubbles contained 35 mol% DSPE-PEG-SPDP, 
the liposomes contained respectively 35% DSPE-mPEG or DSPE-PEG-maleimide.  
Coulter Counter measurements gain further insight in the amount of liposomes 
loaded 
Although flow cytometry experiments revealed clear information on the loading 
of the microbubbles with liposomes, it remained impossible to estimate the 
number of liposomes loaded per microbubble. This information is of interest as it 
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defines the drug dose which can be loaded on the microbubbles’ surface. We 
reasoned that measuring the increase in volume of a microbubble upon loading it 
with liposomes (defined as “liposome volume per bubble”) in equation (2)) could 
give us valuable information. Dividing this “liposome volume per bubble” by the 
volume of one liposome allows us to estimate this number. Figure 6 shows the 
results of these experiments. For microbubbles with covalently attached 
liposomes we estimated that between 600 and 1300 liposomes can be loaded on 
the microbubbles’ surface, which is significantly higher than the number which 
can be loaded through aspecific interactions. These data confirm the results 
obtained by Klibanov et al. [26] where it is claimed that approximately 2000 
liposomes with a diameter of 0.1µm can be bound to one bubble with a diameter 
of 2.5µm. interestingly, the results obtained through Coulter Counter 
measurements confirm the data observed in Figure 5A which were obtained 
through flow cytometry.  
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Figure 6: Estimation of the number of liposomes per bubble: Estimated number of liposomes per 
microbubble (containing 35 mol% DSPE-PEG-SPDP) as measured by Coulter Counter. 
Ultrasound induced DOX release from DOX-liposome-loaded microbubbles  
Next we evaluated whether applying ultrasound on the DOX-liposome 
microbubble results in the release of DOX from the liposomes. As DOX 
encapsulated in liposomes has lower fluorescence intensity than the 
corresponding amount of freely dissolved DOX, an increase in fluorescence could 
be expected upon applying ultrasound to the DOX-liposome loaded 
microbubbles. We measured a significant increase in fluorescence when 
liposome-loaded microbubbles are subjected to ultrasound, which indicates that 
free doxorubicin is released from the liposomes after insonation.  
Biological efficacy of DOX-loaded liposome bubbles treated with ultrasound 
In a next step we evaluated the tumor cell killing efficacy of DOX-liposome 
loaded microbubbles. Figure 7B shows the results of an in vitro cytotoxicity assay 
using different cell killing strategies. Clearly, ultrasound treatment of DOX-
liposome loaded microbubbles (white bars) results in a significantly stronger 
killing of the cells. The x-axes in Figure 7B indicates the concentration of DOX in 
the Opticells™. Note that a higher DOX concentration was obtained through the 
use of microbubbles which were more loaded with DOX-liposomes (i.e. the 
number of DOX-liposome loaded microbubbles per Opticell™ was constant). 
Clearly, the ‘heavier’ the microbubbles are loaded with DOX-liposomes the more 
cytotoxic they are. Importantly, without ultrasound DOX-liposome loaded 
microbubbles do not kill cells (dark gray bars in Figure 7B). As the DOX-liposome 
loaded microbubbles are not cytotoxic as long as they are not subjected to 
ultrasound, we suggest that such bubbles in combination with ultrasound may 
allow targeted release of DOX. We would like to note that, as the cytotoxicity 
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experiments were done on a cell monolayer, cells were occasionally (physically) 
removed from this layer due to the ultrasound energy or the microbubbles 
treatment itself. This could induce false positive results in the cytotoxity 
experiments, although microbubble concentrations are used that induced a 
minimal cell displacement as verified microscopy (data not shown). The bars in 
Figure 7A show that at microbubble concentrations used in the experiments there 
was no significant killing of the cells due to the microbubble destruction itself; the 
observed cytotoxicity was similar to that observed with the blank (optimem).  
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Figure 7: Viability measurements on melanoma cells: (A) Effect of microbubbles alone in presence of 
ultrasound on melanoma cell viability compared to no treatment (optimem). (B) Viability of 
melanoma cells after treatment with DOX-liposome loaded microbubbles, with ultrasound treatment 
(light gray bars), DOX-liposome loaded microbubbles without ultrasound treatment (dark gray bars) 
and DOX-liposomes alone were measured using augmenting amounts of DOX-liposomes in an 
Opticell™ plate.  
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Can dose reduction be achieved with DOX-liposome loaded microbubbles? 
In the experiments in Figure 7 the DOX-liposome loaded microbubble dispersions 
did still contain an amount of free DOX-liposomes as it was experimentally 
difficult to separate free liposomes from the microbubbles. We were especially 
interested in the cell killing properties of the DOX-liposome loaded microbubbles 
themselves. We described above that between 600 and 1300 liposomes can be 
bound per microbubble. Therefore we prepared a DOX-liposome microbubble 
dispersion using an amount of DOX-liposomes which is expected to become fully 
loaded on the microbubbles. One can calculate that, when the microbubbles are 
loaded with this amount of liposomes, approximately 5 µg of DOX is loaded on 
the microbubbles present in 1 mL dispersion. Under these conditions we 
performed the cytotoxicity measurements, which results in a DOX-concentration 
of 0.5 µg/ml in the Opticells™ after applying the DOX-liposome microbubble 
dispersion to the cells. Figure 8 compares the cell killing at a DOX concentration 
of 0.5 µg/ml in the Opticells™, respectively when free DOX and DOX-liposome 
microbubble dispersion (without free DOX-liposomes) were applied. Despite the 
very low DOX-concentration in the Opticells™, DOX-liposome loaded 
microbubbles were clearly cytotoxic (in case ultrasound was applied). In contrast, 
free DOX did not cause any significant tumor cell death. Our results indicate that 
very low amounts of doxorubicin can become significantly effective when loaded 
onto microbubbles and exposed to ultrasound. An interesting observation 
towards the delivery of DOX as a lower dose may become sufficient in the 
treatment of patients.  
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Figure 8: Viability measurements on melanoma cells with reduced dose: Viability of melanoma cells 
after exposure to respectively DOX-liposome loaded microbubbles (with and without ultrasound (US) 
treatment) and free DOX. The DOX- concentration in the wells was 0.5 µg/ml. Note that in these 
experiments we did not expect free DOX-liposomes to be present in the DOX-liposome loaded 
microbubble dispersion.  
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DISCUSSION 
Here, it is shown that it is possible to design a safe and simple system for 
ultrasound guided drug delivery and we show that this system is very efficient in 
vitro, even when low amounts of model drug (DOX) are used. However, these in 
vitro experiments were performed in an ideal setting, because microbubbles were 
contacting the melanoma cells while sonicated, which probably leads to a more 
efficient sonoporation. In this respect, one could speculate on how to apply this 
system in an in vivo setting. Since microbubbles are relatively large particles, they 
will not pass the endothelial barrier in the tumor tissue; hence drug release has to 
occur in the blood vessels. The possible future clinical application of this system 
will depend on how efficient the drug will penetrate the tissue under ultrasound 
application. Fortunately it has been recently shown that ultrasound and 
microbubbles can lead to a permeabilization of the endothelial barrier in (tumor) 
tissue which causes extravasation of coinjected molecules or drugs [27], other 
studies prove that ultrasound and microbubbles can even cause a local opening of 
the Blood Brain Barrier (BBB) [28]. In our measurements we have clearly shown 
that active compound is released out of the liposomes after implosion of the 
microbubbles, this release of free DOX can diffuse into the tissue after disruption 
of the endothelial barrier and can have a fast effect on the tumor cells. 
Furthermore, it is likely that not every liposome is destructed after ultrasound 
insonation, but is released in the surrounding environment. These liposomes can 
also be delivered into the tissue after endothelial barrier disruption. Another 
mechanism of tumor killing in vivo can be the specific killing of the endothelial 
cell layer directly contacting the microbubbles that are affected by the ultrasound. 
This mechanism is directly comparable with the in vitro experiments performed in 
this chapter. The specific killing of endothelial cells will impair blood flow in the 
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tumor and induce necrosis of the tumor. To even improve contact between these 
endothelial cells and the liposome-loaded microbubble a targeting ligand might 
be introduced in the system. The use of liposome-loaded microbubbles will in the 
end allow killing of tumor cells using less drug, because the drug will only be 
delivered where and when ultrasound is applied. Furthermore, future in vivo 
experiments with this system will have to answer the question whether the 
efficiency of the therapy will be improved too, if sonoporation allows direct 
delivery of the drug in endothelial cells and increased uptake in tumor cells. 
Another issue which is still prone to discussion is the drug dose which can be 
maximally loaded on and thus delivered by the microbubbles. A microbubble is 
relatively small, which limits the space for drug loading. We believe that binding 
(drug containing) vesicles (like liposomes) on the surface of the bubbles 
maximizes the amount of drug that can be loaded. From this point of view this 
strategy may be an advantage when compared with other approaches reported to 
load microbubbles with drugs, like e.g. ones which load the drug into an inner oil 
layer or in the bubble shell itself [17,18]. Though we showed that approximately 
600 to 1300 liposomes can be bound per single microbubble the amount of DOX 
which becomes loaded in this way still remains rather limited. The loading may 
be further improved by applying multiple layers of liposomes around the 
microbubbles. The materials reported here can only be further clinically evaluated 
provided one can overcome the low drug loading obstacle. Nowadays cancer 
patients are treated with a relatively high dose of DOXYL™, i.e. 40-50 mg DOX 
per injection. Designing drug-loaded microbubbles which would allow such a 
high DOX dosing is highly likely impossible unless really high amounts of 
bubbles (in the order of 1 x 1013 bubbles/ml) could be injected. However, 
considering the targeted and more efficient delivery of DOX when ultrasound 
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and DOX-liposome loaded bubbles are used, we believe that such high DOX-
doses might be no longer necessary, which may also reduce the severe side-effects 
of DOX-therapy in particular and chemotherapy in general. Since apparati, that 
deliver ultrasound into a specific region deep into the tissue, are already under 
full development [29], the clinical evaluation of the drug-loaded microbubbles 
reported in this paper will smoothly move on and hopefully make it from bench 
to bedside. 
CONCLUSIONS 
This work showed that that DOX-liposome loaded microbubble can be obtained 
through self-assembly of (functionalized) phospholipids, drug-loaded liposomes 
and perfluorobutane gas. Importantly, this single step process results in a 
material which meets all criteria for clinical applicability: (a) no immunogenic 
compounds are used; (b) sterilization can easily be achieved through 
straightforward techniques and (c) adequate amounts of liposomes can be stably 
loaded on the surface of the bubbles. Through flow cytometry and Coulter 
Counter measurements we showed a maximal loading of the microbubbles with 
liposomes when the lipid shell of the microbubbles was composed of 35 mol% of 
DSPE-PEG-SPDP, resulting in approximately 600 to 1300 liposomes bound per 
single microbubble. Importantly, the liposomes remained bound to the 
microbubbles' surface upon incubation in plasma, being a clear requirement for 
clinical application. Ultrasound induced microbubble collapse clearly induced the 
release of DOX. When compared with free DOX and DOX-liposomes, we 
observed that DOX-liposome loaded microbubbles in combination with 
ultrasound showed a significantly stronger killing of cancer cells. It is our opinion 
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that the DOX-liposome loaded microbubbles described in this paper provide an 
opportunity for ultrasound targeted cancer therapy. 
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One of the main problems in cancer treatment is disease-relapse through 
metastatic colonization which is caused by circulating tumor cells 
(CTCs). This work reports on liposome-loaded microbubbles targeted to 
N-cadherin, a cell-cell adhesion molecule expressed by CTCs. It is shown 
that such microbubbles can indeed bind to N-cadherin at the surface of 
HMB2 cells; interestingly, in a mixture of cells with and without N-
cadherin expression, binding of the liposome-loaded microbubbles 
mainly occurs to the N-cadherin expressing cells. Importantly, applying 
ultrasound results in the intracellular delivery of a model drug (loaded 
in the liposomes) in the N-cadherin expressing cells only. As described 
in this chapter, such liposome-loaded microbubbles may find 
applications as theranostics and in devices aimed for the specific killing 
of CTCs in blood. 
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INTRODUCTION 
One of the main problems in cancer is disease-relapse due to metastases. 
Metastases cause most cancer deaths and originate from invasive cells that are 
formed in the primary tumor. Invasive cells can enter the bloodstream or the 
lymphatic system and spread out, to finally colonize a distant organ. Recently, 
new insights in the molecular processes that cause cancer have defined the switch 
of a non-invasive into an invasive phenotype as a hallmark of cancer [1,2]. 
The reason why cancer cells obtain this invasive phenotype may relate to a 
process called Epithelial-Mesenchymal Transition (EMT) [3]. Epithelial cells are 
characterized by a tight cell-cell adhesion, which involves specific adhesion 
molecules such as E-cadherin [4,5]. When such cells become invasive, E-cadherin 
expression becomes downregulated while other types of cadherins, namely the 
N-cadherins or mesenchymal cadherins, become upregulated [6]. Although a lot 
of debate on this matter is still ongoing, mesenchymal cadherins can be one of the 
key components that induce cell motility [7] and invasiveness [8]. Indeed, CTCs 
from patients with advanced solid tumors express mesenchymal markers 
including N-cadherin [9,10]. Consequently, mesenchymal cadherins may become 
ideal targets for selective drug delivery to Circulating Tumor Cells (CTCs). The 
idea of identifying such CTCs via (N-cadherin) antibody coated materials [11] 
inspired us to try to design N-cadherin targeted microbubbles aiming to 
selectively deliver therapeutic molecules (loaded on the microbubbles) to CTCs. 
As shown in previous chapter and in more work by our group [12-14] and others 
[15-17], microbubbles show potential for ultrasound induced time- and space-
controlled drug release. For this purpose, microbubbles can be coated with drug-
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loaded nanoparticles that are associated with the shell of the bubbles. Their 
mechanism of action relies upon their specific interactions with the ultrasound 
wave. If a gas bubble encounters such a wave it will start to resonate due to the 
pressure fluctuations exerted by the ultrasound (named cavitation) [18]. If higher 
acoustic pressures are used, cavitation will result in a microbubble collapse 
(inertial cavitation) which can result in the release of the drugs or nanoparticles 
attached to or incorporated in the microbubbles. It has been observed that when 
microbubble collapse occurs in the vicinity of cell membranes, a transient opening 
of the cell membrane can be induced (“sonoporation”), which may improve drug 
uptake by cells  [19,20]. 
Recently, microbubbles coated with antibodies [21] or nanobodies [22] directed 
against specific antigens have been reported as molecular imaging agents. As 
mentioned above and envisioned in Figure 1, in this paper we aim to evaluate 
whether a) it is possible to design a targeted drug-loaded microbubble, b) 
targeted microbubbles are able to selectively adhere to N-cadherin positive cells 
and c) whether (small) molecules can be selectively delivered to N-cadherin 
positive cells upon binding with N-cadherin targeted liposome-loaded 
microbubbles followed by exposure of ultrasound. 
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Figure 1: Schematic representation of the envisioned concept: drug loaded microbubbles, targeted 
through the use of N-cadherin antibodies, specifically adhere to circulating tumor cells expressing N-
cadherin; subsequent ultrasound exposure may induce selective drug delivery to the circulating 
tumor cells. 
Cell specific ultrasound-triggered drug delivery 3 
 
110 
 
MATERIALS AND METHODS 
Preparation of functionalized liposomes  
Liposomes were prepared as described earlier  [12,14]. Briefly, 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N- [maleimide(polyethylene glycol)-2000] (DSPE-PEG-
maleimide) (Avanti polar lipids, Albaster, AL) and cholesterol (Sigma-alldrich, 
Bornem, Belgium) dissolved in CHCl3 were mixed in a round bottom flask. After 
solvent evaporation, the remaining lipid film was dissolved in HEPES-buffer (50 
mM, pH 7.4, Sigma-alldrich, Bornem, Belgium), to obtain a liposome dispersion 
with a lipid concentration of 16mg/ml. This dispersion was extruded through a 
200 nm filter with a mini-extruder at 60°C (Avanti-polar lipids, Albaster, AL). 
Finally all produced batches were characterized with a Zetasizer (Nano-zs, 
Malvern, Worcestershire, UK) to evaluate the size-distribution.  
Preparation of functionalized antibodies and targeted liposomes 
Antibodies were functionalized with 2-imminothiolane or Traut’s reagent 
(Thermo-scientific, Bornem, Belgium). 200 µl of aqueous solution containing N-
cadherin (Mouse N-cadherin, Clone GC4, Sigma-aldrich, Bornem, Belgium) with 
a protein concentration of 3 mg/ml were mixed with 48 µl of Traut’s reagent (1 
mg/ml in HEPES-buffer). The mixture was allowed to react for 20 min in presence 
of the reducing agent dithiotreitol. (DTT) (Sigma-alldrich, Bornem, Belgium). 
Subsequently, reaction aliquots of this mixture were added to 100 µl of 
functionalized liposomes to obtain targeted liposomes. 
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Preparation of fluorescently labeled non-targeted and targeted liposomes 
Fluorescently labeled targeted or non-targeted liposomes were prepared by 
adding the green- or red-fluorescent dyes: respectively cholesteryl-bodipy or 1,1'-
dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine (DiD) (life-technologies, 
Merelbeke, Belgium) to the lipid mixture. DPPC , DSPE-PEG-maleimide and 
cholesterol dissolved in CHCl3 were mixed with the fluorescent dye in a molar 
ratio of respectively 49:15:35:1. 
Preparation of propidium iodide (PI)-loaded liposomes 
Liposomes were prepared as described above by mixing DPPC, DSPE-PEG-
maleimide and cholesterol dissolved in CHCl3 in a round bottom flask. After 
solvent evaporation the lipid film was rehydrated with a 2 mg/ml PI (life 
technologies, Merelbeke, Belgium) solution dissolved in HEPES (50 mM, pH7.2). 
Subsequently, the liposomes were extruded through a 200 nm filter with a mini-
extruder. After extrusion the resulting liposomes were centrifuged (Beckman L8-
70M, Beckman-coulter, Brea, CA) at 109000 x g for 1h to remove unencapsulated 
PI. After centrifugation the supernatant was removed and the remaining PI-
loaded liposomes were dissolved in HEPES buffer. 
Preparation of functionalized microbubbles 
Microbubbles were prepared via the method earlier described by our group [12]. 
Briefly, these microbubbles were prepared starting from a mixture of DPPC and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [PDP(polyethylene glycol)-
2000] (DSPE-PEG-PDP) (Avanti polar lipids, Albaster, AL) in a 1:2:7 
glycerine:propyleneglycol:H2O mixture. DPPC and DSPE-PEG-PDP were 
dissolved in this mixture with a molar ratio of 95:5. The lipid solution was 
prepared by mixing the different lipids dissolved in CHCl3 in a round bottom 
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flask. After solvent evaporation, the remaining lipid film was dissolved in the 
glycerine:propyleneglycol:H2O mixture. 1 ml aliquots of the lipid solution were 
transferred in glass vials and the headspaces of the vials were subsequently filled 
with C4F10 gas (F2 chemicals, Preston, UK). Microbubbles are obtained by 
mechanical activation of this solution in a Capmix™ (3M-ESPE, Diegem, Belgium) 
mechanical shaker. 
Preparation and characterization of targeted liposome-loaded microbubbles 
Targeted liposome-loaded microbubbles were prepared by adding targeted 
liposomes to the lipid solution. This mixture was transferred into glass vials and 
the headspace of the vials was filled with C4F10 gas. Targeted liposome-loaded 
microbubbles were then obtained by mechanical activation of the vials with a 
Capmix™ mechanical shaker. The constructs were characterized by confocal 
scanning laser microscopy (CSLM) (Nikon EZC1, Nikon, Brussels, Belgium) 
equipped with a 60 x oil immersion lens with a numerical aperture of 1.2. 
Subsequently, we labeled the liposomes with cholesteryl-bodipy as described 
above, antibodies were labeled by adding 30µl of allophycocyanin (APC) labeled 
goat anti-mouse secondary antibodies (BD-pharmingen, Erembodegem, Belgium) 
to 1 ml of the targeted liposome-loaded microbubble dispersion. After reaction 
(10 min) and a short centrifugation step (300 x g for 1 min) to separate unbound 
secondary antibody from the microbubble dispersion, the microbubbles were 
imaged with CSLM using a Ar-ion laser with an excitation wavelength of 488 nm 
and a diode-pumped solid state laser with an excitation wavelength of 632 nm. 
Fluorescence was detected at emission wavelengths of 551 nm and 660 nm 
respectively. Non-targeted (without antibodies) liposome-loaded microbubbles 
were prepared via the same method. 
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Quantification of antibody-loading of the microbubbles 
Targeted liposomes were prepared by adding 25, 50, 100 and 200 µl of 
functionalized N-cadherin antibodies (2.14 µg/µl) to 100 µl of liposomes. Targeted 
liposome-loaded microbubbles were subsequently prepared as described above. 
Antibody-loading was characterized with flow cytometry (BD FACScalibur, 
Beckton Dickinson, Erembodegem, Belgium) after labeling the targeted liposomes 
with secondary allophycocyanin-(APC) labeled goat anti-mouse antibodies. 
Again, the microbubble dispersion was centrifuged shortly (300 x g, 1 min) to 
remove unbound secondary antibodies before flow cytometry analysis. The APC-
label was excited using a 630nm red diode laser installed on the flow cytometer 
and fluorescence was detected at 670nm. All measurements were performed in 
triplicate. 
Cell cultures 
HMB2, BLM and H1299 cells were cultured in different media. HMB2 cells were 
cultured in F12-supplemented Dulbecco’s modified Eagles medium (DMEM) 
containing 1% penicillin/streptomycin; 2 mmol/ml L-glutamine and 10% Fetal 
bovine serum (all purchased from Life Technologies, Merelbeke, Belgium). H1299 
cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 phenol red 
supplemented medium additionally supplemented with 1% 
penicillin/streptomycin; 2mmol/ml L-glutamine and 10% fetal bovine serum. 
BLM cells were cultured in F12-supplemented Dulbecco’s modified Eagles 
medium (DMEM) containing 1% penicillin/streptomycin; 2mmol/ml L-glutamine 
and 10% Fetal bovine serum and 100 mmol/l HEPES pH 7.2. All cell types were 
cultured in 75cm2 flasks in a humidified incubator at 37°C under 5% CO2 
atmosphere 
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Evaluation of targeting efficiency to HMB2 cells in vitro 
Targeting efficiency was determined on HMB2 cells labeled with an aspecific 
green dye Cell Tracker™ bodipy (life technologies, Merelbeke, Belgium). HMB2 
cells cultured in 75cm2 flasks as described above were washed with phosphate 
buffered saline (PBS, life technologies, Merelbeke, Belgium). Subsequently, 10 ml 
optimem (life technologies, Merelbeke Belgium) was added to the cells together 
with 50 µl of Cell Tracker™ bodipy reagent (dissolved in DMSO 1mg/ml, life 
technologies, Merelbeke, Belgium). The cells were cultured for 15 min and 
afterwards washed with PBS. Subsequently the cells were detached with calcium 
supplemented trypsin prepared according to the protocol by Boterberg et al. [33]. 
The detached cells were resuspended in cell culture medium and centrifuged at 
300 x g during 7 min. Finally the cells were resuspended in 4 ml PBS. 200 µl 
aliquots of the cell suspension were transferred into eppendorf tubes and 100 and 
250 µl of targeted or non-targeted liposome-loaded microbubbles (1 x 107 
microbubbles/ml) labeled with a red-fluorescent dye (DiD) as described earlier 
were added to the eppendorf tubes containing the suspension of HMB2 cells. The 
resulting mixtures were analyzed with flow cytometry (BD FACScalibur, Beckton 
Dickinson, Erembodegem, Belgium) in triplicate. The Cell Tracker label was 
excited with the 488nm laser and detected in the 530 nm channel, the DiD-labeled 
microbubbles were excited with the 635 nm laser and fluorescence was detected 
in the 660nm channel. Events that showed significant fluorescence in both 
channels were regarded as cells with adherent microbubbles due to antibody-
antigen interactions. The percentage of targeting was determined via quadrant 
analysis of the plots showing green against red fluorescence and were calculated 
via equation (1). 
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(1) 
% 𝐻𝐻𝐻𝐻𝐻𝐻2 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐=  𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐 𝑚𝑚𝑜𝑜 𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐 𝑐𝑐𝑐𝑐 𝑞𝑞𝑚𝑚𝑐𝑐𝑞𝑞𝑐𝑐𝑐𝑐𝑐𝑐𝑒𝑒 𝑚𝑚 
𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐 𝑚𝑚𝑜𝑜 𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐 𝑐𝑐𝑐𝑐 𝑞𝑞𝑚𝑚𝑐𝑐𝑞𝑞𝑐𝑐𝑐𝑐𝑐𝑐𝑒𝑒 𝑐𝑐 + 𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐 𝑚𝑚𝑜𝑜 𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐 𝑐𝑐𝑐𝑐 𝑞𝑞𝑚𝑚𝑐𝑐𝑞𝑞𝑐𝑐𝑐𝑐𝑐𝑐𝑒𝑒 𝑚𝑚  
Evaluation of N-cadherin expression on HMB2 cells 
Cells were cultured as described above in 75 cm2 cells and upon washing with 
PBS incubated with anti-N-cadherin antibody for 10 min at 37°C. Subsequently, 
unbound antibodies were removed and upon a second washing step (PBS) 
secondary goat anti-mouse Alexa-488-labeled antibodies (BD, Erembodegem, 
Belgium) were added to the cells. Upon incubation at 37°C the medium was 
removed and cells were detached with calcium supplemented trypsin and 
resuspended in PBS. Finally, flow cytometry was performed using with a BD 
FacsCalibur using the 488 nm excitation laser.  
Evaluation of specific targeting in a mixture of cell types with flow cytometry 
HMB2 and BLM cells were cultured in 75 cm2 flasks and cells were washed with 
PBS before the experiments. HMB2 cells were stained with the green-fluorescent 
Cell Tracker™ dye as described in the previous section, washed and cells were 
detached with calcium supplemented trypsin. BLM cells were detached with 0.05% 
Trypsin-EDTA (life-technologies, Merelbeke, Belgium). After detachment of the 
cells, trypsin was inactivated with their respective cell culture media and 
centrifuged at 300 x g for 7min. After centrifugation cells were resuspended in 2 
ml PBS and 200 µl aliquots of each cell type were transferred into eppendorf 
tubes. 250 µl of non-targeted and targeted liposome-loaded microbubbles (1 x 107 
microbubbles/ml) with a red-fluorescent DiD label, were added to this cell 
suspension and subsequently analyzed with flow cytometry by plotting green 
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against red fluorescence in density plots. These density plots were divided in 
quadrants (a,b,c and d) based upon measurements of cells and microbubbles only. 
All measurements were performed in triplicate. 
Microscopic evaluation of specific targeting in a mixture of cell types  
HMB2 and H1299 cells stably expressing enhanced green-fluorescent protein 
(EGFP) were used for these experiments. Again, cells were cultured in 75 cm2 cell 
culture flasks and washed with PBS before experiment. HMB2 cells were 
detached with calcium supplemented trypsin and 0.25% trypsin-EDTA was used 
to detach the H1299 cells. Afterwards, trypsin was inactivated with the respective 
cell culture media and cells were centrifuged at 300 x g for 7min. After 
centrifugation the supernatant was removed and cells were resuspended in PBS. 
200 µl aliquots were transferred into eppendorf tubes and 250 µl DiD-labeled 
targeted or non-targeted microbubbles (1 x 107 microbubbles/ml) where added to 
the aliquots. The suspensions were transferred to slides to be analyzed with 
CSLM (Nikon EZC1, Nikon, Brussels Belgium) equipped with a 60 x water 
immersion objective with a numerical aperture of 1.2. EGFP-was excited with the 
488 nm Ar-ion laser and fluorescence was detected at 550 nm. DiD was excited 
with the 630 nm diode pumped laser and fluorescence was detected at 660 nm. 
Ultrasound enhanced cell specific small molecule delivery 
HMB2 and BLM cells were cultured in 75 cm2 cell culture flasks and washed with 
PBS before experiment. HMB2 cells were labeled with Cell Tracker™ bodipy, 
afterwards detached with calcium supplemented trypsin and centrifuged as 
described above. BLM cells were detached with 0.05% Trypsin-EDTA (life 
technologies, Merelbeke, Belgium), trypsin was inactivated with cell culture 
medium and the cells were centrifuged as described above. After centrifugation 
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250µl aliquots were transferred into eppendorf tubes and 250 µl targeted- or non-
targeted PI-liposome-loaded microbubbles (1 x 107 microbubbles/ml) were added 
to the cell suspension. The eppendorf tubes were submerged in a warm water 
bath (37°C) with an absorbing rubber and ultrasound was delivered during 20 s 
with a sonitron device (Artison Corporation, Inola, OK). The ultrasound 
frequency was 1 MHz, with a duty cycle of 50 %. Corresponding to 
measurements with a needle hydrophone, a maximum acoustic pressure of 600 
kPa was obtained in the focus of the transducer. Samples were analyzed in 
triplicate by means of flow cytometry. Cell Tracker™ and PI were excited with 
the 488nm laser, and fluorescence was detected at respectively 530 nm and 670 
nm. The percentage of PI positive cells was evaluated by quadrant analysis of 
plots, plotting Cell tracker™- against PI-fluorescence. Quadrants were chosen 
analogue with the analysis of the measurements described in section 5.11 and the 
percentage of HMB2 and BLM cells positive for PI was respectively calculated via 
equations (2) and (3).  
(2) % 𝐻𝐻𝐻𝐻𝐻𝐻2 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑝𝑝𝑚𝑚𝑐𝑐𝑐𝑐𝑒𝑒𝑒𝑒𝑐𝑐 𝑜𝑜𝑚𝑚𝑐𝑐 𝑃𝑃𝑃𝑃 =
𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐  𝑚𝑚𝑜𝑜  𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐  𝑐𝑐𝑐𝑐  𝑞𝑞𝑚𝑚𝑐𝑐𝑞𝑞𝑐𝑐𝑐𝑐𝑐𝑐𝑒𝑒  𝑚𝑚
𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐  𝑚𝑚𝑜𝑜  𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐  𝑐𝑐𝑐𝑐  𝑞𝑞𝑚𝑚𝑐𝑐𝑞𝑞𝑐𝑐𝑐𝑐𝑐𝑐𝑒𝑒  𝑞𝑞+𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐  𝑚𝑚𝑜𝑜  𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐  𝑐𝑐𝑐𝑐  𝑞𝑞𝑚𝑚𝑐𝑐𝑞𝑞𝑐𝑐𝑐𝑐𝑐𝑐𝑒𝑒  𝑚𝑚 
(3) % 𝐻𝐻𝐵𝐵𝐻𝐻 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑝𝑝𝑚𝑚𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐𝑒𝑒𝑐𝑐 𝑜𝑜𝑚𝑚𝑐𝑐 𝑃𝑃𝑃𝑃 = 𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐  𝑚𝑚𝑜𝑜  𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐  𝑐𝑐𝑐𝑐  𝑞𝑞𝑚𝑚𝑐𝑐𝑞𝑞𝑐𝑐𝑐𝑐𝑐𝑐𝑒𝑒  𝑐𝑐  
𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐  𝑚𝑚𝑜𝑜  𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐  𝑐𝑐𝑐𝑐  𝑞𝑞𝑚𝑚𝑐𝑐𝑞𝑞𝑐𝑐𝑐𝑐𝑐𝑐𝑒𝑒  𝑐𝑐+𝑐𝑐𝑚𝑚𝑚𝑚𝑚𝑚𝑐𝑐𝑐𝑐  𝑚𝑚𝑜𝑜  𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑐𝑐  𝑐𝑐𝑐𝑐  𝑞𝑞𝑚𝑚𝑐𝑐𝑞𝑞𝑐𝑐𝑐𝑐𝑐𝑐𝑒𝑒  𝑐𝑐 
Statistics 
All data are presented as means +/- one standard deviation. A student’s t-test was 
performed to determine whether datasets differed significantly. A p-value 
smaller than 0.05 was regarded significant. 
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RESULTS 
Preparation and characterization of targeted liposome-loaded microbubbles 
As described above  [12], liposome-loaded microbubbles can be formed via 
mechanical activation of a solution of lipids (DPPC and DSPE-PEG-SPDP) in the 
presence of (chemically functionalized) liposomes and a hydrophobic (C4F10) gas. 
In this paper we use the same procedure, the only difference being the use of 
targeted (antibody containing) functionalized liposomes. First, free thiol (SH) 
groups were introduced on N-cadherin antibodies with Traut’s reagent (2-
Iminothiolane-HCl). Subsequently, targeted liposomes were made by addition of 
the SH enriched antibodies to maleimide-containing liposomes. The 
SH/maleimide ratio was kept low, leaving enough free maleimide groups 
available on the liposomes for coupling them to the microbubbles. The 
maleimide-containing liposomes were subsequently added to a vial containing a 
lipid solution composed of DPPC and DSPE-PEG-SPDP and covered with C4F10 
gas. In this way, the remaining free maleimide-groups on the surface of the 
liposome are able to form a stable bond with the DSPE-PEG-SPDP lipids. 
Subsequent mechanical activation of this dispersion (containing lipids and 
liposomes) results in the formation of targeted liposome-loaded microbubbles, as 
envisioned in Figure 2A, and as evidenced from confocal microscopy images 
(Figure 2 C-E) which clearly show co-localization of bodipy-labeled liposomes 
and secondary antibodies (against the N-cadherin antibodies). A detailed 
description of the preparation method can be found in the materials and methods 
section. 
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Figure 2: Schematic depiction of a targeted liposome-loaded microbubble (A) and corresponding 
microscopy images (B-E). Transmission (B) and confocal fluorescent images (C-E) of a microbubble 
loaded with (green fluorescent labeled) N-cadherin targeted liposomes. (C) Shows green fluoresecence 
while (D) shows red fluorescence due to red-labeled secondary antibodies (against the N-cadherin 
antibodies). (E) is a merged image. 
Optimal antibody-loading 
As explained above, the same functionalized lipid in the liposomal bilayer (DSPE-
PEG-maleimide) is used to a) equip the liposomal surface with N-cadherine 
antibodies and b) couple the targeted liposomes to the microbubbles (see Figure 
2A). Therefore it was crucial to determine the maximal amount of antibodies that 
could be attached to the liposomal membrane without compromising 
microbubble coupling. To evaluate the amount of antibodies on the surface of the 
liposome-loaded microbubbles, we performed flow cytometry with red-
fluorescent secondary antibodies (against the N-cadherin antibodies). Figure 3 
shows that the addition of 25 to 50 µl of thiol-activated antibody to 100 µl 
liposomes results in a maximal amount of antibodies loaded per microbubble 
(Figure 3A). Higher amounts of antibody might result in a higher antibody load 
per liposome but limits the amount of liposomes loaded per microbubble. To verify 
this, we used green- (cholesteryl-bodipy) labeled liposomes to measure the 
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amount of targeted liposomes loaded on the surface of the microbubbles with 
flow cytometry. Figure 3B shows that the use of higher amounts of N-cadherin 
antibodies indeed hampers liposome loading of the microbubbles. Based upon 
the data in figure 3A we decided to use 50 µl of N-cadherin antibody per 100 µl 
liposomes in the continuation of this work, corresponding to 107 µg of N-
cadherin antibody added to 100 µl liposomes.  
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Figure 3: Quantitative flow cytometry analysis showing: (A) the red fluorescence (amount of N-
cadherin antibodies) per microbubble and (B) the green fluorescence (amount of liposomes) per 
microbubble, as a function of the amount of N-cadherin antibodies added to the liposomes. 
Cell specific ultrasound-triggered drug delivery 3 
 
122 
 
Selectivity of the concept: targeting-efficiency to N-cadherin expressing HMB2 
cells 
To evaluate the ability of the designed microbubbles to adhere to N-cadherin 
expressing metastatic tumor cells we performed flow cytometry and quantified 
the number of HMB2 cells (melanoma cell line derived from lymph node 
metastases) containing adhered microbubbles. Earlier, Van Marck et al. [23] 
showed that the HMB2 cell line is distinguished by a strong expression of the N-
cadherin protein. For this experiment, we prepared red-labeled liposomes by 
incorporating the red-fluorescent lipophilic dye DiD (1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine) in the liposomal membrane. Subsequently, these 
red-fluorescent N-cadherin targeted liposomes were coupled onto the 
microbubble surface resulting in red-labeled microbubbles. HMB2 cells were 
labeled in green by loading them with the aspecific intracellular dye Cell 
Tracker™ bodipy. 
Figure 4 shows the number  of HMB2 cells with and without microbubbles at 
their surface; note that in the experiments a) respectively 100µL and 250µL 
microbubble suspension (1x107 bubbles/ml) was added per 1 x 106 cells, b) 
targeted and non-targeted liposomes were used. In figure 4A, microbubble red 
fluorescence intensity is plotted on the Y-axis against the green fluorescence 
intensity coming from the HMB2 cells (X-axis). As a result, microbubbbles can be 
found in the upper left quadrant a, HMB2 cells are seen in the lower right 
quadrant c while HMB2 cells with adhered microbubbles will be observed in 
quadrant b. Figure 4A shows a significant increase in events in quadrant b if 
targeted microbubbles are used, indicating adherence of the N-cadherin targeted 
microbubbles to the HMB2 cells. Adherence of non-targeted liposome-loaded 
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microbubbles to HMB2 cells is significantly lower, although some aspecific 
binding was observed. This may be caused by thiol-groups present on the surface 
of the cells interacting with some free maleimide-groups on the surface of the 
liposomes [24]. 
 
Figure 4: (A) Red (DiD)-labeled microbubbles (y-axis) and green (bodipy)-labeled HMB2 cells (x-axis) 
‘only’ were used to define the quadrants (a,b,c). Binding of N-cadherin targeted liposome-loaded 
microbubbles to green HMB-2 cells was compared with the aspecific adherence of non-targeted 
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liposome-loaded microbubbles to the HMB-2 cells. (B) Percentage of HMB2 cells carrying 
microbubbles (as calculated from the number of events in quadrants b and c in (A)). C) Green 
fluorescence intensity plot of HMB2 cells after exposing them to N-cadherin antibodies and 
subsequent staining with green-fluorescent secondary antibodies (HMB2 cells without N-cadherin 
staining were used as controls).  
Subsequently, we measured the percentage of HMB2 cells carrying microbubbles, 
in case targeted and non-targeted liposomes were used. Figure 4B clearly shows 
that using targeted liposomes, the percentage of HMB2 cells carrying 
microbubbles is significantly higher. At the highest microbubble concentration 
used (which corresponds to approximately 2.5 microbubbles/cell, see materials 
and methods) up to 32% of the cells carried microbubbles targeted to N-cadherin. 
Without targeting maximally 5% of the HMB2 cells were ‘”microbubble positive”. 
To have a more accurate view on microbubble targeting we measured which 
percentage of the HMB2 cells indeed expressed N-cadherin. Flow cytometry 
(Figure 4C) revealed that approximately 70% of the HMB2 cells expressed 
significant amounts of N-cadherin. Hence, we concluded that, under the 
experimental conditions used, about 1 out of 2 N-cadherin expressing cells was 
‘found’ by the targeted liposome-loaded microbubbles.  
Specificity of the concept: do targeted microbubbles specifically bind to N-
cadherin expressing cells in a mixture of cells? 
The next aim was to get an idea on the binding specificity of N-cadherin targeted 
liposome-loaded microbubbles in a mixture of different cell types. Therefore we 
analyzed to which extent targeted liposome-loaded microbubbles were able to 
bind specifically to HMB2 cells in a cell suspension composed of HMB2 cells 
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(with a significant expression of N-cadherin) and BLM melanoma cells which 
show only limited N-cadherin expression (Van Marck et al  [23]). 
HMB2 cells were labeled with the aspecific green dye Cell Tracker™ bodipy (as 
described above) while BLM cells were not fluorescently labeled, targeted and 
non-targeted microbubbles were red-labeled with DiD. Figure 5A shows density 
plots in which the red-fluorescent events, originating from DiD-labeled 
microbubbles, are plotted on the y-axis against the green fluorescent events from 
the green-labeled HMB 2 cells in the mixture of HMB2 and BLM cells. These plots 
were divided in quadrants based upon measurements with cells and 
microbubbles ‘only’. Quadrant a represents events positive for red fluorescence 
(microbubbles) only, quadrant b represents events positive for both red and green 
fluorescence (microbubbles  bound to HMB2 cells), quadrant c represents non-
fluorescent events (BLM cells) and quadrant d represents events positive for 
green fluorescence only (HMB2 cells). Note that in Figure 5A the darker colored 
areas within the plots represent areas with a higher number of events occurring. 
In Figure 5A one can clearly observe that there is a shift in the number of events 
from quadrant a to quadrant b upon loading microbubbles with N-cadherin 
targeted liposomes (with targeting), indicating specific binding of targeted 
microbubbles to green-labeled HMB2 cells and not to BLM cells as this would 
result in an increase in events in quadrant a. Figure 5B shows the green 
fluorescent intensity plot obtained on a mixture of green-labeled HMB2 cells and 
non-labeled BLM cells, with indication of the two cell populations and 
corresponding quadrants in the density plots. 
Cell specific ultrasound-triggered drug delivery 3 
 
126 
 
 
Figure 5: (A) shows flow cytometry density plots of green fluorescence (from HMB2 cells) against red 
fluorescence (from microbubbles) after addition of respectively non-targeted and N-cadherin targeted 
liposome-loaded microbubbles to a mixture of green-labeled HMB2 cells and non-labeled BLM cells 
(1:1). (B) Histogram showing the number of green fluorescent events in the mixture of green-labeled 
HMB2 cells and non-labeled BLM cells (without microbubbles). BLM cells only were used as a 
reference for quadrant analysis. 
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The flow cytometry observations described above were subsequently confirmed 
by confocal microscopy, using H1299 [25] lung carcinoma cell with impaired N-
cadherin expression but expressing EGFP which allows to distinguish them 
under the microscope from the HMB2 cells; note that the H1299 cells were 
trypsin-EDTA treated which reduces the amount of surface proteins (including 
N-cadherin) significantly (data not shown). Figure 6 shows confocal images of a 
cell suspension with non-labeled HMB2 cells and EGFP expressing H1299 cells. 
We observed that the HMB2 cells have red-fluorescent (DiD-labeled) targeted 
liposome-loaded microbubbles closely bound to their surface while the 
microbubbles did not attach to the surface of the green H1299 cells. 
 
Figure 6: (A) Overlay of confocal fluorescent images of a cell suspension composed of EGFP 
expressing H1299 cells (lacking N-cadherin), HMB2 cells (expressing N-cadherin) and DiD-labeled 
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(red-fluorescent) targeted liposome-loaded microbubbles. (B and C) Show detailed zooms of both cell 
types. 
Drug delivery to a specific cell type 
To evaluate specific drug delivery to cells expressing N-cadherin as a metastatic 
marker, we loaded the targeted liposomes with propidium iodide (PI) as a model 
compound, as depicted in Figure 7A. PI is not able to spontaneously diffuse 
through cell membranes under normal conditions unless sonoporation and 
subsequent pore formation occurs [26,27]. 
Figure 7 gives an overview of the results obtained by flow cytometry. For this 
experiment, N-cadherin targeted PI liposome-loaded microbubbles were added to 
a mixture of green-labeled HMB2 cells and unlabeled BLM cells. The mixture 
contained 25% of HMB2 cells and 75% of BLM cells and was exposed to 
ultrasound, as described in the materials and methods section. We calculated the 
percentage of respectively HMB2 cells and BLM cells that showed PI uptake upon 
applying ultrasound by analyzing the events that were positive for both PI and 
bodipy fluorescence; the results are shown in Figure 7B. When targeted bubbles 
were used up to 20 % of the HMB2 cells were PI positive, while only 5% PI 
positive HMB2-cells were observed when non-targeted microbubbles were used. 
The BLM cells did not show any significant PI uptake (+/- 1%). These results 
indeed show that, under the given experimental conditions, drug delivery to 
specific cell types can be enhanced using targeted liposome-loaded microbubbles. 
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Figure 7: (A) Schematic representation of propidium iodide (PI)-loaded targeted liposomes loaded on 
lipid microbubbles. (B) Quantitative analysis of flow cytometry experiments on delivery of PI to 
green-fluorescent labeled HMB2 mixed with non-labeled BLM cells. 
DISCUSSION 
Above it is shown that a) coupling of N-cadherin antibodies to liposomes and 
subsequent loading of such constructs to lipid-shelled microbubbles via thiol-
maleimide linkages is feasible, b) such targeted liposome-loaded microbubbles 
can adhere to N-cadherin expressing HMB2 cells, c) in a mixture of N-cadherin 
expressing HMB2 cells with BLM cells or H1299 cells, the microbubbles 
specifically adhere to the HMB2 cells and d) that microbubbles can deliver a small 
molecule (PI) into the target (HMB2) cells. 
Clearly, a major question remains whether the concept introduced above has 
indeed the potential to kill circulating tumor cells in vivo. In this study a 
simplified experimental setup was used, i.e. only two cell types (dispersed in cell 
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medium) were mixed at high concentrations of target cells, while no flow was 
applied. In vivo, one can expect that only few circulating tumor cells present in a 
huge pool of blood cells have to be targeted. Hence, the ideal technology should 
not only be cell specific but also sufficiently sensitive. 
To work under conditions as used in this study, and hence make the proposed 
system applicable in practice, cells should be isolated from blood ex vivo. Indeed, 
microfluidic devices are currently under full development to filter CTCs from 
blood  [28-30] . Targeted (liposome-loaded) microbubbles might be applied in 
such devices allowing specific capturing and subsequent ultrasound induced 
killing of CTCs.  
As introduced above, microbubbles are used clinically as imaging agents. In this 
regard the materials reported could be promising as a theranostic [31]. For 
example, microbubbles could be covered with drug-loaded liposomes and 
targeted to the Vascular Endothelial Growth Factor Receptor (VEGFR) which is 
involved in angiogenesis, a process of abnormal vessel growth that occurs in 
inflammation but also occurs when solid tumors are formed [32]. Such targeted 
microbubbles might adhere to the expressed VEGF receptors thereby enhancing 
tumor contrast, subsequently, upon using destructive ultrasound settings the 
delivery of anticancer drugs into the tumor could become promoted, through 
enhanced extravasation and sonoporation of the cancer cells. Targeting 
microbubbles to tumor endothelial cells would allow closer contact between 
microbubbles and these cells as well, increasing drug-delivery efficiency to these 
endothelial cells and hence tumor killing due to a loss of blood supply.  
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Microbubbles indeed, show great potential for time-and space-
controlled drug delivery. In this work we wanted to evaluate the impact 
of shell composition and liposomal membrane composition on 
ultrasound induced drug-release from liposome-loaded microbubbles in 
vitro and the biophysical mechanisms behind it. We observe that 
liposome-loaded lipid-shelled microbubbles release more anticancer 
drug doxorubicin (DOX) and kill more cells in vitro upon ultrasound 
application, than when microbubbles are composed out of a polymer 
shell (poly-L-lactic acid-pentadecafluoro-octanol PLLA-PFO). Moreover, 
if thermosensitive liposomes are loaded at the surface of the 
microbubbles drug-release and in vitro cell killing is even more efficient. 
Fluorescence microscopy during ultrasound application reveals that 
upon loading microbubbles with thermosensitive liposomes free drug 
may be released from the microbubble instead of the particulate 
materials that is released from “standard” liposome-loaded 
microbubbles. This study hence reveals that (thermosensitive) liposome-
loaded lipid-shelled microbubbles might be the most suitable carriers 
for further in vivo evaluation of ultrasound-triggered drug-delivery with 
liposome-loaded microbubbles. 
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INTRODUCTION 
Microbubbles are stabilized by a (lipid, polymer or protein) shell. As shown in 
previous work [1-6] , such microbubbles show potential for ultrasound induced 
time- and space-controlled drug release. Their mechanism of action relies upon 
their specific interactions with the ultrasound wave. If a gas bubble encounters 
such a wave it will start to resonate due to the pressure fluctuations exerted by 
the ultrasound (called cavitation) [7]. If higher acoustic pressures are used, 
cavitation will result in a microbubble collapse (inertial cavitation) which can 
result in the release of the drugs or nanoparticles attached to or incorporated in 
the microbubbles. It has been observed that when microbubble collapse occurs in 
the vicinity of cell membranes a transient opening of the cell membrane can be 
induced (“sonoporation”), which can improve drug uptake by the sonoporated 
cells [8,9]. In the past it is shown [10-13] that the concept of nanoparticle loaded 
microbubbles can be beneficial to induce local drug release and uptake at the same 
time. 
Microbubbles made from stiffer shell materials, like e.g. polymers, respond 
differently to ultrasonic pressure fluctuations than the more elastic lipid-shelled 
microbubbles [14,15]. This suggests that the composition of the microbubble shell 
could have an influence on drug-delivery efficiency when drug-loaded liposomes 
or other nanoparticles are loaded on their surface. 
Additionally, not only the microbubble shell itself but the liposomes’ 
phospholipid membrane can be tuned for more efficient drug-release as well. It 
has been shown that microbubble cavitation induces temperature changes of up 
to a 4°C and thus causes mild hyperthermia (41-42 °C) in the vicinity of an 
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oscillating microbubble [16,17]. Microbubble oscillations have as well been shown 
to induce a temperature increase of 1000°K in the vicinity of the microbubble 
[18,19]. Hence loading microbubbles with temperature sensitive liposomes may 
enhance the percentage of free drug released from these carriers. Liposomes can 
be made sensitive to temperature by incorporating phospholipids with a Tm 
around 40°C in their membranes (1,2-dipalmitoyl-sn-glycero-3-phosphocholine or 
DPPC), additional incorporation of so-called lysolipids (1-palmitoyl-2-hydroxy-
sn-glycero-3-phosphocholine or MPPC) [20-22] may improve destabilization of 
the liposomal membrane at higher temperatures.  
As schematically depicted in figure 1, this study aims to estimate the impact of 
microbubble shell composition (polymer or lipid) and liposome composition 
(standard or thermosensitive) on the drug-delivery efficiency from drug-loaded 
microbubbles upon ultrasound application.  
  
The influence of microbubble shell and type of liposome loaded 4 
 
139 
 
 
 
Figure 1: Schematic representation of the studied liposome loaded microbubbles. Microbubbles 
loaded with two different liposome types (standard or thermosensitive) (A) and with two different 
types of microbubble shells (polymer or lipid) are investigated (B).  
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MATERIALS AND METHODS 
Preparation and characterization of Standard Doxorubicin (DOX) Loaded 
Liposomes (SDLL) 
SDLL were prepared via the method described in earlier publications by our 
group [23,24]. Briefly, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene 
glycol)-2000] (DSPE-PEG-maleimide) or 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000] (DSPE-PEG-biotin) 
and cholesterol dissolved in CHCl3 at a concentration of 20 mg/ml and 10 mg/ml 
respectively, were transferred in a round bottom flask in a 49:15:36 molar ratio. 
After evaporation, the remaining lipid film was rehydrated with buffer (NH4)2SO4 
(250 mm) to obtain a liposomal dispersion with a final lipid concentration of 16 
mg/ml. The resulting liposome dispersion was extruded through a 200 nm filter 
using a mini-extruder at 60 °C. After extrusion the excess of ammonium sulfate 
was removed by ultracentrifugation at 109000 x g (Ultrafuge, Beckman-Coulter, 
Brea, CA). Hereafter the liposomal dispersion was aliquoted into 450 µl aliquots 
and liposomes were loaded with DOX by adding 50 µl of a doxorubicin.HCl 
(Sigma-alldrich, Bornem, Belgium) 10 mg/ml solution, afterwards this mixture 
was incubated at 50°C for 2hrs. Non-encapsulated DOX was removed in a second 
ultracentrifugation step at 109000 x g (Ultrafuge, Beckman-Coulter, Brea, CA). 
Final DOX concentration was evaluated using absorbance spectrometry (500 nm) 
using an Envision plate-reader and reached between 0.5 and 0.8 mg/ml (Perkin-
elmer, Waltham, MA) 
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Preparation and characterization Thermosensitive Doxorubcin (DOX) Loaded 
Liposomes (TDLL) 
TDLL were prepared using a method adapted from de Smet et al. [25]. 2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG-
maleimide) or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[biotinyl(polyethylene glycol)-2000] (DSPE-PEG-biotin) dissolved in CHCl3 at a 
concentration of 20 mg/ml and 10 mg/ml respectively and 1-palmitoyl-2-hydroxy-
sn-glycero-3-phosphocholine (MPPC) dissolved in a CHCl3:EtOH (1:1) mixture at 
a concentration of 13.3 mg/ml were mixed in a round bottom flask in a molar ratio 
(DPPC:DSPE-PEG-maleimide:MPPC) of 82:10:8. After solvent evaporation the 
remaining lipid film was rehydrated with a 250 mM (NH4)2SO4 buffer solution. 
The final lipid concentration of the liposomal dispersion in the flask was 32 
mg/ml. The resulting dispersion was extruded through a 200 nm filter using a 
mini-extruder at 60 °C. After extrusion the excess of ammonium sulfate was 
removed by ultracentrifugation at 109000 x g (Ultrafuge, Beckman-Coulter, Brea, 
CA). Hereafter the dispersion was aliquoted into 400 µl aliquots and 100 µl of 
Doxorubcin.HCl (10 mg/ml) was added to the liposomal dispersion and was 
allowed to incubate at 37°C for 3 hrs. Upon incubation, the remaining 
unencapsulated doxorubicin was removed via ultracentrifugation at 109000 x g 
(Ultrafuge, Beckman-Coulter, Brea, CA). Final DOX concentration was evaluated 
using absorbance spectrometry (500 nm) using an Envision plate-reader and 
reached between 0.5 and 0.8 mg/ml (Perkin-elmer, Waltham, MA).  
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Evaluation of temperature induced Doxorubicin release from SDLL and TDLL 
Both liposomal dispersions (SDLL and TDLL) were dissolved in HEPES buffer (50 
mM, Sigma-alldrich, Bornem, Belgium) until a final concentration of 0.5 mg 
DOX/ml was reached. Samples were incubated at room temperature (25°C), 37°C 
and 43°C respectively for 20 mins. Upon incubation sample fluorescence 
(excitation wavelength 480 nm, emission wavelength 590 nm) was measured with 
an Envision plate reader (Perkin-elmer, Waltham, MA).Subsequently, the 
percentage of DOX-release was determined based on equation (1), Triton X-100 
treated samples (TDLL and SDLL 0.5 mg DOX/ml) were measured as 100 % 
release controls.  
% 𝐷𝐷𝐷𝐷𝐷𝐷 − 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟= 𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟 𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟𝑟𝑟𝑟𝑟𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟 (43/25°𝐶𝐶) − 𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟 𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟𝑟𝑟𝑟𝑟𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟 (37°𝐶𝐶)
𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟 𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟𝑟𝑟𝑟𝑟𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟 (𝑇𝑇𝑟𝑟𝑇𝑇𝑇𝑇𝑓𝑓𝑓𝑓 𝐷𝐷 − 100) − 𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟 𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟𝑟𝑟𝑟𝑟𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟 (37°𝐶𝐶) 
Preparation and characterization of lipid-shelled microbubbles 
Lipid-shelled microbubbles were prepared as described earlier by our group 
(Geers et al. 2011[23]). Briefly, microbubbles were prepared starting from a lipid 
solution being a mixture of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[PDP(polyethylene 
glycol)-2000] (DSPE-PEG-PDP) (Avanti polar lipids, Albaster, AL) in a 1:2:7 
glycerine-propyleneglycol-H2O solvent (Sigma-aldrich,Bornem,Belgium), the 
molar ratio of the lipids in the lipid solutions was 95:5. Aliquots of this lipid 
solution were transferred into 2.5 ml chromatography vials, which headspace was 
filled with C4F10 gas (F2 chemicals, Preston, UK). Finally, functionalized 
microbubbles (with an average size of 3µm) were obtained by high speed shaking 
of the lipid solution in a Capmix™ device (3M-ESPE, Diegem, Belgium) during 15 
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sec. The size and the concentration of the microbubbles in the dispersion (i.e. 
number of microbubbles per mL) were determined with a Beckman-coulter 
Multisizer 4 (Beckman-coulter, Brea, CA). 
Preparation of green-fluorescent labeled lipid-shelled microbubbles 
Green-fluorescent labeled lipid-shelled microbubbles were prepared via the same 
procedure as non-labeled lipid-shelled microbubbles. A lipid solution was 
prepared containing DPPC, DSPE-PEG-SPDP, cholesteryl-bodipy (molecular 
probes, Merelbeke, Belgium) in a 1:2:7 glycerine-propyleneglycol-H2O solvent. 
Preparation and characterization of neutravidin coated poly-L-lactic acid-
pentadecafluoro-octanol (PLLA-PFO) microbubbles 
PLLA-PFO neutravidin coated bubbles were prepared as earlier described by 
Chlon et al. [26]. First, the polymers PLLA-PFO containing 10% w/w PLLA-biotin 
(synthetized at Philips Research Eindhoven) were dissolved in dichloromethane 
at 5% w/w. 250 mg of this solution was added to 100 mg of cyclodecane and 0.9 
mg of dichloromethane and subsequently emulsified in 20 g of a 0.3% (w/w) PVA 
in H2O solution. The obtained premix was passed through an acrodisk glass filter 
(1µm) 10 times. Subsequently the emulsion was stirred for 1 h to allow the 
dichloromethane to dissolve. Afterwards the remaining emulsion was centrifuged 
at 968 x g and the top fraction was retrieved and washed with a 5% Poly-
ethyleneglycol (PEG MW= 3400) in H2O solution containing neutravidin. 
Subsequently the obtained samples were rapidly frozen at -80°C o precooled glass 
vials. To remove ice and the cyclodecane fraction the samples were subsequently 
freeze dried in a Christ Epsilon 2-6 freeze drier (Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany). Samples were 
subjected to 2 freeze dry cycles at 1.98mbar for 20 hrs and at 0.03mbar for 20 hrs 
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respectively at a shelf temperature of -10°C. After freeze drying the system was 
filled wit nitrogen and samples were stored at 4°C. Particle size and 
concentrations were measured using a Multisizer 4 (Beckman Coulter, Brea, CA).  
Preparation of liposome loaded lipid and polymer-shelled microbubbles 
To prepare liposome-loaded lipid-shelled microbubbles adequate amounts of 
SDLL or TDLL containing 15 mol% DSPE-PEG-maleimide were added to the lipid 
solution prior to adding C4F10 and shaking of the vials. To obtain ideal 
concentrations for in vitro experiments (107 microbubbles/ml) HEPES buffer was 
added to the solution. PLLA-PFO capsules were loaded with liposomes by 
adding adequate amounts of DSPE-PEG-biotin containing SDLL or TDLL to the 
capsules dispersed in HEPES buffer (microbubble concentration 2x107 bubbles 
per ml) 
In vitro evaluation of ultrasound induced drug release 
Liposome-loaded microbubbles (lipid or polymer-shelled) with a microbubble 
concentration of approximately 107 microbubbles per ml were dispersed in 
Opticell™ plates containing 9 ml of phosphate buffered saline (PBS) (Gibco, 
Merelbeke, Belgium) with a final doxorubicin concentration of approximately 
5µg/ml. Subsequently the Opticell™ plates were submerged in a water bath and 
samples were subjected to ultrasound during 15 s using the Sonitron device 
(Artison Corporation, Inola, OK, USA) equipped with a 2 cm ultrasound probe. 
This probe was used with an ultrasound frequency of 1 MHz with 50 % duty 
cycle at an ultrasound intensity of 2 W/cm2. The transducers’ beam profile was 
evaluated with a needle hydrophone and the ultrasound settings used in these 
experiments correspond with a maximal acoustic pressure of 600 kPa. Negative 
control samples weren’t subjected to ultrasound and positive control samples 
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were prepared by adding a 1:1 propyleneglycol:H2O mixture to negative control 
samples. Dynamic Light Scattering (DLS) shows that application of this solvent to 
the samples dissolves the liposomal structures in the sample upon ultrasound 
application 100 µl aliquots of the samples were diluted with 100 µl PBS and 
fluorescence (excitation wavelength 480, emission wavelength 590 nm) was 
evaluated with an Envision plate reader. There were no differences in 
fluorescence of DOX at the concentrations used between the different solvents. 
Subsequently the % DOX-release was calculated via equation (2) 
(2) % 𝐷𝐷𝐷𝐷𝐷𝐷 − 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 =
𝐹𝐹𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟𝑟𝑟𝑟𝑟𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟 (𝑈𝑈𝑈𝑈 𝑟𝑟𝑓𝑓𝑠𝑠𝑠𝑠𝑟𝑟𝑓𝑓𝑇𝑇𝑟𝑟𝑠𝑠 𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟)−𝐹𝐹𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟𝑟𝑟𝑟𝑟𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟 (𝑓𝑓𝑟𝑟𝑛𝑛𝑟𝑟𝑇𝑇𝑇𝑇𝑛𝑛𝑟𝑟 𝑓𝑓𝑓𝑓𝑓𝑓𝑇𝑇𝑟𝑟𝑓𝑓𝑟𝑟 𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟)
𝐹𝐹𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟𝑟𝑟𝑟𝑟𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟 (𝑠𝑠𝑓𝑓𝑟𝑟𝑇𝑇𝑇𝑇𝑇𝑇𝑛𝑛𝑟𝑟 𝑓𝑓𝑓𝑓𝑓𝑓𝑇𝑇𝑟𝑟𝑓𝑓𝑟𝑟 𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟)−𝐹𝐹𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟𝑟𝑟𝑟𝑟𝑓𝑓𝑟𝑟𝑓𝑓𝑓𝑓𝑟𝑟 (𝑓𝑓𝑟𝑟𝑛𝑛𝑟𝑟𝑇𝑇𝑇𝑇𝑛𝑛𝑟𝑟 𝑓𝑓𝑓𝑓𝑓𝑓𝑇𝑇𝑟𝑟𝑓𝑓𝑟𝑟 𝑟𝑟𝑟𝑟𝑠𝑠𝑠𝑠𝑟𝑟𝑟𝑟𝑟𝑟) 
Cell culture 
BLM cells (melanoma cells) were cultured in F12-supplemented Dulbecco’s 
modified Eagles medium (DMEM-F12) which contained 1% 
Penicillin/Streptomycin, 2mmol/l glutamine, 10 % Fetal bovine serum (FBS) (all 
purchased from Gibson, Merelbeke, Belgium) and 100 mmol/l HEPES pH 7.2. 
Cells were grown in a humidified incubator at 37°C in a 5 % CO2 atmosphere. 
In vitro evaluation of inherent toxicity of SDLL and TDLL 
BLM cells were seeded in 12-well plates (1 x 105 cells per well) and were grown to 
90% confluence, which was reached two days after seeding. Cells were washed 
with PBS and subsequently 1ml of optimem (Gibco, Merelbeke, Belgium) mixed 
with SDLL or TDLL (5 µg DOX/ml) was added to the cells. After 24 hours cells 
were washed and the MTT reagent (Cell proliferation kit I, Roche diagnostics, 
Leuven, Belgium) was added for 4 hours. Subsequently, the sollubilization 
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reagent was added and cells were incubated overnight to allow cell lysis at 37°C. 
The next day, the absorbance of each plate was measured in an absorbance plate 
reader at respectively 590 nm (OD590) to determine the formed formazan and at 
690 nm (OD690) as a reference. The results of the cytotoxicity measurements are 
expressed as percentages; the viability of the cells which were only treated with 
optimem was considered to be 100 %, while the viability of cells exposed to a 
concentrated DMSO in H2O solution was considered to be 0 %. Experiments were 
performed at least in triplicate.  
In vitro evaluation ultrasound induced cell killing 
BLM cells were seeded in Opticell™ plates (1.3 x 106 cells per Opticell™) and 
were grown to 90 % confluency, which was reached two days after seeding. 
Before experiments were performed, cells were washed with PBS. Subsequently, 
liposome loaded microbubbles were added to the cells. The following samples 
were prepared for the cytotoxicity experiments. A) Lipid microbubbles loaded 
with SDLL or TDLL were prepared by adding adequate amounts of TDLL or 
SDLL liposomes to 700 µl of lipid solution was added until a final volume of 1 ml 
and a DOX concentration of 60µg/ml was reached. After shaking in the Capmix™ 
device. The 1 ml microbubble dispersion was added to 10 ml of optimem and this 
mixture was added to the cells in Opticell™ plates. PLLA-PFO shelled bubbles 
loaded with SDLL or TDLL were prepared by adding adequate amounts of 
DSPE-PEG-biotin containing liposomes to a dispersion of capsules in HEPES 
buffer until a final concentration of 120µg/ml was reached with bubble 
concentration (2 x 107 microbubbles per ml). 500 µl of the obtained dispersion was 
added to 10 ml of optimem and this mixture was added to the cells in the opticell 
plates. Subsequently, these plates were submerged in a warm water bath (37°C) 
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with a bottom of ultrasound absorbing rubber. Ultrasound was delivered by 
moving the Sonitron ultrasound probe over the whole plate during 10-15 sec. We 
used 1 MHz ultrasound with a 20 % duty cycle with an ultrasound intensity of 2 
W/cm2, as described above; the acoustic pressure exerted by the transducer at 
these settings was calculated to be 600 kPa. During ultrasound application cells 
were located on the top membrane of the Opticell™, in this way microbubbles are 
directly contacting the cells during sonication. After ultrasound application cell 
displacement was evaluated by means of microscopy and was always minimal 
with the microbubble concentrations used for these experiments. After 4 hours of 
incubation, microbubbles were removed; cells were washed with PBS and 
incubated in fresh culture medium. After 24 hours cells were washed and the 
MTT reagent (Cell proliferation kit I, Roche diagnostics, Leuven, Belgium) was 
added for 4 hours. Subsequently, the sollubilization reagent was added and cells 
were incubated overnight to allow cell lysis at 37°C. The next day, the absorbance 
of each plate was measured in an absorbance plate reader at respectively 590 nm 
(OD590) to determine the formed formazan and at 690 nm (OD690) as a reference. 
The results of the cytotoxicity measurements are expressed as percentages; the 
viability of the cells which were only treated with optimem was considered to be 
100 %, while the viability of cells exposed to a concentrated DMSO in H2O 
solution was considered to be 0 %. Experiments were performed at least in 
triplicate. 
Microscopy setup 
Microscopy experiments were performed using a custom built setup that allows 
ultrasound application during microscopic imaging. This setup is comparable 
with the setup used in the experiments perfomed by Van Wamel [27,28] and 
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Kooiman et al. [29], but allows fluorescent imaging during ultrasound application. 
A Nikon EZC1 (Nikon, Brussels, Belgium) confocal inverted microscope 
equipped with an LSM tech objective invertor (LSM tech, Etters, PA) and a 40 x 
objective, was mounted with a water tank equipped with a panametrics A303 
transducer. This single element transducer emits an ultrasound beam focused on 
the Opticell™ plate which is installed on the top-side the water tank. The 
ultrasound is generated by an Agilent 33210A arbitrary waveform generator 
(Agilent, Diegem, Belgium) and the signal produced by the waveform generator 
is amplified using an AR 100A400 amplifier (Amplifier Research, Hazerswoude 
Dorp, The Netherlands). The emitted signal is monitored with an oscilloscope. 
Microscopic confocal fluorescence cell and microbubble (loaded with SDLL or 
TDLL) imaging during ultrasound application 
BLM cells were seeded in Opticell™ plates (1.3 x 106 cells per Opticell™) and 
were grown to 90 % confluency, which was reached two days after seeding. 
Before experiments were performed, cell membranes were stained by adding 7 µl 
of Cell Mask™ deep red (Life technologies, Merelbeke, Belgium) (2 mg/ml) to the 
cell medium and were subsequently washed with PBS and filled with 10 ml of 
optimem (Gibco, Merelbeke, Belgium). 100 µl of a 1 in 10 dilution (solvent: PBS) 
of green-fluorescent labeled microbubbles loaded with SDLL or TDLL with a 
DOX concentration of 60µg/ml and a microbubble concentration of 108 
microbubbles/ml or polymer-shelled microbubbles loaded with SDLL (identical 
DOX concentrations) were added to the cells. Afterwards the Opticell™ 
containing the experimental mixture was placed in the microscopy setup for 
microscopic confocal fluorescence imaging during ultrasound application. 
Excitation of the cell mask dye was performed with a diode laser at 630 nm; 
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emitted fluorescence was detected at 660 nm. Both cholesteryl-bodipy and DOX 
were excited with a diode laser at 488 nm; emitted laser light was detected at 550 
and 590 nm respectively. Fluorescent time-lapse images were acquired starting 4 
seconds before ultrasound application and lasted for 20s upon ultrasound 
application. Ultrasound was applied by triggering the arbitrary wave generator to 
emit a sinusoidal wave with a frequency of 1MHz, amplitude of 1.6 Vpp (peak to 
peak). The wave was emitted as a burst of 2000 cycles with a burst period of 8 ms. 
The measured signal after amplification was measured with the oscilloscope and 
equaled 220 V which corresponds with an acoustic pressure of 400 kPa at the 
focus of the transducer as determined with a needle hydrophone. Images were 
analyzed using ImageJ software by defining the intracellular space of at least ten 
cells per acquired time-lapse frame as a ROI. The amount of DOX fluorescence (ex: 
488 nm, em: 590 nm) was afterwards measured per ROI and determined in 
function of time. 
Statistic analysis 
All measurements were performed at least in triplicate unless otherwise stated, 
presented as means +/- one standard deviation and statistical significance was 
determined using a students t-test or ANOVA analysis when multiple samples 
were compared. A p-value smaller than 0.05 was regarded as statistically 
significant. 
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RESULTS 
As mentioned before, the aim of this paper is to evaluate the influence of 
microbubble type and liposome type on (a) the ultrasound induced cell killing (b) 
the ultrasound induced DOX-release and finally (c) we aim to evaluate the 
mechanisms of drug-release of the most efficient formulation with fluorescence 
microscopy during ultrasound application.  
Analysis of temperature induced DOX-release from SDLL and TDLL 
To estimate the impact of liposome formulation on ultrasound induced drug 
release from the microbubbles we prepared two different DOX-loaded 
microbubble formulations a) standard DOX-containing liposomes (SDLL) 
containing DPPC, DSPE-PEG and cholesterol (formulation used in previous 
studies) and b) thermosensitive DOX-containing liposomes (TDLL) containing 
DPPC, DSPE-PEG and MPPC. The latter is based on formulations described 
earlier [20]. 
To verify whether the developed TDLL were indeed thermosensitive, we 
measured the temperature-induced DOX-release from both SDLL and TDLL 
without microbubbles by means of fluorescence measurements as shown in figure 
2. The presence of DOX precipitates in the intraliposomal space significantly 
quenches DOX fluorescence. In contrast, DOX fluorescence increases when the 
liposomes break up (under the influence of surfactants or when temperature is 
increased) and release the encapsulated DOX. This increase was used to estimate 
the % of DOX release from both liposome types as explained in the materials and 
methods section. For the TDLL we observed an increase in DOX fluorescence 
intensity of approximately 60% when liposomes were incubated at 43°C (using 
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37°C as a reference). SDLL on the other hand showed no temperature induced 
DOX release since fluorescence did not increase upon heating the liposomes to 
43°C. We compared DOX fluorescence intensity from both SDLL and TDLL at 
37°C and 25°C as well, but no significant differences between samples were found, 
indicating that both liposome formulations were stable at room temperature. 
 
Figure 2: temperature induced % DOX-release based upon fluorescence intensity measurements of 
SDLL and TDLL upon incubation of the samples at 25°C and 43°C. Fluorescence intensity of Triton X-
100 treated liposomes was regarded as 100% release there where liposomes incubated at 37°C were 
regarded as negative controls. 
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Influence of microbubble shell and liposomal composition on the ultrasound 
induced tumor cell killing efficiency. 
We evaluated the inherent toxicity of the liposomal formulations (SDLL and 
TDLL) at 2 different DOX concentrations (5µg and 10µg DOX per well). As 
shown in figure 3A TDLL induce more cytotoxicity at both incubation times (45 
min and 4 h), most likely this cytotoxicity will be caused by leakage of free DOX 
out of the liposome as described by Tagami et al. [30]. However, if the incubation 
time is limited to 45 min and if low DOX concentrations are used, the effect of 
external events (like ultrasound) will be maximal. Hence, we selected these 
particular incubation times and concentrations for the continuation of this work. 
Next, we determined the ultrasound-triggered cell killing effect of DOX-liposome 
(6µg DOX/ml) loaded microbubbles (107 microbubbles/ml) composed of different 
shell (PLLA-PFO or lipids) materials and loaded with SDLL or TDLL. As shown 
in figure 3B, we observe significant ultrasound-triggered cell killing when using 
lipid-shelled microbubbles. Especially, when TDLL are loaded on the surface of 
these microbubbles the highest cell killing effect is achieved (only 45 % of the 
treated cells remain viable). PLLA-PFO shelled microbubbles (loaded with both 
types of liposomes) on the other hand, didn’t show significant ultrasound 
induced cell killing compared to the unloaded ultrasound treated PLLA-PFO 
control microbubbles. 
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Figure 3: (A) Cytotoxicity measurements (MTT) on melanoma cells comparing the inherent 
cytotoxicity of SDLL and TDLL with two different DOX concentrations (5 and 10 µg DOX per ml) and 
two different incubations times (45 min and 4h). (B) Cytotoxicity measurements (MTT) of ultrasound-
triggered cell killing on melanoma cells. The ultrasound induced cell killing (white bars) of lipid-
shelled and PLLA-PFO shelled microbubbles loaded with TDLL or SDLL (6 µg/ml DOX and 107 
microbubbles/ml), was compared to samples that were not ultrasound treated with ultrasound (gray 
bars). Unloaded ultrasound treated microbubbles were measured as control samples. 
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Influence of microbubble shell and liposomal composition on the ultrasound 
induced drug release. 
To evaluate our hypothesis that an increased DOX release is responsible for the 
observed differences in tumor cell killing, we compared the ultrasound induced 
DOX-release from DOX-liposome loaded microbubbles composed out of different 
shell materials (PLLA-PFO or lipid) and loaded with different liposomal 
formulations (SDLL or TDLL). To calculate the % DOX-release, DOX fluorescence 
intensity after ultrasound exposure of DOX-liposome loaded microbubbles was 
compared to loaded microbubbles without ultrasound application (negative 
controls) and samples treated with a 1:1 propyleneglycol:H2O mixture (positive 
controls). As shown in figure 4 ultrasound application induces a 50% DOX-
release from PLLA-PFO-shelled microbubbles loaded with SDLL. Ultrasound 
application on lipid-shelled microbubbles loaded with SDLL on the other hand 
induces more DOX-release (65%). Indeed, these results indicate that ultrasound-
triggered drug release is more efficient when lipid-shelled microbubbles are used 
compared to PLLA-PFO polymer bubbles. We analyzed ultrasound-triggered 
DOX-release from lipid-shelled microbubbles loaded with TDLL as well and here 
we observed that almost all DOX was released from the microbubbles. This 
indicates that loading lipid-shelled microbubbles with TDLL results in a more 
efficient ultrasound-triggered drug release compared to SDLL loading. 
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Figure 4: % Ultrasound induced DOX-release from PLLA-PFO shelled microbubbles loaded with 
SDLL and lipid-shelled microbubbles loaded with SDLL or TDLL (5 µg/ml DOX and 107 
microbubbles/ml in all samples) based on DOX fluorescence intensity measurements. Liposome 
loaded microbubbles without ultrasound treatment were regarded as 0% controls while 
propyleneglycol:H2O treated samples were regarded as 100% controls. 
Microscopic evaluation during ultrasound application 
We further wanted to evaluate the mechanisms behind ultrasound induced drug-
release from lipid-shelled microbubbles. Hence, we investigated the differences in 
ultrasound-triggered drug release in function of the type of liposome (TDLL or 
SDLL) loaded on lipid-shelled microbubbles as visualized with confocal 
fluorescent imaging during ultrasound application. As schematically shown in 
figure 5, a customized setup was installed on a confocal scanning laser 
microscope (as explained in detail in the materials and methods section) allowing 
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synchronized fluorescent cell and microbubble imaging while the cells were in 
the focus of a single element ultrasound transducer. 
 
Figure 5: Schematic depiction of the microscopy setup used for confocal fluorescent cell imaging 
during ultrasound application. 
Figure 6 shows overlays of confocal fluorescent images of ultrasound-triggered 
drug release from lipid-shelled bubbles loaded with TDLL (figure 6A) or loaded 
with SDLL (figure 6B). One can observe a difference in microbubble implosion 
and subsequent drug release between both types of formulations. It appears that 
ultrasound induces a direct release of free DOX from microbubbles loaded with 
TDLL. The lipid material of the microbubble (green-fluorescent) seems to be 
released in the form of a mist. Looking upon the images of the SDLL loaded 
bubbles one can observe that clumpy material adheres to the cells or is delivered 
into the cytoplasm of the cells upon ultrasound application. Indeed, these data 
suggest that loading lipid-shelled microbubbles with TDLL induces direct 
homogenous release of free DOX upon ultrasound application, there where 
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loading with SDLL results in a release of vesicular material from the 
microbubbles.  
We were not able to investigate polymer-shelled microbubbles with a green-
fluorescent labeled shell. However, we’ve included quantitative data obtained by 
fluorescence microscopy during ultrasound application in the next section.  
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Figure 6: Overlay of confocal fluorescent images of BLM cells exposed to TDLL liposome loaded lipid 
microbubbles (A) and SDLL liposome loaded lipid microbubbles (B) acquired during ultrasound 
application. BLM cell membranes were labeled with Cell Mask™ deep red, microbubble (lipid) shells 
were labeled with cholesteryl-bodipy and DOX-liposomes were visualized by their inherent 
fluorescence. (A) Shows images obtained with TDLL loaded microbubbles before (-2 sec) and during 
(0 sec and 2 sec) ultrasound application. (B) Shows images obtained with SDLL loaded microbubbles 
at the same time points. Images are shown as merged images of red fluorescence with DOX 
fluorescence (top row) and merged images of red-fluorescence with green- (bodipy) fluorescence 
(bottom row). 
Quantitative analysis of confocal fluorescent images during ultrasound 
application of lipid-shelled microbubbles in function of type of liposome 
loaded 
To verify the assumptions on drug-release made in the previous section and to 
analyze DOX-release from polymer-shelled microbubbles, we performed 
quantitative image processing on the fluorescent images in function of time post 
ultrasound application. We defined the intracellular space of (at least) 10 BLM 
cells with red-fluorescent labeled cell membranes as ROIs and we subsequently 
analyzed the DOX fluorescence intensity of these ROIs frame per frame (as a 
function of time). The results of this analysis (shown as relative values to be able 
to compare different results) are shown in figure 7. Here, one can clearly observe 
a significant increase in the mean DOX fluorescence per cell if TDLL are loaded 
on the surface of the lipid-shelled microbubbles. In contrast, SDLL coupling on 
the microbubble shell caused a much slower rise in DOX fluorescence per cell. 
Quantitative image processing hence reveals that a release of free DOX might be 
involved in ultrasound triggered drug delivery from lipid-shelled microbubbles 
loaded with TDLL. Another type of drug-release is clearly involved upon loading 
microbubbles with SDLL, which may relate to the release of vesicles and not free 
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DOX molecules upon ultrasound application. Polymer-shelled microbubbles 
loaded with TDLL don’t show any uptake of DOX upon ultrasound application. 
Instead we observe a decrease in the relative DOX fluorescence per cell which 
may be caused by photo bleaching. Hence, we can conclude that drug release 
from polymer-shelled liposome-loaded microbubbles will be minimal.  
 
Figure 7: Quantitative analysis of DOX fluorescence per cell (based on cell ROIs in time-lapse 
microscopic images) in function of time post ultrasound application. Results are shown as relative 
increase of fluorescence compared with cell fluorescence before ultrasound application (-2 sec). 
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DISCUSSION 
Above is shown that a) ultrasound induces more drug release form lipid-shelled 
drug-loaded microbubbles than from PLLA-PFO shelled drug-loaded 
microbubbles; b) ultrasound induces more drug-release from lipid-shelled 
microbubbles loaded with TDLL than from lipid-shelled microbubbles loaded 
with SDLL; c) in vitro tumor cell killing is significantly higher with lipid-shelled 
TDLL loaded microbubbles and finally; d) these observations may be explained 
by a release of free DOX from TDLL loaded lipid-shelled microbubbles upon 
ultrasound application as shown by confocal fluorescence microscopy during 
ultrasound application.  
The observed differences in drug-delivery efficiency may be due to a difference in 
response to ultrasound between polymer- and lipid-shelled microbubbles. As 
depicted in figure 8A polymer coated microbubbles show gas-release only at the 
weakest point in the polymer coating (so-called “cracking [14]), leaving the other 
parts of the polymer shell and the liposomes loaded on their surface intact. This 
may indeed be caused by cracking of the polymer shell. In contrast to this, lipid 
coatings are damaged more homogeneously (so-called fragmentation [31,32]) 
during microbubble implosion. This fragmentation affects nearly all loaded 
liposomes (figure 8B) and hence drug-release from lipid-shelled microbubble will 
be higher compared to polymer-shelled microbubbles. 
Loading these lipid-shelled microbubbles with thermosensitive liposomes 
enhances drug-delivery efficiency even more. Indeed, this can be due to a local 
and short increase in temperature upon microbubble cavitation as explained in 
the introduction section This sudden increase in temperature might cause the 
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liposomal membrane to melt, releasing the encapsulated drug in free form 
instantaneously (as shown by confocal microscopy during ultrasound 
application). Standard liposomes containing a significant percentage of the 
stabilizing agent cholesterol, are not sensitive for this increase in temperature, 
which explains the release of clumpy material (liposome aggregates) upon 
ultrasound application.  
Releasing free DOX will indeed result in a direct and more efficient uptake of the 
drug by the cells. This will induce more effect because free DOX is more potent 
than DOX encapsulated in a liposome. However, if cells will be incubated for a 
longer period of time, liposomes or liposome-like structures will be taken up by 
the cells and induce effect as well. Depending on the type of drug used and the 
timeframe in which an effect is needed, both types of liposomes loaded on the 
surface of a microbubble may hence be suitable for drug-delivery applications. 
This work shows that the composition of the microbubble shell and the loaded 
liposomes do have a significant influence on ultrasound-induced drug-release 
from liposome-loaded microbubbles. Further evaluation of liposome-loaded 
PLLA-PFO shelled microbubbles in vivo, can be excluded due to inefficient drug 
release and cell killing in vitro, there where lipid-shelled microbubbles loaded 
with TDLL may be promising. However, further in vivo evaluation is needed to 
confirm the observations made in this work. 
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Figure 8: Schematic depiction of drug release mechanisms upon ultrasound application. (A) shows 
cracking of polymer-shelled microbubbles leaving a significant part of the liposomes intact. (B) shows 
fragmentation and subsequent homogenous liposome-destruction and subsequent drug-release from 
lipid-shelled microbubbles. 
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Microbubbles have been shown to be potentially useful in drug-delivery 
applications especially when loaded with drug-containing nanoparticles. 
Up to now we succeeded in optimizing a formulation which allows safe, 
easy and stable production of drug-containing liposome-loaded 
microbubbles, however it wasn’t tested in vivo yet. In this work we 
evaluate the efficiency of indocyanine green (ICG) uptake with 
ultrasound and ICG liposome-loaded microbubbles into tumors in mice 
and compared this with standard ICG liposomes. We observed that all 
experimental groups show ICG uptake into tumors, however standard 
ICG liposomes show the highest uptake.  
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INTRODUCTION 
Microbubbles show potential for ultrasound induced time- and space-controlled 
drug release in vitro [1]. Their mechanism of action relies upon their response to 
the alternating acoustic pressure field exerted by the ultrasound wave. If a gas 
bubble encounters high intensities of acoustic pressure, microbubbles will 
collapse which can result in the release of drugs or nanoparticles attached to or 
incorporated in the microbubbles [2,3]. In the past it has been shown [4-6] that the 
concept of nanoparticle loaded microbubbles can be beneficial to induce local 
drug release and uptake at the same time in vitro. 
Up to now we succeeded in the design of a) an easy to store, to produce and safe 
microbubble formulation loaded with doxorubicin-containing liposomes [7], b) 
we were able to attach antibodies to liposomes loaded on the surface of the 
microbubbles enabling cell type specific drug-delivery in vitro and c) we have 
optimized ultrasound induced drug-release from microbubbles by loading them 
with thermosensitive liposomes.  
In this chapter we will evaluate whether or not optimized liposome-loaded 
microbubbles in combination with localized ultrasound application can induce 
uptake of the small molecule indocyanine green (ICG) into tumors in vivo 
compared to the clinically used liposomal formulations. ICG is a near infrared 
fluorescent dye that does not leave the bloodstream under normal conditions [8] 
and hence is an ideal molecule to study tumor uptake in vivo via near infrared 
biofluorescent imaging [9]. 
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MATERIALS AND METHODS 
Preparation of functionalized indocyanine green (ICG)-loaded liposomes 
Functionalized ICG-loaded liposomes were prepared via the method described 
earlier. Briefly, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene 
glycol)-2000] (DSPE-PEG-maleimide) and cholesterol dissolved in CHCl3 at a 
concentration of 20 mg/ml and 10 mg/ml respectively, were transferred in a round 
bottom flask in a 49:15:36 molar ratio. After solvent evaporation, the remaining 
lipid film was rehydrated with a solution of indocyanine green (ICG) (sigma-
alldrich, Bornem, Belgium) in H2O (5 mg/ml) to obtain a liposomal dispersion 
with a final lipid concentration of 16 mg/ml. The resulting liposome dispersion 
was extruded through a 200 nm filter using a mini-extruder at 60 °C. After 
extrusion the excess of ICG was removed by ultracentrifugation at 109000 x g 
(Ultrafuge, Beckman-Coulter, Brea, CA). Final ICG concentration was evaluated 
using absorbance spectrometry (680 nm) using an Envision plate-reader (Perkin-
elmer, Waltham, MA). 
Preparation of functionalized thermosensitive ICG-loaded liposomes 
Thermosensitive ICG-loaded liposomes were prepared as follows. 2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG-
maleimide) dissolved in CHCl3 at a concentration of 20 mg/ml and 10 mg/ml 
respectively and 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (MPPC) 
dissolved in a CHCl3:EtOH (1:1) mixture at a concentration of 13.3 mg/ml were 
mixed in a round bottom flask in a molar ratio (DPPC:DSPE-PEG-
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maleimide:MPPC) of 82:10:8. After solvent evaporation the remaining lipid film 
was rehydrated 5 mg/ml ICG solution as described in the previous section. The 
final lipid concentration of the liposomal dispersion in the flask was 32 mg/ml. 
The resulting dispersion was extruded through a 200 nm filter using a mini-
extruder at 60 °C. After extrusion the excess of ammonium sulfate was removed 
by ultracentrifugation at 109000 x g (Ultrafuge, Beckman-Coulter, Brea, CA). Final 
ICG concentration was evaluated using absorbance spectrometry (680 nm) using 
an Envision plate-reader (Perkin-elmer, Waltham, MA). 
Preparation of liposome-loaded microbubbles 
Microbubbles were prepared as described previously. Briefly, microbubbles were 
prepared starting from a lipid solution being a mixture of 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[PDP(polyethylene glycol)-2000] (DSPE-PEG-PDP) 
(Avanti polar lipids, Albaster, AL) in a 1:2:7 glycerine-propyleneglycol-H2O 
solvent (Sigma-aldrich, Bornem, Belgium), the molar ratio of the lipids in the lipid 
solutions was 95:5. Aliquots of this lipid solution were transferred into 2.5 ml 
chromatography vials, together with 100 µl of freshly made (targeted, 
thermosensitive or standard) ICG liposomes, which headspace was filled with 
C4F10 gas (F2 chemicals, Preston, UK). Finally, functionalized microbubbles (with 
an average size of 3µm) were obtained by high speed shaking of the lipid solution 
in a Capmix™ device (3M-ESPE, Diegem, Belgium) during 15 sec. The size and 
the concentration of the microbubbles in the dispersion (i.e. number of 
microbubbles per mL) were determined with a Beckman-coulter Multisizer 4 
(Beckman-coulter, Brea, CA). 
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Animal model and xenograft tumor implants 
6 weeks old nude athymal NMRI mice (Harlan, Boxmeer, The Netherlands) were 
kept in individual ventilated cages under constant temperature (22-25°C) and 
humidity (45-65%). Xenograft tumors were implanted when the animals were 7 
weeks old by injecting 100 µl of a suspension of BLM cells [12,13] (1*106 cells per 
ml) in PBS at the dorsal side of the animal subcutaneously. Prior to injection these 
cells were cultured in 75cm2 cell culture flasks in Dulbecco’s modified eagles 
medium (DMEM) F12 supplemented, and additionaly supplemented with 1 % 
penicillin-streptomycin, 10% Fetal Bovine Serum (FBS), L-glutamine and 100 mM 
HEPES buffer (all purchased from Gibco, Merelbeke, Belgium) under 5% CO2 at 
37°C. Tumors were allowed to grow for 5 weeks upon implantation. 
Animal experiments and ultrasound application 
When tumor volume reached approximately 500 mm3-1 cm3 experiments were 
performed. 100 µl of pure ICG liposome or microbubble (loaded with standard or 
thermosensitive ICG liposomes) (1 x 107 microbubbles/ml) dispersion containing 
120 µg ICG was injected via the tail vain of the animal. Before experiment, the 
concentration of ICG in all experimental materials was evaluated with the IVIS, in 
order to make sure that the materials injected contained comparable amounts of 
ICG. Per group at least 3 animals were treated. During all experimental 
procedures the animals were anesthetized with isoflurane (O2 1 l/ min), 5% 
isoflurane was used for induction and 1.5% during the procedure. Animals were 
imaged directly after the injection and 24 h after injection using an IVIS lumina II 
system (Caliper Life sciences, Zaventem, Belgium). The 780 nm line was used to 
excite ICG, where the 820 nm line was detected in the emission channel. Tumors 
from animals injected with microbubbles were treated with a commercially 
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available sonidel SP100 ultrasound sonoporation device (5 W/cm2 for 2 min). 
Therefore, tumors were covered with gel and gradually insonified as depicted in 
figure 2. 24 h post injection, the animals were sacrificed by cervical dislocation; 
tumors were excised and imaged with the IVIS lumina II to analyze the exact 
amount of ICG in the tumor. The amount of fluorescence in the tumors was 
corrected for tumor size. All animal experiments were approved by the ethical 
committee of the faculty of veterinary sciences of Ghent University  
 
Figure 1: Schematic overview of ultrasound application in implanted tumors. 
Statistical analysis 
All data are presented as means +/- one standard deviation. A student’s t-test was 
performed to determine whether datasets differed significantly. A p-value 
smaller than 0.05 was regarded significant 
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RESULTS 
This work gives an overview of the behavior of the materials developed for 
ultrasound-triggered drug-delivery by our group in tumor bearing mice. Tumor 
uptake of ICG will be evaluated as a function of the drug-delivery vehicle used, 
namely: a) standard liposomes, b) liposome-loaded microbubbles in combination 
with ultrasound,  and c) thermosensitive liposome-loaded microbubbles in 
combination with ultrasound.  
Kinetics 
As shown in figure 2, directly after injection of the liposomes or liposome-loaded 
microbubbles combined with ultrasound application, a strong accumulation of 
ICG fluorescence in the liver is observed. However, the accumulated liver and 
overall fluorescence in animals treated with liposomes is much higher. Indeed, if 
ICG is delivered via ultrasound assisted drug-delivery from liposome-loaded 
microbubbles less ICG will initially accumulate in the liver because more 
molecules are delivered in the tumor where ultrasound is applied. However this 
tumor uptake is still much lower than liver uptake. Free liposomes however, will 
distribute throughout the animal with maximal liver uptake directly after 
injection. 
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Figure 2: Fluorescent images (IVIS lumina II) of BLM tumor bearing mice directly upon injection of 
liposomes only or liposome-loaded microbubbles in combination with ultrasound (US). 
After 24 hours fluorescence has distributed over the complete animal. However, 
upon injection of liposomes a strong accumulation of fluorescence in the tumor 
area can be observed as shown in figure 3. Liposome-loaded microbubbles show 
less accumulation in the tumor, as well as upon ultrasound application. Because it 
is hard to distinguish tumor ICG accumulation into the tumor from ICG, which is 
excreted via biliary excretion [14] into the intestines of the animals, we decided to 
excise tumors. 
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Figure 3: Fluorescent images (IVIS lumina II) of BLM tumor bearing mice 24 h upon injection of 
liposomes only or liposome-loaded microbubbles in combination with ultrasound (US). Circles 
indicate the location of the tumors. 
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Tumor accumulation and quantitative results 
Upon excision and subsequent imaging of the tumors (figure 4) one can clearly 
observe significant ICG accumulation in tumors treated with ICG-loaded 
liposomes only. ICG accumulation can be observed in the other experimental 
groups as well. However, significantly less ICG accumulates in these 
experimental groups.  
 
Figure 4: Fluorescent images (IVIS lumina II) of excised tumors 24 h after injection of BLM tumor 
bearing mice with liposomes or liposome-loaded microbubbles in combination with ultrasound 
application.  
To quantify the amount of ICG delivered into the tumors, we calculated the 
amount of fluorescence per cm2 tumor for the different treatment groups in 
different animals. Additionally we calculated this for tumors treated with 
ultrasound and thermosensitive ICG liposome-loaded microbubbles as well. 
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Indeed, one can observe significant ICG uptake in tumors treated with liposomes 
only and a significant uptake of ICG in all other groups compared with PBS 
treated control tumors. Interestingly, we could observe a slightly higher ICG 
uptake in ultrasound treated tumors in combination with thermosensitive ICG 
liposome-loaded microbubbles, although this increase was not statistically 
significant compared with other ultrasound treated groups. 
 
Figure 5: Quantitative analysis of fluorescence intensity per cm2 tumor of the different treatment 
groups in BLM tumor bearing mice.(** significant with regard to control tumors) 
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CONCLUSIONS AND DISCUSSION 
This work shows that ultrasound indeed enables release and subsequent tumor 
uptake of a molecule (ICG) that is not able to penetrate into tissues via the 
bloodstream safely (none of the animals endured severe side effects during the 
intervention). However, standard liposomal formulations still enable a better 
uptake of these molecules into tumors.  
Indeed, standard liposomal formulations will circulate for a significantly longer 
period of time in the bloodstream [15] allowing constant accumulation of these 
nanoparticles in the tumor via enhanced permeation and retention (EPR) [16,17], 
especially in well vascularized tumors. Ultrasound treatment on the other hand 
only lasts for 2 min and microbubbles only circulate for maximally 10 min [18]. 
Hence, accumulation over a long period of time by nanoparticles and drug, as 
with liposomes, will not occur which explains why less ICG uptake was observed 
in tumors treated with ultrasound and liposome-loaded microbubbles. On the 
other hand, a slight though statistically insignificant increase in ICG uptake was 
observed when the microbubbles were loaded with thermosensitive liposomes. 
This observation correlates nicely with our previous findings (in vitro) on 
ultrasound triggered drug release from microbubbles loaded with these 
thermosensitive liposomes. 
One could argue that these materials aren’t suited for small molecule delivery 
into tumors. However, more research is needed to evaluate the real potential of 
ultrasound triggered drug-delivery. The tumors used in this study showed to be 
well vascularized, making them very well suited for liposome accumulation via 
EPR. Ultrasound assisted drug delivery may hence be more useful in tumors that 
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are less vascularized. Additionally, we observed significantly less overall 
distribution and liver accumulation of ICG in mice directly after 
injection/treatment. This suggests that ultrasound mediated drug-delivery may 
cause less side-effects because lower drug doses may be delivered more 
efficiently. Moreover, it may become possible to treat patients multiple times 
using these lower doses enabling a more efficient therapy.  
The type of drug loaded on the microbubbles will have an influence on delivery 
as well. Macromolecules like pDNA, mRNA or siRNA for example that need to 
be transported into cells can benefit from ultrasound induced sonoporation 
[19,20]. The results in this work also point out that microbubbles are still too large 
(2-3 µm); one should be able to lower the size of the microbubbles or other 
ultrasound responsive particles to below 200 nm. This will allow tumor 
accumulation via EPR and subsequent ultrasound application may increase 
delivery of the drug in the tumor. This can be achieved by a strategy described by 
Rapoport and co-workers. [21-24] making use of drug-loaded perfluorocarbon nano-
emulsions, which are phase-convertible small nanoparticles (150 nm), that may 
become microbubbles upon heating due to liquid-gas phase conversion upon 
heating (40°C). 
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Microbubbles are FDA approved contrast agents for ultrasound 
imaging. It has been reported that applying ultrasound on drug loaded 
microbubbles facilitates drug uptake by cells, due to so named 
sonoporation. However, the biophysics behind sonoporation is not fully 
understood. It is believed that sonoporation results in a ‘direct’ delivery 
of drugs in the cytoplasm of cells, though, it has been suggested as well 
that sonoporation facilitates endocytosis which would improve 
internalization of drugs by cells. To get a better understanding of 
sonoporation this study reports on the ultrasound assisted delivery of 
adeno-associated virus (AAV) loaded on the surface of microbubbles. 
AAV’s rely on endocytosis for efficient transduction of cells and are, 
consequently, an elegant tool to evaluate whether endocytosis is 
involved in ultrasound induced sonoporation. Applying ultrasound on 
AAV-loaded microbubbles clearly improved the internalization of 
AAV’s by cells, though transduction of the cells did not occur, 
indicating that by sonoporation substances become directly delivered in 
the cytosol of cells. 
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INTRODUCTION 
Since a few years the interest in microbubbles as drug delivery carriers has grown 
exponentially. A major reason for this is that microbubbles, with some of them 
being approved by FDA as contrast agents for diagnostic ultrasound, may allow 
time and space controlled drug delivery upon mechanical activation of the 
bubbles by ultrasound [1]. Such micron sized bubbles are usually filled with an 
inert hydrophobic gas while their shell consists out of lipids, polymers or proteins 
[2,3].  
The mechanism of action of these microbubbles is based on the specific response 
of the bubbles upon exposure to ultrasound [4]. Because of the difference in 
density between the gas core of the microbubble and the surrounding aqueous 
fluid, microbubbles start to oscillate once subjected to the pressure fluctuations as 
exerted by an ultrasonic wave. This process of oscillation is called cavitation [5]. 
“Stable cavitation” occurs when microbubbles are subjected to an ultrasonic field 
with a low acoustical pressure; stably cavitating microbubbles expand and 
contract around a given diameter. “Inertial cavitation” on the other hand involves 
a more violent process: the bubbles do not longer oscillate around a given 
diameter, their movement is more violent and ultimately they become destroyed 
[6]. It has been shown that cell membranes neighboring a cavitating or collapsing 
microbubble become temporarily permeabilized (“sonoporation”) [7] which is 
believed to result in a more efficient uptake of the drug by cells. 
However, the biophysics behind this mechanism is not yet fully understood. Our 
group showed that when drug molecules are attached to the microbubble surface 
microbubble collapse is able to locally release drug molecules, which become 
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directly delivered into the cytosol of the surrounding cells [8]. However other 
studies described that sonoporation might facilitate the formation of endosomes 
which would explain the more efficient drug uptake by the cells [9]. Hence, there 
is a need to further elucidate the biophysical effects involved in sonoporation. In 
order to prove if sonoporation involves endocytosis or not, we decided to use a 
viral gene delivery vector, namely adeno-associated-virus (AAV), which totally 
relies on receptor mediated endocytosis to achieve cell transduction [10,11]. 
Especially, we made use of “non-active AAV”, being AAV-vectors chemically 
modified at their surface with a polyethylene glycol (PEG) brush. This PEGylation 
strongly reduces the endocytosis of AAV-vectors and, subsequently, lowers their 
transduction properties [12,13]. Since our research group is mainly focusing on 
surface-loaded lipid-shelled microbubbles [14-16], we decided to construct 
PEGylated AAV-loaded lipid-shelled microbubbles. PEGylation of the vectors 
also allows the straightforward insertion of a biotin group on the capsid by 
introducing heterofunctional PEGs. As shown in Figure 1a these PEG-
biotinylated AAV vectors can easily be attached to the surface of a lipid coated 
microbubble by means of avidin-biotin linkages. 
Consequently, we believe that PEGylated AAV-vectors are an ideal tool to study 
whether sonoporation enhances endocytosis or not, as a better transduction of the 
cells upon applying ultrasound and microbubbles will be only observed if 
sonoporation promotes endocytosis and hereby, we hope to deliver more insight 
in the interactions between ultrasound and cellular processes. 
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METHODS AND MATERIALS 
Preparation and characterization of biotinylated microbubbles 
Microbubbles were prepared following the protocol published by Lentacker et al 
[17]. Briefly, the phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-Biotinyl 
(polyethylene glycol)-2000] (DSPE-PEG-biotin) (Avanti polar lipids, Albaster, AL) 
both dissolved in CHCl3 were added in a round bottom flask in an 85:15 molar 
ratio. After CHCl3 evaporation, the lipid film was dissolved in HEPES buffer 50 
mM, pH 7.4 (Sigma-alldrich, Bornem, Belgium). This mixture was extruded using 
a 200 nm polycarbonate membrane filter in a mini-extruder (Avanti polar lipids, 
Albaster, AL) at 60°C to obtain liposomes with a minimal size of 200 nm, as 
measured by dynamic light scattering (Nano-zs, Malvern, Worcestershire, UK). 
An aliquot of the liposomal dispersion was transferred into a 15ml tube and 
subsequently C4F10 gas (MW238 g/mol, F2 chemicals, Preston, UK) was added to 
this dispersion. Microbubbles could be obtained by ultrasonication of the 
liposomes with a 20 kHz probe (Branson 250 sonicator, Branson ultrasonics, 
Danbury, CT). After sonication the microbubbles were centrifuged to remove the 
remaining liposomes. Microbubbles were washed with 3 ml of HEPES buffer. To 
allow coupling of biotinylated AAV-vectors, the microbubbles were subsequently 
incubated with 500 µl of avidin (10 mg/ml). After another washing step with 3 ml 
HEPES buffer and subsequent centrifugation, microbubbles were incubated with 
biotinylated AAV-vectors. Microbubble concentration was evaluated using light 
microscopy in a Burker chamber and equaled 1x107 microbubbles per ml. 
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Preparation and characterization of PEG--biotinylated AAV-vectors 
Recombinant adeno-associated virus serotype 2 (rAAV2) expressing enhanced 
green fluorescent protein (EGFP) was provided by the German Cancer Research 
Centre, with a stock concentration of 1012 particles/ml. To obtain PEGylated or 
PEG-biotinylated AAV-vectors, a 100 µl aliquot of the AAV-vectors was 
incubated with a desired amount of alpha-methoxy-omega-carboxylic acid 
succinimidyl ester poly(ethylene glycol) (MW 2000 g/mol, Iris Biotech GmbH, 
Marktdrewitz, Germany) (NHS-MPEG200) or alpha-biotin-omega-carboxy 
succinimidyl ester poly(ethylene glycol) (NHS-PEG-biotin) (MW 3000 g/mol, Iris 
Biotech Gmbh, Marktredwitz, Germany) respectively. Therefore the NHS-
MPEG200 and NHS-PEG-biotin were dissolved in HEPES-buffer just before 
adding to the AAV-vector dispersion. The vectors were incubated with the 
PEGylation agent during 30 min. Subsequently HEPES buffer was added to 
obtain a final volume of 200µl with a concentration of 5*1010 particles/ml. 
PEGylation of the AAV was characterized by measuring the electroforetic 
mobility of the viral particles with a zetasizer (Nano-zs, Malvern, Worcestershire, 
UK).  
Preparation of fluorescent AAV-vectors 
AAV-vectors were fluorescently labeled with red- or green-fluorescent labels. For 
labeling in red, 100µl of PEG-biotinylated AAV-vectors (freshly prepared) were 
incubated with 3-5 µl of NHS-dyelight633 labeling reagent (2mg/ml, Thermo 
Scientific, Bornem, Belgium) for 30 min. After incubation the dye excess was 
removed by dialysis against distilled water (MWCO 15000 Da, Microdispo 
dialyser, Spectra/Por, Compton, CA). Green-fluorescent AAV-vectors were 
obtained by labeling 100µl of PEG-biotinylated AAV-vectors (freshly prepared) 
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with 3-5 µl of NHS-alexa488 (2mg/ml, Invitrogen Molecular probes, Merelbeke, 
Belgium). The same protocol as described for the labeling of the viruses in red 
was followed.  
Preparation and characterization of AAV-loaded microbubbles 
AAV-loaded microbubbles were prepared by mixing 3 ml of PEG-biotinylated 
microbubbles with 300 µl of the PEG-biotinylated AAV-vectors. To remove 
unbound AAV-vectors, microbubbles loaded with the AAV-vectors were washed 
and centrifuged twice. The percentage of vectors present in the subnatans after 
every centrifugation step was analyzed with an AAV titration ELISA assay 
(Progen GmbH, Heidelberg, Germany). The remaining bubble fraction after these 
washing steps was then dispersed in 3 ml of HEPES and the amount of AAV-
vectors bound to the microbubbles was analyzed with the same assay. We 
quantified the amount of AAV-vectors on the microbubbles to assure that in all 
experiments the same vector titers were used.  
To visualize AAV-loading on the microbubbles, the microbubbles were incubated 
with alexa488-avidin (Invitrogen Molecular probes, Merelbeke, Belgium) and 
mixed with red-fluorescent PEG-biotinylated AAV-vectors. Colocalization of 
(green) avidin and (red) AAV was studied by confocal microscopy, using a Nikon 
EZC1 confocal microscope (Nikon, Brussels, Belgium) equipped with a 60x lens. 
Excitation of the alexa488 avidin was done using the 490 nm line while 
fluorescence was detected at 551 nm. Excitation of the AAV-vectors labeled with 
the red NHS-dyelight633 dye was done using the 630 nm line while fluorescence 
was detected at 660 nm.  
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Cell culture 
BLM cells (melanoma cells) were cultured in F12-supplemented Dulbecco’s 
modified Eagles medium (DMEM-F12). This medium also contained 1% 
Penicillin/Streptomycin, 2 mmol/ml L-glutamine, 10 % Fetal bovine serum (FBS) 
(all purchased from Gibco, Merelbeke, Belgium) and 100 mmol/l HEPES pH 7.2. 
Cells were grown in a humidified incubator at 37°C in 5% CO2 atmosphere.  
Transduction of melanoma cells with PEGylated AAV-vectors  
BLM melanoma cells were seeded at 1.3 x 106 cells and grown up to 70% 
confluence in Opticell™ plates (Biocrystal, Westerville, OH). Before the 
transduction medium was added, cells were washed with phosphate buffered 
saline (PBS). AAV-vectors were PEGylated as described above using 20, 40, 100 
and 200 µg NHS-MPEG200. 200 µl of PEGylated rAAV2 expressing EGFP was 
added to 9.8 ml of cell culture medium and transferred into the Opticells™, 
afterwards cells were incubated for 45 min at 37°C. Subsequently cells were 
washed with PBS, fresh cell culture medium was added and cells were incubated. 
After 48 hours cells were washed and incubated with 2 ml of a 0.05% trypsin-
EDTA solution (GIBCO, Merelbeke, Belgium), after 5 min of incubation trypsin 
was inactivated with 8 ml of fresh culture medium and centrifuged for 7 min at 
1100 rpm. Subsequently medium was removed and cells were resuspended in 
buffer containing 1% of bovine serum albumin, 0.1% of sodium azide in PBS 
(chemicals were purchased from Sigma-alldrich, Bornem, Belgium). EGFP 
expression was measured using flow cytometry with a BD Facscalibur flow 
cytometer (Beckton Dickinson, Erembodegem, Belgium). The flow cytometer was 
equipped with a 488 nm laser and emitted fluorescence was detected in the 
530nm channel FL1. Results are expressed as % EGFP positive cells compared 
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with blank untransducted cells. All experiments were performed at least in 
triplicate and data are expressed as the mean of all three measurements.  
Cytotoxicity assay 
BLM melanoma cells were seeded in 12-well plates at 1*105 cells and grown up to 
70 % confluence. Cells were washed and 10 µl free AAV or inactive PEGylated 
AAV with a  stock concentration of 1012 particles/ml dispersed in cell medium to a 
final volume of 1 ml was added to the cells.  PEGylation occurred via the method 
described above. Subsequently, cells were incubated for 24 h at 37 °C in a 5 % CO2 
atmosphere. After incubation, cells were washed with PBS and afterwards 50 µl 
of MTT-reagent (Roche, Leuven, Belgium) dissolved in cell medium up to 500 µl 
was added to the cells and subsequently cells were incubated for 4 h at 37°C in 5 
% CO2 atmosphere. Finally, 500 µl of solubilization reagent was added. The next 
day, cell viability was determined by measuring the absorbance of the formed 
formazan. The absorbance of each plate was measured in an absorbance plate 
reader at respectively 590 nm to determine the formed formazan and at 690 nm as 
a reference. The results of the cytotoxicity measurements are expressed as 
percentages; the viability of the cells which were only treated with cell medium 
was considered to be 100 %, while the viability of cells exposed to DMSO was 
considered to be 0 %. Experiments were performed in triplicate. 
Transduction of melanoma cells with AAV-loaded microbubbles and 
ultrasound 
BLM melanoma cells were seeded at 1.3 x 106 cells and grown up to 70% 
confluency in Opticell™ plates as mentioned above. Microbubbles were loaded 
with rAAV2 vectors expressing EGFP, that were first PEG-biotinylated using 20 
or 100 µg NHS-PEG-biotin, according to the method described above under 2.2. 
On the mechanisms behind sonoporation 6 
 
192 
 
Control experiments were performed using respectively non-PEGylated AAV-
vectors and “free” PEGylated AAV-vectors (i.e. not bound to microbubbles). In 
each transduction experiment the same AAV concentration was used. After 
washing the cells, 1ml of AAV-loaded microbubbles, with a concentration of 
approximately 1x107 microbubbles per ml, was mixed with 9ml of fresh culture 
medium and added to the cells. Subsequently, Opticell™ plates were submerged 
in a warm water bath (37°C) with a bottom of ultrasound absorbing rubber. 
Ultrasound was delivered by moving a Sonitron™ ultrasound probe over the 
whole plate during 10-15 sec. We used 1 MHz ultrasound with a 10% duty cycle, 
the ultrasound intensity was 2W/cm2. After 45min of incubation, microbubbles 
were removed; cells were washed with PBS and incubated in fresh culture 
medium. 48 hrs. later, cells were trypsinized, centrifuged and resuspended in 
flow buffer for flow cytometry analysis as described above. Results were 
expressed as % EGFP positive cells compared with untreated cells. All 
experiments were performed at least in triplicate and data are expressed as the 
mean of all three measurements.  
Internalization of AAV in melanoma cells treated with AAV loaded 
microbubbles and ultrasound 
BLM cells were grown under the conditions as described above. For these 
experiments microbubbles were loaded with green Alexa488-labeled rAAV2 and 
PEG-biotinylated using 100 µg NHS-PEG-biotin and 1 ml of bubbles (1x107 
microbubbles/mL). The AAV loaded microbubbles were dispersed in fresh 
culture medium and added to the Opticells™. Subsequently, OpticellTM plates 
were subjected to ultrasound as described under 2.7. Cells were washed and fresh 
culture medium was added. The intracellular localization of the green-fluorescent 
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AAV-vectors was analyzed by confocal microscopy using the 488nm laser line. 
The cells were analyzed as well by flow cytometry as described under section 2.5 
However, before flow cytometry analysis, cells were incubated with trypane blue 
to quench extracellular fluorescence. 
Colocalization of endosomes with inactive AAV-vectors loaded on 
microbubbles after ultrasound application 
BLM melanoma cells were grown under the conditions described above and 
transferred in Opticell™ plates. Endosomal labeling was performed by means of 
transduction with the BacMam™ 2.0  Cellight™ Reagent (Invitrogen, Merelbeke, 
Belgium). Briefly, the cells were washed with PBS and according to the 
manufacturers’ recommendations, 150 µl of BacMam™ 2.0 reagent together with 
9.85 ml of cell medium was subsequently added to the cells. Afterwards the cells 
were incubated for 24 h at 37°C under 5% CO2 atmosphere.  
Before the ultrasound experiments, microbubbles were prepared as described 
above and loaded with red-fluorescent labeled inactive PEGylated AAV. 
PEGylation of the vectors was performed as described in previous sections using 
100 µg NHS-PEG-biotin and the vectors were fluorescently-labeled with 2µl of 
NHS-dyelight633 (2 mg/ml). These fluorescent AAV-loaded microbubbles were 
suspended in cell medium and this mixture was added to the cells. Subsequently, 
the Opticell™ plates were subjected to the same ultrasound conditions as used in 
the other ultrasound experiments. The cells were visualized with confocal 
microscopy as described above, 15 min post insonation using both the 488 nm 
laser line and the 633 nm laser line. 
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Statistical analysis 
All data are presented as means +/- one standard deviation. A student’s t-test was 
performed to determine whether datasets differed significantly. A p-value 
smaller than 0.05 was regarded as significant. 
RESULTS 
Design of an AAV-loaded microbubble using PEG-biotinylated AAV 
Figure 1a schematically shows the structure of the AAV-loaded microbubbles we 
designed. The microbubbles consist of a lipid shell, composed of the 
phospholipids DPPC and DSPE-PEG-biotin, which surrounds a perfluorobutane 
gas core. The presence of biotin-containing lipids allowed the coupling of PEG-
biotinylated AAVs through an avidin linker. Therefore the AAV-vectors were 
chemically modified making use of the NHS-PEG-biotin reagent. As shown in 
Figure 1b, this occurred via the amine-groups on lysine residues, present on the 
viral capsid, and the succimidin ester group of the NHS-PEG-biotin reagent. This 
reaction leads to the formation of an amide, which should covalently bind the 
biotinylated PEG-chains to the capsid.  
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Figure 1: (A) Schematic representation of an AAV-loaded microbubble. The microbubble consists of a 
pefluorobutane (C4F10) gas core, surrounded by a lipid monolayer containing 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
biotinyl(polyethylene glycol)-2000] (DSPE-PEG-biotin). Via avidin-biotin bridging, PEG-biotinylated 
AAV-vectors were loaded on the surface of the microbubbles. (B) Chemical coupling of PEG-biotin 
molecules to the viral capsid. The alpha-biotin-omega-carboxy succinimidyl ester poly(ethylene 
glycol) (NHS-PEG-biotin) reagent interacts with amine-groups on lysine residues present on the AAV 
capsid and binds PEG-biotin molecules onto the viral capsid through an amide bound.  
To confirm successful PEGylation of the AAV-vectors, we measured the zeta-
potential of the AAV-vectors respectively before and after the PEGylation 
reaction; Note that NHS-mPEG instead of NHS-PEG-biotin was used in these 
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experiments. As shown in Figure 2, the PEGylation reaction clearly increased the 
zeta-potential of the AAV-vectors, indicating that PEG-molecules shielded the 
negative charges on the viral capsid. As only a (relatively) low amount of NHS-
MPEG per amine present on the viral capsid was used, the PEGylation of the 
AAV-vectors through the NHS coupling strategy seems to be an efficient process. 
 
Figure 2: Zeta potential (ζ) measurements on non-PEGylated AAV-vectors (-PEG) And PEGylated 
AAV-vectors (+PEG). The higher zeta-potential of the PEGylated AAVs indicates a successful 
coupling of NHS-MPEG to the viral capsid. Experiments were performed using 15µg of NHS-MPEG 
per 5x1010 viral particles. (*p<0.05) 
In a next step we tried to load the lipid microbubbles with the PEG-biotinylated 
AAV-vectors. The successful loading of the AAV-vectors on the microbubbles’ 
surface was confirmed by confocal microscopy. Figure 3 shows that green-
fluorescent avidin binds to the surface of biotinylated lipid microbubbles (Figures 
3b and 3d). Binding of the red-fluorescent PEG-biotinylated AAV-vectors to the 
microbubbles is shown in Figure 3e. Figure 3f clearly shows colocalization of 
green-labeled avidin and red-labeled AAV-vectors on the microbubble’s surface 
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proving loading of microbubbles with AAV-vectors through avidin-biotin 
linkages.  
 
Figure 3: Confocal images of unloaded (A-B) and AAV-loaded (C-F) microbubbles carrying green-
labeled avidin (B,D). (A,C) are the corresponding transmission images. Figure (F) shows colocalization 
of the green labeled avidin and red labeled AAV-vectors onto the shells of the microbubbles. 
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The influence of PEGylation of AAV-vectors on their transduction properties  
To evaluate the influence of PEGylation on the transduction efficiency of the 
AAV-vectors we performed flow cytometry experiments using EGFP expressing 
rAAV2 vectors. We measured the percentage of EGFP positive cells as a function 
of the PEGylation degree of the AAV-vectors. Therefore, AAV-vectors were 
PEGylated using increasing amounts of PEG, ranging from 20 to 200µg NHS-
MPEG per 5 x 1010 viral particles. As can be seen in Figure 4, the transduction 
efficiency of the AAV-vectors became clearly impaired if more than 40µg of PEG-
reagent was used. Using 20 µg of NHS-MPEG, the PEGylated AAVs were still 
able to transduct approximately 10% of the cell population. These results indicate 
that PEGylation of AAV-vectors clearly hampers their transduction efficiency, 
which is likely; since the PEG brush is expected to shield the viral capsid proteins 
thereby preventing optimal interactions with cell membrane components which is 
essential for their receptor mediated internalization (see below).  
Since we wanted to investigate the effect of sonoporation on endocytosis, we 
considered to perform our further experiments with AAV-vectors that were not 
able to transduce cells on their own, i.e.: “inactive vectors” (being vectors which 
were strongly PEGylated through the use of 100µg PEG-reagent per 5 x 1010 viral 
particles). As Figure 4 shows, these inactive and strongly PEGylated vectors are 
completely incapable to transduce cells, which consequently means no 
endocytosis could have occurred.  
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Figure 4: (A) Percentage of EGFP positive cells after transduction with (free) non-PEGylated AAV 
(black bar) and (free) PEGylated AAV-vectors (white bars). PEGylation of the AAV-vectors was 
performed with respectively 20, 40, 100 and 200µg of NHS-MPEG per 5 x 1010 particles. (B) Cell 
viability of melanoma cells after transduction with free AAV and inactive PEGylated AAV compared 
with no treatment. (*p<0.05) 
The influence of ultrasound and microbubbles on transduction of cells by 
inactive AAV 
We measured the transduction efficiencies of AAV-loaded microbubbles, with 
and without ultrasound exposure. As described in the materials section, we 
determined the amount of AAV that became loaded on the surface of the 
microbubble to make sure that in all experiments the amount of vectors was the 
same. Again, the percentage of transducted cells was estimated by flow cytometry 
(Figure 5). Experiments were performed using inactive PEGylated vectors (see 
above), respectively in free form or bound to the microbubbles. We observed that, 
binding inactive PEGylated AAVs to microbubbles and applying ultrasound did 
not restore their transduction properties indicating that the mechanism of 
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internalization cannot involve endocytosis. If endocytosis would have been 
stimulated by sonoporation, these PEGylated AAV-vectors would have been 
internalized by endosomes, which would consequently have led to an enhanced 
transduction if ultrasound was applied. Unfortunately these flow cytometry data 
did not reveal any significant increase in transduction of the vectors, which can 
only mean that endocytosis was not enhanced. 
 
Figure 5: Percentage of EGFP positive cells, as measured by flow cytometry, after transduction of 
melanoma cells with AAV-loaded microbubbles in the presence (white bars) and absence (black bars) 
of ultrasound. As a control free non-PEGylated AAV-vectors were used and compared with free 
PEGylated AAV (black bars). (*p<0.05) 
Internalization of AAV in melanoma cells treated with inactive AAV loaded 
microbubbles and ultrasound 
Although these transduction studies prove no enhanced transduction of the 
vectors, we could not determine whether these vectors were internalized are not. 
An internalization of the vectors would mean that sonoporation involves a 
different mechanism compared to endocytosis and that enhanced cytoplasmic 
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delivery as described by Lentacker et al. [8] is really the case. Therefore we aimed 
to evaluate whether ultrasound and microbubbles enhance the cellular 
internalization of the inactive AAV-vectors, which showed no transduction as 
described in the previous section and as shown in Figure 5. 
 As shown in Figure 6, we quantified the internalization of the vectors with and 
without ultrasound exposure using flow cytometry: a clear shift in overall 
fluorescence of the cells could be observed if ultrasound was applied. These 
results indicate that most cells show a significant internalization of vectors when 
ultrasound was applied, while there was no internalization without ultrasound. 
Clearly, Figure 6 shows cellular internalization of the inactive PEGylated AAV-
vectors, while the cells did not became transducted (Figure 5). To confirm these 
internalization data we performed confocal microscopy as a control with green 
fluorescent inactive PEGylated AAV-vectors loaded on the microbubbles, these 
experiments confirmed the data obtained by flow cytometry.  
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Figure 6: cellular internalization of green fluorescent inactive PEGylated AAV-vectors loaded on 
microbubbles (A) with (+US) and without ultrasound (-US) radiation, as obtained by flow cytometry. 
Remark that the extracellular fluorescence was quenched with trypane blue. Results show the 
fluorescence of the cells (RLU) in function of the number of cells counted by the flow cytometer 
(‘events’).The inlet (B) shows confocal and corresponding transmission images of the internalization of 
green fluorescent non-active PEGylated AAV-vectors loaded on microbubbles respectively with (US+) 
and without (US-) applying ultrasound measurements were performed 15 minutes after ultrasound 
exposure. 
  
On the mechanisms behind sonoporation 6 
 
203 
 
Endosomal colocalization studies to confirm direct cytoplasmic delivery upon 
ultrasound  
To really confirm the hypothesis that ultrasound evades endocytosis as suggested 
by the internalization and transduction experiments, confocal microscopy on cells 
with labeled endosomes needed to be performed. As described in the 
experimental section, cells were transducted using the BacMam™ 2.0 technique. 
This technique allows transduction of a GFP-reporter gene targeting the Rab5a 
sequence which is specific for early endosomes. After staining, the cells were 
exposed to microbubbles loaded with red-fluorescent labeled inactive AAV-
vectors and ultrasound was applied. Directly after ultrasound application we 
performed microscopy and we specifically checked for any colocalization 
between red and green fluorescence. 
As shown in figure 7 we could not observe any significant colocalization of these 
red-labeled vectors with the green-labeled endosomes, since no merged green 
and red (orange) signals could be observed inside the cells. Consequently these 
data clearly show that ultrasound enables direct delivery of the particles loaded 
on the surface of the bubbles in the cytosol of the cell without endosomal 
internalization.  
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 Figure 7: Confocal images of green-labeled endosomes merged with red-labeled inactive AAV-
vectors (A) the inlet shows a magnification of a region with a high density of red-labeled vectors 
inside the cell. (B) and (C) respectively show confocal images of green-labeled endosomes inside the 
cell and red-labeled inactive AAV-vectors. (D) shows a transmission image merged with confocal 
images of green and red fluorescence. Note that some bubbles remain attached to the cell after 
insonation. 
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CONCLUSIONS AND DISCUSSION 
Earlier studies indicated that an enhanced deposition of drug molecules in cells 
through the use of microbubbles and ultrasound relies on the formation of 
transient pores in the cell membrane which arise upon implosion of the 
microbubbles. Recently we showed that, due to sonoporation, nanoparticles (like 
nucleic acid containing lipoplexes) which were attached to the surface of 
microbubbles become ‘directly’ delivered in the cytosol of cells upon imploding 
the bubbles with ultrasound, thus avoiding internalization of the nanoparticles 
through endosomes [8]. In this study we used PEGylated AAV-loaded 
microbubbles to elucidate the cellular entrance mechanism behind sonporation. 
Shielding the viral capsid with PEG chains, makes it impossible to interact with 
cell membrane receptors essential to promote receptor mediated endocytosis. This 
blocks cellular transduction, as the endosomal acidification of the capsid and 
subsequent increase of its phospholipase activity is not induced [10,18]. As shown 
in literature, receptor mediated endocytosis is essential to obtain an effective 
AAV transduction [10,11]. This makes PEGylated AAV vectors an elegant tool to 
study the contribution of endocytosis to ultrasound induced sonoporation. 
PEGylated AAV-vectors were obtained by chemically modifying the AAV capsid 
with NHS-PEG-biotin. We showed that these PEG-biotinylated AAV-vectors can 
be linked to lipid-shelled microbubbles via biotin-avidin linkages. This was 
confirmed with confocal microscopy, where colocalization of the AAV-vectors 
with avidin-labeled microbubbles was clearly shown. Flow cytometry 
experiments indeed confirmed that transduction efficiency becomes inhibited, 
once increasing amounts of PEG polymers are introduced on the AAV’s surface. 
Flow cytometric analysis of the transduction efficiency with PEGylated (EGFP 
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expressing) AAV-vectors showed that transduction of cells could not be observed 
when highly PEGylated AAV-vectors (i.e. “inactive AAV-vectors”) were used. 
Interestingly, flow cytometry measurements revealed that the cellular 
internalization of inactive AAV-vectors was enhanced upon binding of the 
vectors to these microbubbles and applying ultrasound. 
Figure 8 illustrates what we believe, may happen during and right after 
microbubble collapse. Ultrasound exposure of AAV loaded microbubbles will 
cause implosion of the microbubbles thereby releasing the attached vectors. At 
the same time, microbubble implosion “perforates” the cell membrane enabling 
the entry of the AAV-vectors, directly in the cytoplasm. Since the only pathway 
causing efficient transduction of the AAV-vectors is endocytosis and clearly no 
transduction has been observed by flow cytometry. Sonoporation can only 
involve a delivery of the vectors directly into the cytoplasm as the internalization 
studies clearly prove.  
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Figure 8: Schematic representation of ultrasound mediated internalization of PEGylated AAV-vectors. 
Sonoporation will cause direct cytoplasmic entry of the inactive AAV-vectors. These vectors however 
stay trapped in the cytoplasm.  
With the results presented in this chapter, one can conclude that sonoporation 
enables direct access to the cell cytoplasm. However, we believe that this 
sonoporation also strongly depends on the ultrasound parameters used, which 
can be the cause of the different conclusions in other studies. As said before, at 
lower ultrasound intensities microbubbles will stably oscillate. If this oscillation 
occurs in the vicinity of cells the movement of the bubbles gently massages the 
cell membrane. This phenomenon is shown in different studies by Van Wamel et al. 
[19-21] and it is possible that this process induces endocytosis in some cases [9]. 
However, at higher ultrasound intensities when microbubble collapse occurs in 
the vicinity of cells, the cell membrane becomes perforated because of microjets 
and shockwaves produced by the bubble collapse [22], which is the case in this 
study. 
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Here, we showed the potential of sonoporation, a mechanism that really 
perforates the cell membrane which allows an adequate delivery of particles to 
cells. This type of direct delivery can be very useful, but can also have a negative 
influence on the outcome of experiments when a particle or vector is used that 
needs a certain cellular mechanism for its efficiency. We believe that we have 
made an important step by determining this new cellular delivery mechanism 
that could be a next step for further research in ultrasound mediated drug 
delivery. 
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Cancer is one of the main causes of death in Europe. Although the scientific 
community has made significant progress in the understanding of this disease in 
the past quarter century, no real therapeutic breakthrough has been achieved so 
far. Cancer therapy (especially chemotherapy) still faces severe side-effects and 
there is no therapeutic moiety that allows selective targeting of the therapeutic 
moiety to the tumor. The ideal cancer therapy hence would allow selective 
treatment of cancer cells without causing damage in healthy cells and tissues.  
In chapter 1 of this thesis we highlight the most important molecular mechanisms 
behind cancer and their relation with cancer therapy that were elucidated in the 
past decade. We have seen cancer developing from a group of “out of control” 
cells to a tissue characterized by cells that express cancer hallmarks and that has a 
changed communication with the surrounding tissue (i.e. the tumor micro-
environment). In this chapter we suggest a novel technique that allows site-
specific image-guided drug delivery using ultrasound contrast agents 
(“microbubbles”) and ultrasound (imaging) in tumors. This technique may allow 
the delivery of a therapeutic moiety only there where ultrasound is applied. 
These microbubbles can be loaded with drug-containing nanoparticles that 
release their (drug) payload upon insonation with a high intensity ultrasound 
pulse. This type of ultrasound pulse will induce a violent oscillation of the 
microbubble resulting in implosion of the bubble and hence release of a 
therapeutic payload attached to the surface of the bubble.  
Although substantial evidence was present that these nanoparticle-loaded 
microbubbles were indeed able to deliver a molecule controlled by ultrasound, 
the existing materials were mostly not suitable for further preclinical and clinical 
development. In chapter 2 we describe the design of a safe, stable and easy to use 
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formulation of liposome-loaded microbubbles that may be suitable for further 
clinical development. This formulation is based on the simple self-assembly of the 
microbubble upon shaking a solution containing all phospholipid constituents of 
the microbubble and DOX-filled liposomes. We have measured the in vitro cell 
killing activity of this formulation and observed that only upon ultrasound 
application significant cell killing (concentration dependent) could be observed. 
Interestingly, we observed significant cell killing at doses that didn’t show any 
cell killing even with free DOX. This shows that ultrasound triggered drug-
delivery with microbubbles allows a more efficient delivery of the drug into cells.  
We decided to increase the selectivity of our microbubble formulation by 
introducing a targeting moiety into the drug-filled liposomes loaded on the 
microbubbles as described in chapter 3. Here, we show that liposome-loaded 
microbubbles targeted against N-cadherin (a protein which is upregulated in 
invasive tumor cells) are able to adhere specifically to N-cadherin expressing 
HMB2 cells in a mixture of 2 different cell types. Ultrasound application allows 
delivery of the model drug propidium iodide to these HMB2 target cells. 
In chapter 4, we wanted to compare drug-delivery efficiency of our newly 
developed formulation of liposome-loaded lipid-shelled microbubbles with 
liposome-loaded microbubbles composed out of (custom-made) polymers. We 
clearly observe that ultrasound induced cell killing and DOX-release is lower for 
polymer shelled microbubbles compared with lipid-shelled microbubbles. This 
could be explained by the different physical response to ultrasound by both types 
of microbubble shell. The more elastic lipid-shelled microbubbles will be 
fragmented upon implosion by a high intensity ultrasound pulse, there where the 
polymer coated microbubbles only “crack” upon such ultrasound pulses. This 
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“cracking” only affects small percentages of the drug-filled liposomes loaded on 
the surface of the microbubbles, where fragmentation of lipid-shelled 
microbubbles will affect nearly all loaded liposomes and hence increases drug-
release and efficiency. We also loaded the microbubbles with thermosensitive 
liposomes and saw a significant increase in ultrasound cell killing and DOX-
release. This may be explained by an increase in temperature that is induced by 
microbubble cavitation, which is able to destabilize these thermosensitive 
liposomes loaded on the surface of the microbubbles and hence induce drug 
delivery. 
Finally the improvements made for optimizing lipid-shelled microbubbles for 
delivery of small molecules to tumors needed to be put to an (in vivo) “acid test”. 
In chapter 5 we have tested the efficiency of ultrasound triggered drug-release 
from (thermosensitive) liposome-loaded microbubbles with different 
modifications in tumor bearing mice and compared this with standard liposomes. 
Indocyanine green (ICG) (a small molecule that does normally not diffuse from 
the bloodstream into tissues) was used as a model drug and was loaded inside 
the liposomes. We observed significant uptake of ICG into tumors in all treatment 
groups, however most ICG was taken up in tumors treated with standard 
liposomes and thermosensitive liposome-loaded microbubbles upon ultrasound 
application. Indeed, standard liposomes will circulate for a significantly longer 
period of time, which allows gradual infiltration of the liposomes into the tumor 
via enhanced permeation and retention (EPR). 
In vitro ultrasound assisted drug-delivery is shown very efficient (in chapter 1 we 
showed that even at very low doses ultrasound assisted drug-delivery was still 
efficient), which may be caused by the temporal opening of cell membranes upon 
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microbubble implosion (so-called sonoporation). Unfortunately, the specific 
biophysical mechanisms behind sonoporation are not yet fully understood. In 
chapter 6, we analyzed the intracellular fate of adeno associated virus (AAV) 
loaded on the surface of the microbubbles via avidin-biotin chemistry. AAV is a 
viral vector that needs endocytosis for efficient gene transduction, but upon 
ultrasound application on AAV-loaded microbubbles AAV particles were 
detected intracellularly, while no efficient transduction was observed. This 
indicates that sonoporation does not induce endocytosis (which would have 
certainly leaded to efficient gene transduction), but involves direct cytoplasmic 
delivery of the loaded liposomes.  
What are the biggest issues that need to be tackled in future work on ultrasound 
assisted drug-delivery with microbubbles? As observed, ultrasound-triggered 
drug-delivery from liposome-loaded microbubbles is very efficient in vitro 
probably due to local sonoporation effects, however as soon as we test the 
materials in vivo standard therapeutic liposomes perform better. This is probably 
due to the very short circulation time of the bubbles that do not allow 
accumulation of the drug-filled nanoparticles over a longer period of time. 
Therefore, further emphasis has to be put on the development of “smaller” drug-
filled ultrasound responsive drug-delivery systems. Making these systems 
smaller will allow longer circulation and hence higher uptake of the particles into 
tumors via EPR. Ultrasound can in this case be used to make the uptake of 
anticancer drugs into tumor cells more efficient via sonoporation.  
Not only the size of the bubble is an important issue, the type of molecule to 
deliver and the type of disease to tackle can be important too. Nucleic acids like 
pDNA, siRNA and mRNA theoretically need only 1 molecule to be efficiently 
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delivered into the cell cytoplasm to work. In this work we only focus on small 
molecules (anticancer drugs) which need much higher target cell concentrations 
to be therapeutically effective. As shown sonoporation helps in delivering 
molecules intracellularly, this is particularly useful for larger therapeutic 
molecules like (pDNA, siRNA, mRNA). To conclude, we would advise that 
research on ultrasound guided drug-delivery and more specifically the 
development of microbubbles for this purpose should focus on a) the 
development of smaller (100-200 nm) ultrasound responsive drug-filled particles, 
b) that the mechanisms behind sonoporation should be elucidated more 
elaborately with advanced microscopy technique and finally c) that a clinically 
useful microbubble formulation for nucleic acid delivery should be developed. 
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Kanker is een van de belangrijkste doodsoorzaken in Europa. Hoewel de 
wetenschappelijke gemeenschap de voorbije kwarteeuw belangrijke vooruitgang 
heeft geboekt in het basiswetenschappelijk onderzoek naar kanker, is er nog 
steeds geen doorbraak bereikt in een efficiënte kankertherapie. Kankertherapie 
(en dan voornamelijk chemotherapie) leidt nog steeds tot zeer nadelige 
bijwerkingen, bovendien bestaat er geen therapeuticum dat doelgericht tumoren 
aanpakt. Het ideale antikanker geneesmiddel zou dus een selectieve behandeling 
van de tumor moeten bewerkstelligen zonder ernstige schade aan gezonde 
weefsels toe te brengen. 
In het eerste hoofdstuk van deze thesis lichten we de belangrijkste moleculaire 
mechanismes, die in het voorbije decennium werden opgehelderd, toe die aan de 
oorzaak liggen van kanker en staan stil bij hun relatie tot kankertherapie. Hier 
zien we dat de definitie van kanker evolueerde van een groepje 
“ongecontroleerde” cellen, naar een weefsel dat gekarakteriseerd wordt door 
cellen die kanker “kenmerken” vertonen en die een gewijzigde communicatie met 
het naburige weefsel vertonen. In dit hoofdstuk brengen we ook voornamelijk een 
nieuwe techniek aan die plaats-specifieke geneesmiddelafgifte kan realiseren in 
de tumor onder controle van medische beeldvorming, waarbij minder 
geneesmiddel terechtkomt op plaatsen waar het niet thuishoort. Hiervoor maakt 
men gebruik van ultrageluid contrastmiddelen (“microbellen”) en ultrageluid 
(beeldvorming) in tumoren. Deze techniek stelt ons in staat om een 
therapeuticum af te leveren alleen daar waar een ultrageluidsgolf wordt 
toegepast (dus in de tumor). Deze microbellen kunnen worden beladen met 
geneesmiddel-beladen nanopartikels die geneesmiddel kunnen bevatten en dat in 
de omgeving van de tumor kunnen loslaten. Dit kan doordat de microbellen 
onder invloed van ultrageluid met een hoge intensiteit op een hevige manier gaan 
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oscilleren, dit leidt uiteindelijk tot de implosie van de microbel. Deze implosie 
leidt dan tot de verspreiding van het therapeuticum dat op het oppervlak van de 
bel is geladen in het gewenste weefsel. 
Hoewel er voldoende bewijs was dat zo’n nanopartikel-beladen microbellen 
inderdaad in staat waren om moleculen op een bepaalde plaats af te leveren 
onder controle van ultrageluid, was er geen materiaal beschikbaar dat kon 
worden gebruikt voor verdere preklinische en klinische studies. In hoofdstuk 2 
beschrijven we het ontwerp van een veilige, stabiele, en makkelijk te hanteren 
formulering van liposoom-beladen microbellen die geschikt zou moeten zijn voor 
verdere klinische ontwikkeling en evaluatie van deze systemen. Deze formulering 
is gebaseerd op het in elkaar schuiven van de betrokken moleculen door 
eenvoudigweg een oplossing met de benodigde ingrediënten (fosfolipiden en 
geneesmiddel (doxorubicine)-beladen liposomen) te schudden aan een hoge 
snelheid. We hebben het effect op celviabliteit gemeten van deze formulering en 
konden constateren dat er een significant effect was indien er ultrageluid werd 
toegepast op de microbellen beladen met doxorubicine-liposomen. Zelfs wanneer 
een zeer lage dosis aan geneesmiddel werd gebruikt konden we evengoed een 
significant effect op het afdoden van kankercellen door dit systeem constateren. 
Op die manier kunnen we dus besluiten dat deze techniek ons in staat stelt op 
een zeer efficiënte manier geneesmiddel af te leveren met een materiaal dat 
geschikt is voor klinisch gebruik. 
Vervolgens hebben we besloten om de selectiviteit van ons systeem op te drijven 
door het meer doelgericht te maken, dit door de liposomen beladen op de 
microbellen met een antilichaam te bedekken zoals beschreven in hoofdstuk 3. 
Hier tonen we aan dat liposoom-beladen microbellen gericht tegen N-cadherine 
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(een proteïne dat is upgereguleerd in invasieve tumorcellen) in staat zijn om 
specifiek te “binden” aan HMB2 cellen die specifiek dit N-cadherine tot expressie 
brengen in een mengsel met 2 verschillende celtypes. Bovendien tonen we hier 
ook aan dat we het modelgeneesmiddel propidium jodide specifiek in de 
doelcellen kunnen afleveren met deze techniek. 
In het vierde hoofdstuk, wilden we de efficiëntie van het 
geneesmiddelafgifteproces vergelijken tussen liposoom-beladen microbellen met 
een verschillend type schaal dat hen omvat (enerzijds lipiden en anderzijds 
polymeren). We konden duidelijk vaststellen dat ultrageluid geïnduceerde 
celdood en DOX vrijstelling lager was voor polymeer gestabiliseerde dan voor 
lipide gestabiliseerde microbellen. Dit kan worden verklaard door het verschil in 
eigenschappen tussen deze twee verschillende schaaltypes. De eerder elastische 
lipidenschaal zal fragmenteren als gevolg van de implosie die volgt op een hoge 
intensiteit ultrageluid golf, daar waar de stuggere polymeerschaal eerder zal 
“scheuren”. Het scheuren van de bellen leidt ertoe dat niet alle liposomen zullen 
worden aangetast na ultrasound applicatie, daar waar dat wel gebeurt bij 
fragmentatie van de lipidenbellen. We hebben de microbellen ook opgeladen met 
temperatuurgevoelige liposomen en zagen een significante toename van het effect 
op ultrasound geïnduceerde celdood met DOX-beladen liposomen op de 
microbellen. Dit kan worden verklaard door een toename van de lokale 
temperatuur als de microbel gaat oscilleren in het ultrageluidsveld, dit leidt tot 
een destabilisatie van het liposomale membraan waardoor het geneesmiddel 
vlotter vrijkomt in de omgeving van de cel. 
Uiteindelijk moesten we een in vivo lakmoesproef uitvoeren op de materialen die 
werden ontwikkeld. In hoofdstuk 5 hebben we de efficiëntie van ultrageluid 
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gestuurde geneesmiddelafgifte van liposoom-beladen microbellen met 
verschillende modificaties (gericht naar VEGFR of beladen met thermosensitieve 
liposomen) getest in tumor dragende muizen en dit werd vergeleken met 
standaard liposomen. Indocyanine groen (ICG) werd gebruikt als 
modelgeneesmiddel (beladen in liposomen) omdat deze molecule niet vanuit de 
bloedbaan in een weefsel (zoals een tumor) kan accumuleren. We observeerden in 
elke behandelde groep dieren een significante opname van het ICG in de tumor, 
hoewel de standaard liposomen het efficiëntst bleken te zijn voor dit doel. 
Inderdaad, deze liposomen zijn in staat gedurende lange tijd in de bloedbaan te 
circuleren en kunnen dus makkelijk in de tumor accumuleren via het EPR-effect. 
In vitro zien we dat ultrageluid in combinatie met geneesmiddel-beladen 
microbellen zeer efficiënt is in het afleveren van geneesmiddelen in cellen. Een 
tijdelijke opening van het celmembraan (de zogenaamde sonoporatie) zou 
hiervan aan de basis kunnen liggen. Spijtig genoeg zijn de biofysische 
mechanismen achter sonoporatie nog niet opgehelderd. In hoofdstuk 6 
analyseerden we het intracellulaire lot van adeno geässocieerde virussen (AAV) 
beladen op het oppervlak van microbellen via avidine-biotine koppeling. AAV is 
een virale vector die endocytose nodig heeft voor een efficiënte gentransductie. 
Echter observeren we na ultrageluidsapplicatie op deze bellen dat de AAV 
partikels zich in het cel cytoplasma bevinden zonder dat dit aanleiding geeft tot 
een efficiënte transductie. Dit toont aan dat sonoporatie de endocytose niet 
induceert, maar eerder een directe cytoplasmatische afgifte bewerkstelligt.  
Wat zijn nu de belangrijkste problemen waarmee we in de toekomst moeten 
rekening houden bij de verdere ontwikkeling van dit platform? Zoals aangetoond 
is ultrasound gecontroleerde geneesmiddelafgifte een zeer efficiënte techniek in 
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vitro hoogstwaarschijnlijk door toedoen van sonoporatie. Desondanks zien we in 
vivo echter geen toegenomen efficiëntie. Waarschijnlijk speelt de zeer korte 
circulatietijd van de microbellen hier een uitermate belangrijke rol in. Daarom 
moeten we verder inzetten op het verkleinen van de microbellen. Hoe kleiner de 
microbel, hoe langer hun circulatietijd en dus ook hoe meer microbellen kunnen 
accumuleren in de tumor. 
Niet alleen de grootte van de bellen zijn een belangrijk gegeven, het type af te 
leveren geneesmiddel speelt ook een rol. Bij nucleïnezuren zoals pDNA, siRNA 
en mRNA moet er theoretisch slechts 1 molecule in de cel worden afgeleverd om 
een therapeutisch effect te bekomen. In dit werk hebben we gewerkt met kleine 
antikankergeneesmiddelen die vooral in relatief hoge concentratie de doelcellen 
moeten bereiken. Bovendien kan, zoals aangetoond, sonoporatie worden 
aangewend om moleculen intracellulair af te leveren en zullen dus vooral 
geneesmiddelen die in een kleine hoeveelheid efficiënt in het cytoplasma moeten 
worden afgeleverd het meest kunnen gebruik maken van deze techniek (dus 
vooral grote moleculen zoals nucleïnezuren). Om te besluiten kunnen we zeggen 
dat het onderzoek naar deze techniek zich in de toekomst vooral zich moet 
toespitsen op a) de ontwikkeling van kleinere microbellen (100-200nm), b) de 
mechanismen achter sonoporatie moeten worden opgehelderd en c) moet er een 
manier komen waarmee we ook grotere moleculen (zoals nucleïnezuren) kunnen 
koppelen aan de microbellen op een manier die ons in staat stelt dit materiaal ook 
klinisch te testen. 
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